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ABSTRACT 
 
 Transglutaminase (TGase), nature’s biological glue, catalyzes the 
post-translational modification of proteins by formation of intra- and intermolecular 
protein cross-links or by primary amine incorporation. TGase has various 
physiological functions, such as skin-barrier formation and blood clot stabilization, 
whereas increasing evidence indicates they may also involved in neurodegenerative 
diseases including Huntington’s disease (HD), Alzheimer disease’s, and progressive 
supranuclear palsy. Mutant huntingtin (htt) and small G proteins (e.g. Rac 1) are 
potential substrates of TGases. The purpose of this dissertation was to characterize the 
mechanisms by which 5-HT2A receptor signaling and calmodulin (CaM) regulate 
TGase-catalyzed transamidation of Rac1 and htt in cultured neuronal cells and HD 
transgenic animals, respectively. 
5-HT2A receptors are G-protein coupled receptors which are widely expressed in 
the brain, peripheral vasculature, platelets and skeletal muscle. They are involved in 
diverse physiological functions, from platelet aggregation to neuroendocrine release. 
In A1A1v cells, a rat cortical cell line, stimulation of 5-HT2A receptor induces small G 
protein Rac1 transamidation and activation. An inhibitory agent or knockdown of 
TGase by siRNA revealed that TGase is responsible for transamidation and activation 
of Rac1. Moreover, serotonin was identified as an amine that becomes transamidated 
 xv 
to Rac1 by TGase. The classical signal transduction pathway of 5-HT2A receptors is 
Gq/11-coupled activation of phospholipase C (PLC), which hydrolyzes 
phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3) and 
diacyglycerol. IP3 mobilizes Ca2+ from the endoplasmic reticulum and thereby 
increases intracellular Ca2+ and consequently, it may enhance TGases enzymatic 
activity. Inhibition of PLC or manipulation of intracellular Ca2+ by a chelating agent 
suppressed 5-HT2A receptor-mediated Rac1 transamidation, whereas an elevation in 
intracellular Ca2+ via an ionophore can mimic 5-HT2A receptor-induced cytosolic Ca2+ 
increases and is sufficient to induce TGase-catalyzed Rac1 transamidation. Moreover, 
a CaM inhibitor decreased 5-HT2A receptor-stimulated Rac1 modification by TGase in 
a dose-dependent manner. These results suggest that PLC, Ca2+ and CaM signaling 
are required for 5-HT2A receptor-mediated transamidation of Rac1 by TGase. 
In the next study, we propose that interrupting CaM interactions with htt is 
therapeutically beneficial in HD. This hypothesis was based on the observations that 
CaM regulates TGase-modification of mutant htt in cells and co-localizes with TGase 
and htt in intranuclear inclusions in HD cortex. Furthermore the association of CaM 
with mutant htt was demonstrated by affinity purification and coimmunoprecipitation 
approaches. Our previous studies demonstrated that in HEK293 and SH-SY5Y cells, 
expression of a CaM-fragment, consisting of amino acids 76-121 of CaM, decreased 
binding of CaM to mutant htt, decreased TGase-modified htt, decreased cytotoxicity 
associated with mutant htt and normalized intracellular calcium release. In this study, 
 xvi 
an adeno-associated virus (AAV) that expresses the CaM-fragment was injected into 
the striatum of HD transgenic R6/2 mice and littermate control mice. The HD mice 
with CaM-fragment expression had significantly reduced body weight loss and 
improved motor function compare to HD control mice. Without affecting the activity 
of CaM-dependent enzymes such as CaM-dependent kinase II, CaM-fragment 
specifically reduced TGase-modified htt, the percentage of htt-positive nuclei and the 
size of intranuclear htt aggregates in HD mouse striatum. Thus, disrupting CaM-htt 
interaction with CaM-fragment may provide a new therapeutic strategy for HD 
patients. 
The data presented here support our hypothesis that stimulation of 5-HT2A 
receptors induces TGase-catalyzed Rac1 transamidation and activation by PLC and 
Ca2+/CaM signaling, whereas disruption of CaM-htt interaction inhibits 
TGase-catalyzed modification of htt and provides neuronal protection in HD. These 
results further suggest that CaM regulates the TGase transamidation reaction and 
TGase modification of htt is involved in the formation and stabilization of 
htt-aggregates and may play a role in the pathogenesis of HD. 
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CHAPTER ONE 
BACKGROUND 
 
 
INTRODUCTION 
Transglutaminases (TGases, EC 2.3.2.13) are a family of calcium 
(Ca2+)-dependent enzymes that catalyze the formation of a covalent bond between 
peptide-bound glutamine residues and either peptide-bound lysine residues or mono- 
or polyamines (Folk and Finlayson, 1977, Folk et al., 1980, Walther et al., 2003). 
TGases are widely distributed in the human body with various physiological functions, 
such as extracellular matrix organization, skin-barrier formation and blood 
coagulation (Griffin et al., 2002;Lorand and Graham, 2003). TGases are subject to 
transcriptional regulation by retinoic acid and steroid hormones (Fujimoto et al., 
1996;Ou et al., 2000), and require the binding of Ca2+ for their activity (Burgoyne and 
Weiss, 2001).  
Serotonin signaling may also regulate TGases activity possibly by increasing 
cytosolic Ca2+ (Walther et al., 2003, Guilluy et al., 2007). Stimulation of 5-HT2A 
receptors activate phospholipase C (PLC) through Gq/11, leading to an accumulation 
of inositol 1,4,5-trisphosphate (IP3) and consequent release of Ca2+ from the 
endoplasmic reticulum. In platelets, activation of 5-HT2A receptors stimulate 
TGase-catalyzed transamidation of serotonin to small G proteins, RhoA and Rab4, 
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making them constitutively active (Walther et al., 2003). TGase-dependent RhoA 
transamidation and activation by serotonin stimulation was also observed in vascular 
smooth muscle cells (Guilluy et al., 2007). Neuronal differentiation of SH-SY5Y cells 
induced by retinoic acid increases the expression and activation of TGases, resulting 
in transamination of putrescine to RhoA and activation of RhoA (Singh et al., 2003).  
Small G proteins are a family of monomeric 20~30 kDa GTP-binding proteins, 
which are homologous to the alpha subunit of heterotrimeric G-proteins. Small G 
proteins regulate a wide variety of processes in the cell, including growth, cellular 
differentiation, cell movement and lipid vesicle transport (Matozaki et al., 2000). 
Rac1 belongs to the Rho family of small G proteins, a subgroup of the Ras 
superfamily. Members of the Rho family are involved primarily in the regulation of 
cytoskeletal organization (Etienne-Manneville and Hall, 2002). Bearing 5 glutamine 
residues (Gln 2,61,74,141,162) and 17 lysine residues in the amino acid sequence 
(Matos et al., 2000), Rac1 might serve as a suitable substrate of TGases. 
TGase-catalyzed transamination of small G proteins may result in constitutive 
activation of the proteins (Walther et al., 2003). Investigating the regulatory 
mechanisms of TGase-modification of small G proteins and the functional 
consequences in a neuronal cell line may further explore the role of TGase in neuronal 
differentiation and neurite outgrowth. 
Calmodulin (CaM), another Ca2+-binding protein, has also been shown to play 
a role in regulating TGase. CaM is a 17 kDa protein that activates a host of enzymes 
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during Ca2+ binding (Cheung, 1982). CaM coimmunoprecipitated with TGase in 
transfected cells (Zainelli et al., 2004) and increased TGase activity in human 
erythrocyte (Billett and Puszkin, 1991), platelets and chicken gizzard (Plank et al., 
1983). Recently, a series of studies showed that the activity of TGase is critical for the 
pathology of a number of neurodegenerative diseases, such as Huntington's disease 
(HD)(Karpuj and Steinman, 2004;Violante et al., 2001). CaM may also be involved in 
HD based on its interaction with both TGase and huntingtin (htt) (Bao et al., 1996, 
Zainelli et al., 2004). 
HD is an autosomal dominant neurodegenerative disorder with progressive 
neurological symptoms and mental decline such as chorea, rigidity, gait disturbance, 
abnormal posturing, seizure, depression and dementia (Harper, 1991). HD occurs in 
individuals whose HTT gene has more than 36 CAG repeats, resulting in a mutant 
protein with abnormal expansions of the polyglutamine domain in the N-terminus. 
The pathological hallmark of HD is intranuclear inclusions and cytoplasmic 
aggregates composed of mutant htt protein (DiFiglia et al., 1997;Ross et al., 1998). In 
vitro and in cell culture, mutant htt is an excellent substrate for TGases (Gentile et al., 
1998;Kahlem et al., 1998;Karpuj et al., 1999). The mRNA, protein, and enzymatic 
activity of TGases are elevated in HD brain (Karpuj et al., 1999;Lesort et al., 
1999;Zainelli et al., 2003). Increasing evidence indicates that TGases may contribute 
to the formation of mutant htt aggregates in HD (Cooper et al., 1999). Htt protein 
colocalizes with TGase2 and its product, -( -glutamyl) lysine covalent bond in 
4 
 
 
intranuclear inclusions in the frontal cortex of HD (Zainelli et al., 2004). On the other 
hand, our lab and others reported CaM associates with mutant htt as demonstrated by 
coimmunoprecipitation (Zainelli et al., 2004) and affinity purification (Bao et al., 
1996). Furthermore, CaM colocalizes with TGase2 and with htt in HD intranuclear 
inclusions (Zainelli et al., 2004). Taken together, these studies suggest that mutant htt 
may bind to CaM resulting in increases TGase-modification to htt. This modification 
may stabilize htt monomers or polymers and contribute to htt-containing aggregate 
formation and cytotoxicity. 
Both TGases and CaM have been explored as therapeutic targets for HD. 
Administration of the TGase inhibitor, cystamine, extended survival, improved motor 
performance and increased neuroprotective gene transcription in HD transgenic mice 
(Dedeoglu et al., 2002, Karpuj et al., 2002a). TGases2 ablation in HD transgenic mice 
results in a drastic reduction in -( -glutamyl) lysine bond levels and neuronal death 
in the cortex and striatum (Mastroberardino et al., 2002). CaM inhibitor, W5, can 
decrease TGases-catalyzed cross-linking of htt in cells transfected with TGase2 and 
mutant htt (Zainelli et al., 2004). However, direct inhibition of CaM or TGase may not 
be the best therapeutic approach, since both enzymes have a lot of other biological 
functions and long-term inhibition might cause untoward effects. A new strategy is to 
identify the htt-binding domain in CaM, and express this CaM fragment in HD 
models. It might disrupt CaM-htt interaction by competing with endogenous CaM, 
and thereby decrease TGase-modified htt, htt-aggregates and cell death. This 
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therapeutic strategy has been tested in cell models of HD and will next be tested in an 
HD transgenic mouse model. 
We hypothesize that stimulation of 5-HT2A receptors induces 
TGase-catalyzed Rac1 transamidation and activation by increasing intracellular 
Ca2+, whereas disruption of CaM-htt interaction inhibits TGase-catalyzed 
modification of htt and provides neuronal protection in HD. Three specific aims 
are proposed to test this hypothesis. 
Specific Aim 1: To determine if the activity and transamidation of Rac1 by 
TGase are increased by 5-HT2A receptor signaling. 
The first specific aim is to determine if the activity and transamidation of Rac1 
are increased by 5-HT2A receptor signaling in a rat cortical cell line, A1A1v cells. We 
will use either a TGase inhibitor or siRNA targeting TGase to determine if Rac1 
transamidation and activation are mediated TGase. In addition, we will determine if 
serotonin is incorporated into Rac1 by TGase following 5-HT2A receptor stimulation. 
Lastly, we will test if DOI, a 5-HT2A/2c receptor agonist, selectively increases 
TGase-catalyzed transamination of Rac1 in vivo. 
Specific Aim 2: To determine if 5-HT2A receptor-regulated transamination of 
Rac1 by TGase is dependent on an increase of intracellular Ca2+ mediated by PLC 
signaling, and if calmodulin regulate TGase-modification of Rac1. 
The second specific aim designed is to explore the downstream mechanistic 
pathways in 5-HT2A receptor-mediated Rac1 transamidation. We will determine if 
6 
 
 
inhibition of PLC prevents the increase of intracellular Ca2+ and transamination of 
Rac1 in response to activation of 5-HT2A receptors. A Ca2+ chelator or Ca2+ ionophore 
will be used to manipulate intracellular Ca2+ and determine if the increase in 
intracellular Ca2+ is necessary and sufficient to induce Rac1 transamination. We will 
also determine if inhibiting calmodulin prevents 5-HT2A receptor-stimulated 
transamidation of Rac1. 
Specific Aim 3: To determine if disrupting the interaction of calmodulin and 
huntingtin decreases TGase-modified huntingtin and huntingtin-aggregates, improves 
motor function and increases survival of HD transgenic mice. 
We will use a viral vector to deliver a calmodulin-fragment, which can 
interrupt calmodulin and mutant huntingtin binding, to the striatum of R6/2 HD 
transgenic mice, then monitor survival and body weight, evaluate motor performance 
by behavioral tests such as DigiGait, Actometer and Rotarod. We will also measure 
neuropathological changes such as intranuclear htt-aggregates and striatal atrophy by 
immunofluorescence and Nissl staining. The specificity of calmodulin-fragment will 
be tested by measuring calmodulin-dependent protein kinase II (CaMKII) and TGase 
activity. 
7 
 
 
REVIEW OF RELEVANT LITERATURE 
In the literature review, the family of TGases will be introduced first, 
followed by their physiological functions. The next section will focus on regulatory 
mechanisms and substrates of TGases. The regulation of TGases-mediated 
transamidation of small G protein by 5-HT2A receptor signaling will be highlighted. 
Rac1, as a potential substrate of TGases, will be presented. Regulation of TGases by 
calmodulin will also be discussed in this section. Lastly, the pathological role of 
TGases in neurodegenerative diseases including Alzheimer disease, Parkinson disease 
and especially Huntington’s disease will be reviewed. 
Transglutaminases (TGases), a family of enzymes 
TGases (EC 2.3.2.13) are a family of Ca2+-dependent enzymes. Once activated, 
TGases catalyze the cross-linking of proteins via the γ-carboxamide group of 
peptide-bound glutamine and the є-amino group of peptide-bound lysine, forming a 
inter- or intramolecular isodipeptide bond (Griffin et al., 2002). The enzyme can also 
covalently link biogenic amines and polyamines, such as spermine or serotonin 
(5-Hydroxytryptamine; 5-HT), to a peptide-bound glutamine residue (Dale et al., 
2002;Folk et al., 1980). 
To date, nine isoforms of transglutaminase have been identified, each encoded 
by different but structurally and functionally related related gene. Family members 
include keratinocyte transglutaminase (TGase1), tissue transglutaminase (TGase2), 
epidermal transglutaminase (TGase3), prostate transglutaminase (TGase4), 
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transglutaminase X (TGase5), transglutaminase Y (TGase6), transglutaminase Z 
(TGase7), factor XIII-A subunit (fibrin-stabilizing factor) and ATP-binding 
erythrocyte membrane protein band 4.2 (B4.2) (Lorand and Graham, 2003). 
At least 4 isoforms, TGase1, 2, 3 and TGase7, are expressed in normal human 
brain tissue (Kim et al., 1999, Grenard et al., 2001) and mutant huntingtin protein is 
identified as a substrate of the first three TGase isoforms (Zainelli et al., 2005). 
However, of the nine known human isozymes, tissue TGase (TGase2) is ubiquitously 
expressed and most well characterized. 
Physiological functions of TGases 
TGases are widely distributed in various tissues and are involved in various 
physiological functions such as blood clot formation, wound healing, skinbarrier 
formation, extracellular matrix assembly, cell death, and cell differentiation (Griffin et 
al., 2002, Lorand and Graham, 2003). 
For example, following exposure to thrombin and Ca2+, fibrin stabilizing 
factor (factor XIII) is activated and converted to factor XIII-A containing only the A 
subunit that, in turn, catalyzes the formation of Nε(γ-glutamyl)lysine 
protein-to-protein side chain bridges within the clot network. Introduction of these 
covalent crosslinks greatly stabilize the fibrin and augments its resistance to 
fibrinolytic enzymes (Lorand, 2001).  
In addition to cytoplasmic and nuclear localization, a significant part of the 
TGase2 protein pool is present on the cell surface. Cell surface TGase2 acts as a 
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coreceptor of integrins, coordinating binding of extracellular matrix (ECM) proteins 
(Zemskov et al., 2006). It also crosslinks the fibronectin (as well as other ECM 
proteins) to improve cell adhesion (Aeschlimann and Thomazy, 2000). TGase2 
functions to stabilize the ECM by forming large polymeric structures that are resistant 
to proteolytic/chemical degradation and mechanical stresses (Griffin et al., 2002). 
The homozygous null TGase2 mice are viable and have normal size and 
weight with no severe phenotype (De Laurenzi and Melino, 2001, Nanda et al., 2001), 
suggesting that other TGase isoforms may compensate for the lack of TGase2 to some 
extent. However, TGase2-/- mice do have altered fibroblast function, defective wound 
healing (Nanda et al., 2001), decreased phagocytic clearance of apoptotic cells 
(Szondy et al., 2003, Rose et al., 2006), mild glucose intolerance and hyperglycemia 
likely due to reduced insulin secretion (Bernassola et al., 2002). Therefore, it is 
plausible that under disease or stress, TGase2 play an essential role in tissure repair or 
healing and that further testing of these mice will reveal how TGase2 is critical in 
other physiologic states. 
Regulatory mechanisms and substrates of TGases 
TGases are Ca2+-dependent enzymes containing a cysteine in their active site 
that is unmasked only in the presence of Ca2+ (Hand et al., 1993) and Ca2+ activation 
of TGase is further regulated by other signal modulators such as GTP (Monsonego et 
al., 1998), phospholipids (Griffin et al., 2002, Beninati and Piacentini, 2004), tumor 
necrosis factor alpha (Chen et al., 2000), nitric oxide (Bernassola et al., 1999) and 
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CaM (Puszkin and Raghuraman, 1985, Zainelli et al., 2004).  
An elevation in intracellular Ca2+ is the required element for activation of 
TGases. Elevations in intracellular Ca2+ needed to activate TGases may arise via 
extracellular influx, release from intracellular stores, or decreased levels of other Ca2+ 
binding proteins (Lorand and Conrad, 1984). The binding of Ca2+ to TGases induces 
conformational changes and exposes the active site to substrate proteins (Hand et al., 
1993, Casadio et al., 1999).  
TGase2 has been reported to be a GTP-binding protein with GTPase activity 
(Achyuthan and Greenberg, 1987). GTP binding to the enzyme can inhibit its 
transamidation activity at physiological Ca2+ levels (Bergamini et al., 1987). Binding 
of GTP to TGase keeps the enzyme in a conformation such that the C-terminus blocks 
the enzyme's catalytic core (Monsonego et al., 1998, Casadio et al., 1999). 
Interestingly, an elevation in cytosolic Ca2+ will overcome GTP inhibition and activate 
TGase (Bergamini, 1988). 
Other regulatory effects may also occur through the interaction of TGase with 
phospholipids, nitric oxide and CaM. When phospholipid vesicles are in the 
crystalline-liquid transition state, they can interact with and inhibit TGase activity. 
The inhibition may be due to the hydrophobic environment provided by the 
phospholipid hydrocarbon chain when the enzyme is inserted into the bilayer (Fesus 
et al., 1983). Exposure to tumor necrosis factor alpha causes fibronectin 
multimerization in lung endothelial matrix by increasing TGase activity (Chen et al., 
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2000). Nitric oxide has an inhibitory effect on both TGase2 and coagulation factor 
XIII, probably via S-nitrosylation of their crucial thiol groups (Bernassola et al., 
1999). CaM increased TGase activity in human erythrocyte (Billett and Puszkin, 
1991), platelets and chicken gizzard (Plank et al., 1983). A CaM inhibitor can 
decrease TGases-catalyzed cross-linking of htt in cells transfected with TGase2 and 
mutant htt (Zainelli et al., 2004). 
Small G proteins have emerged as the new substrates of TGase. It has 
been reported that neuronal differentiation of SH-SY5Y cells induced by retinoic 
acid increases the expression and activation of TGases, resulting in transamidation of 
putrescine to RhoA and activation of RhoA (Singh et al., 2003). In platelets and aortic 
smooth muscle cells, TGases can catalyze the incorporation of serotonin into 
small GTPases ("transamidation"), such as RhoA and Rab4. This process of 
transamidation renders these small GTPases constitutively active (Walther et al., 
2003, Guilluy et al., 2007). Activation of 5-HT2A receptors, which increases Ca2+ 
availability, induces serotonin transamidation to small GTPases (Walther et al., 
2003). Therefore, the next section will introduce the 5-HT2A receptor, including 
its structure, signal transduction, distribution and pathophysiological roles. 
5-HT2A receptor signaling and small G protein transamidation 
Overview and classification of 5-HT receptors  
As one of the most complex families of neurotransmitter receptors, 5-HT 
receptors have at least 16 distinct members cloned, identified and classified into 7 
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different subfamilies according to their ligand recognition profiles, signal transduction 
mechanisms, and structural characteristics (Humphrey et al., 1993, Hoyer et al., 1994, 
Hoyer et al., 2002). Except for the 5-HT3 receptor, which is a ligand-gated ion 
channel, the rest of 5-HT receptors belong to the G protein-coupled receptor (GPCR) 
superfamily.  
The 5-HT1 receptor class includes 5 members, 5-HT1A, 5-HT1B, 5-HT1D, 
5-HT1F and 5-HT1F, which are classically coupled to the Gi/o proteins that 
negatively regulate adenylyl cyclase and induces the opening of K+ channels. They 
are expressed both pre and post-synaptically and involved in the regulation of 
serotonin release (Hoyer et al., 2002).  
The 5-HT2 family consists of 5-HT2A, 5-HT2B and 5-HT2C receptors that 
primarily activate phospholipase C (PLC) via coupling with Gq/11. Activation of 
5-HT2A receptors also mediates neuronal depolarization, a result of the closing of K+ 
channels (Aghajanian and Marek, 1999, Lambe and Aghajanian, 2001).  
The 5-HT3 receptor is unique among the currently known subtypes not only 
because it is one of the first 5-HT receptors identified, corresponding to the M 
receptor (Gaddum and Picarelli, 1957), but also because it belongs to the ligand-gated 
channel superfamily instead of coupling to G proteins or second messenger systems. 
The 5-HT3 receptor mediates the rapid excitatory electrophysiological response due 
to a transient inward current, subsequent to the opening of nonselective cation 
channels (Na+, Ca2+ influx, K+ efflux) (Peters et al., 1992, Hoyer et al., 2002). 
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The 5-HT4, 5-HT6 and 5-HT7 receptors are single members in different families 
that mainly stimulate adenylyl cyclase through the activation of Gαs proteins 
(Raymond et al., 2001).  
The 5-HT5 family (5-HT5A and 5-HT5B receptors) is neither coupled to adenylyl 
cyclase nor PI-PLC. The effector systems of this family remain unclear, but some 
evidence indicates 5-HT5A receptor is implicated in the action of LSD (Grailhe et al., 
1999, Nelson, 2004). 
5-HT2A receptor distribution and pathophysiological roles 
5-HT2A receptors are widely distributed in central and peripheral tissues. In the 
central nervous system (CNS), these receptors have been found mainly in the cortical 
areas (neocortex, entorhinal and pyriform cortex, claustrum), caudate nucleus, nucleus 
accumbens, olfactory tubercle and hippocampus (Hoyer et al., 1986, Pazos et al., 
1987). In the cortex the great majority of labeled cells were pyramidal neurons 
(Wright et al., 1995, Willins et al., 1997). In the periphery, 5-HT2A receptors are 
located in platelets (de Chaffoy de Courcelles et al., 1987), vascular smooth muscle 
(Cohen et al., 1981), and uterine smooth muscle (Wilcox et al., 1992), inducing 
vasoconstriction and platelet aggregation. Studies that have investigated the 
subcellular location of the 5-HT2A receptor indicate that the majority of 5-HT2A 
receptors in the human cerebellum and rat CNS are in cytosol, rather than the cellular 
membrane (Cornea-Hebert et al., 1999, Eastwood et al., 2001).  
The 5HT2A receptor has been shown to be involved in a number of different 
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processes including endocrine modulation (Van de Kar et al., 2001), pain modulation 
(Sommer, 2004), thermoregulation (Ootsuka and Blessing, 2006), cognitive function 
and memory (Meneses, 2002, Williams et al., 2002). In addition, 5-HT2A receptor 
signaling is implicated in a number of disorders including hypertension, 
atherosclerosis, and different psychiatric diseases such as anxiety, stress, suicide 
behavior and schizophrenia (Roth, 1994, Weisstaub et al., 2006). 
Serotonin is one of many neurotransmitters that influence the activation of 
hypothalamic-pituitary-adrenal (HPA) axis and stimulate secretion of oxytocin, 
adrenocorticotrophic hormone (ACTH), corticosterone (Van de Kar et al., 2001, 
Hemrick-Luecke and Evans, 2002, Zhang et al., 2002). Serotonergic terminals from 
the medial raphe nucleus make synaptic interaction with the corticotrophin releasing 
factor (CRF) synthesizing neurons in the paraventricular nucleus of rat hypothalamus 
(Liposits et al., 1987). Moreover, 5-HT2A receptors are found in hypothalamic 
paraventricular nucleus and in both CRF synthesizing neurons and 
oxytocin-containing neurons (Van de Kar et al., 2001, Zhang et al., 2002). When CRF 
is released, it induces ACTH secretion from the anterior pituitary gland, which in turn 
stimulates the release of corticosterone from the adrenal cortex. Administration of 
DOI, a 5-HT2A/2C receptor agonist increases plasma levels of oxytocin, ACTH, 
corticosterone in rats. The 5-HT2A receptor selective antagonist, MDL 100,907, but 
not the 5-HT2C receptor antagonist SB242084 can dose-dependently inhibit the 
neuroendocrine effects of DOI (Van de Kar et al., 2001, Zhang et al., 2002). 
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5-HT2A receptors are the target of some therapeutic agents for a variety of 
psychiatric disorders. Atypical antipsychotic drugs such as clozapine display potent 
5-HT2A receptors antagonism with relatively weak blockade at D2 dopamine (DA) 
receptors, various effects at D1 receptors (Meltzer et al., 1989, Arora and Meltzer, 
1994). Moreover, the clinical response to the selective serotonin reuptake inhibitors 
(SSRI) in treatment-resistant patients is augmented by atypical antipsychotic drugs 
and some antidepressants (Ostroff and Nelson, 1999, Carpenter et al., 2002, 
Marangell et al., 2002). The common feature of these agents is that they are able to 
occupy 5-HT2 receptors and to block the responses mediated by those receptors, in 
particular by 5-HT2A receptors (Marek et al., 2003). These reports support a role for 
5-HT2A receptors in antipsychotic drug action.  
5-HT2A receptors not only mediated the effects of some antipsychotic drugs, but 
also are involved in pathophysiology of psychiatric disorders. Abnormalities in 
5-HT2A receptors have been proposed to be implicated in the pathology of 
schizophrenia (Woolley and Shaw, 1954, Dean, 2003). Direct evidence supporting this 
hypothesis came from radioligand binding studies in post-mortem schizophrenia 
patients, which suggest there is a decrease in the density of cortical 5-HT2A receptors 
in those patients (Arora and Meltzer, 1991, Dean and Hayes, 1996). The levels of 
mRNA encoding the 5-HT2A receptors were also reduced in the superior temporal 
gyrus of schizophrenic subjects (Hernandez and Sokolov, 2000). In depressed patients 
and suicide victims, the postmortem studies indicated an elevated level of 5-HT2A 
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receptor in the cortex, amygdala and hippocampus (Arango et al., 1990, Hrdina et al., 
1993, Pandey et al., 2002). However, positron emission tomography (PET) and 
radioligand binding studies detected a significant decrease in 5-HT2A receptor density 
in hippocampus of both young and old depressed patients (Mintun et al., 2004, 
Sheline et al., 2004). Furthermore, 5-HT2A receptors are also involved in modulating 
anxiety-related behaviors in humans and rodents. For example, global disruption of 
5-HT2A receptor signaling in htr2a–/– mice reduces the inhibition in conflict anxiety 
paradigms, whereas selective restoration of 5-HT2A receptor signaling to the cortex 
normalized conflict anxiety behaviors (Weisstaub et al., 2006).   
5-HT2A receptor structure and signal transduction 
The serotonin 5-HT2A receptor gene is located on human chromosome 13q14-q21 
and comprises 471 amino acid in rats, mice, and humans (Hoyer et al., 2002). It 
contains three exons, separated by two introns, with the coding region of the gene 
spanning 1.4 kb (Sanders-Bush et al., 2003).  
The 5-HT2A receptor is coupled via the Gq/11 proteins to the phospholipase С 
(PLC) signaling cascade. PLC hydrolyzes phosphatidyl-inositol 4,5-bisphosphate 
(PIP2) to diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). IP3 mobilizes 
Ca2+ from the endoplasmic reticulum and thereby leads to an increase of cytosolic 
Ca2+ concentration (Roth et al., 1998). 
In addition to the major pathways mentioned above, extensive evidence suggests 
that 5-HT2A receptors couple to other effector pathways. 5-HT2A receptor stimulation 
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also induces the activation of phospholipase A2 and the release of the second 
messenger arachidonic acid, which is involving Gβγ-mediated ERK1/2 activation and 
Gα12/13-coupled, Rho-mediated p38 activation (Felder et al., 1990, Kurrasch-Orbaugh 
et al., 2003). Through interaction with ADP-ribosylation factor 1 (ARF1) via its 
C-terminal domain, 5-HT2A receptor is able to signal through the phospholipase D 
(PLD) pathway (Mitchell et al., 1998, Robertson et al., 2003).  
5-HT2A receptor is known to trigger MAPK activation via PKC/Raf-1 pathway 
(Hershenson et al., 1995, Watts, 1996). The JAK/STAT signaling pathway is activated 
by a number of G protein coupled receptors including 5-HT2A receptors 
(Guillet-Deniau et al., 1997, Singh et al., 2009).  
Depending on the cell types, 5-HT2A receptor is able to increase or diminish 
cyclic adenosine monophosphate (cAMP) accumulation. It increases cAMP in a cell 
line derived from embryonic rat cortex (A1A1 cells) by protein kinase C-dependent 
and calcium/calmodulin-dependent mechanisms (Berg et al., 1994a) and in FRTL-5 
thyroid cells through a pertussis toxin-sensitive mechanism (Tamir et al., 1992). 
However, in rat renal mesangial cells, 5-HT2A receptor activation can inhibit adenylyl 
cyclase activity and forskolin-stimulated cAMP accumulation (Garnovskaya et al., 
1995).  
Because transamidation of small G proteins (e.g. RhoA and Rab4) mediated by 
5-HT2A receptor signaling leads to platelet α-granule release and aggregation (Walther 
et al., 2003), and TGase-dependent Rho A transamidation also inhibits contraction of 
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vascular smooth muscle cells, a brief introduction of small G proteins especially Rac1 
whose transamidation is extensively studied in this dissertation will be presented in 
the next section.   
Small G proteins 
Small G-proteins, short for small guanine nucleotide-binding proteins, are 
monomeric G proteins with molecular masses of 20–30 kDa. They are homologous to 
the alpha subunit of heterotrimeric G-proteins, but they can function on their own by 
cycling between an inactive GDP-bound state and an active GTP-bound state. The 
GTP/GDP cycling is controlled by many regulator molecules such as 
GTPase-activating proteins (GAPs), guanine nucleotide exchange factors (GEFs) and 
GDP dissociation inhibitors (GDIs) (Hakoshima et al., 2003). GTP hydrolysis is 
accelerated by GAPs, resulting in inactivation of the cognate G-protein. 
GAP-dependent signaling is antagonized by GEF, which activate small G proteins by 
promoting the nucleotide exchange of GTP for GDP. Furthermore, small G proteins 
are regulated by GDIs, which maintain small G proteins in their inactive GDP-bound 
form, in addition to preventing their association to the plasma membrane (Figure 1). 
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Figure 1. Molecular switch of the small G-proteins. The activation of small G protein 
is mediated by three types of regulatory proteins: GDI (guanine nucleotide 
dissociation inhibitor), GAP (GTPase activating protein), and GEF (guanine 
nucleotide exchange factors). 
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Biological functions of Rac1 
Rac1, short for Ras-related C3 botulinum toxin substrate 1, belongs to the Rho 
family of small G proteins, a subgroup of the Ras superfamily. Binding to a variety of 
downstream target proteins (effectors), members of the Rho family (e.g. RhoA, Rac1, 
Cdc42) are associated with a wide array of cellular processes such as cytoskeletal 
organization, vesicular transport, cell cycle progression, cell adhesion and migration, 
neuronal differentiation and a variety of enzymatic activities (Etienne-Manneville and 
Hall, 2002, Burridge and Wennerberg, 2004). 
Rac1 is best known as a regulator for the assembly of the actin cytoskeleton, 
thereby playing a role in neurite outgrowth and neuronal differentiation. Expression of 
a constitutively active mutant of Rac1 in neuroblastoma cells leads to the formation of 
neurites (Leeuwen et al., 1997), and production of filopodia and lamellipodia in the 
developing growth cone (Kozma et al., 1997). In contrast, over-expression of 
dominant negative Rac1 in SH-SY5Y cells blocks retinoic acid (RA)-induced neurite 
outgrowth and expression of neuronal markers, suggesting that activation of Rac1 
regulates neuronal differentiation (Pan et al., 2005). Rac1 play an essential role in 
fibroblasts cell growth in response to mitogenic stimulation since microinjection of 
Rac1 stimulated cell cycle progression through G1 and subsequent DNA synthesis. 
This effect can be blocked by microinjection of dominant negative forms of Rac1 
(Olson et al., 1995). In growth factor-stimulated fibroblasts and neuronal cells, Rac1 
was transiently activated in a broad area of the plasma membrane, followed by a 
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localized activation at nascent lamellipodia (Kurokawa et al., 2005). Consistent with 
this finding, Rac1 is required to stimulate the formation of lamellipodia and 
membrane ruffles. 
Rac1 is also involved in multiple cell death pathways. Depending on the 
interaction with other signaling molecules and on the type of cells, it becomes 
pro-apoptotic (Embade et al., 2000, Aznar and Lacal, 2001, Harrington et al., 2002) or 
anti-apoptotic (Nishida et al., 1999, Deshpande et al., 2000, Murga et al., 2002). For 
example, neurotrophin receptor p75 activates Rac1, which in turn activates c-Jun 
N-terminal kinase (JNK) and causes apoptosis in neuronal cells (Harrington et al., 
2002). On the other hand, Rac1 protects endothelial cells from tumor necrosis 
factor-alpha-induced apoptosis (Deshpande et al., 2000) and promotes COS7 cell 
survival by the activation of phosphatidylinositol 3-kinase (PI3K) and Akt (Murga et 
al., 2002).  
Structure of Rac1 
The Rho family are monomeric globular proteins consisting of less than 300 
amino acids (Wennerberg and Der, 2004). Like all members of the Rho family, Rac1 
functions as a conformational switch by cycling active GTP and inactive GDP-bound 
forms. Rho GTPases share a common GTPase domain, which carries out the basic 
function of nucleotide binding and hydrolysis. The GTPase domain consists of a 
six-stranded β-sheet surrounded by α-helices (Vetter and Wittinghofer, 2001). Most 
typical Rho proteins consist only of the GTPase domain and short N- and C-terminal 
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extensions. C-terminal post-translational modifications such as isoprenoid addition 
facilitate specific subcellular location and association with specific membranes, which 
is crucial for their function (Wennerberg and Der, 2004). The differences between the 
GDP- and GTP- bound structural forms of RhoA are confined primarily to two 
segments, referred to as switch I and switch II, and this feature is probably shared by 
all Rho GTPases (Ihara et al., 1998, Vetter and Wittinghofer, 2001). 
Bearing five glutamine residues in the amino acid sequence (Matos et al., 2000), 
Rac1 might serve as a suitable substrate of TGases. The transamidation of primary 
amines to RhoA and Rab4 by TGases renders these small G proteins constitutively 
active (Walther et al., 2003, Guilluy et al., 2007). Similarly, post-translational 
modifications, such as transamidation and phosphorylation of Rac1 may affect its 
ability to interact with regulatory proteins (e.g. GAPs, GEFs and GDIs) or to convert 
GTP back to GDP, resulting in increased activation of Rac1 and stimulation of its 
signaling cascade in the cells.  
The Conserved Domain Database (CDD) (http://www.ncbi.nlm.nih.gov/ 
entrez/query.fcgi? db=cdd) provides an interactive tool to identify conserved domains 
present in protein sequences. The residues, which regulate Rac1 activity after 
post-translational modifications, are most likely to be located at GTP/Mg2+ binding 
sites, and GAPs, GEFs and GDIs interaction sites in the Rac1 sequence. Two 
glutamine residues (Q61, Q74) and three lysine residues (K5, K16, and K116), 
potential tagets of TGase-catalyzed modification, are identified within these 
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activity-related domains using CDD search of the Rac1 sequence (PSSM-Id: 57957). 
In line with this finding, it has been reported that site-specific deamidation of a Gln 
residue in the Rho family of G proteins (Q61 in Rac and Cdc42, Q63 in RhoA) by 
CNF-1 inhibits both intrinsic and GAPs-stimulated GTP hydrolysis activity, resulting 
in constitutive activation of these proteins (Flatau et al., 1997, Schmidt et al., 1997). 
CNF-1 has also been shown to possess in vitro TGase activity. In the presence of 
primary amines, RhoA is transamidated in vitro at Q63 by CNF-1 and at positions 52, 
63 and 136 by guinea pig liver TGase (Schmidt et al., 1998). Similarly, in addition to 
Q61 which is critical in regulating Rac1 activity, the other four glutamine residues in 
Rac1 may also be modified by TGase.  
Calmodulin (CaM) 
The other regulator molecule of TGase that will be focused on this dissertation is 
CaM. It is a 17 kDa, dumbbell shaped, Ca2+ binding protein that is ubiquitously 
expressed in cells (Babu et al., 1985). There are two EF hand motifs at each end of its 
dumbbell-like structure, separated by a helical linker region. The C-terminal EF hand 
motifs have three to five fold higher affinity for Ca2+ than those in the N-terminal 
(Chin and Means, 2000). Upon Ca2+ binding to the EF hand motifs, both N-terminal 
and C-terminal domains adopt an open confirmation, exposing hydrophobic surfaces, 
which then interact with a variety of proteins triggering events such as the release of 
autoinhibitory domains (for CaM-dependent kinases and calcineurin), active site 
remodeling (anthrax adenylyl cyclase), and CaM-induced dimerization of membrane 
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proteins (Bachs et al., 1994, Hoeflich and Ikura, 2002). However, CaM can interact 
with target proteins in both Ca2+ dependent as well as independent manners. In the 
absence of Ca2+, the N-terminal domain adopts a closed confirmation whereas the 
C-terminal domain is in a semi-open state with partial exposure of a hydrophobic 
patch. Thus the C-terminal domain of CaM could interact with target proteins even in 
the absence of Ca2+ (Swindells and Ikura, 1996).  
The temporal and spatial associations between changes in Ca2+ and the function of 
CaM have been identified in numerous studies. Changes in intracellular Ca2+ 
concentration induce dynamic compartmentalization and mobilization of CaM 
including translocation from the cytosol to the nucleus (Luby-Phelps et al., 1995, 
Deisseroth et al., 1998, Craske et al., 1999). CaM activation is coupled to elevation in 
intracellular Ca2+ and also correlates with the spatial pattern of increased Ca2+ (Hahn et 
al., 1992). 
CaM not only acts as a ubiquitous transducer of intracellular Ca2+ signals but also 
modulates intracellular Ca2+ concentrations. CaM can act as intracellular Ca2+ buffer, 
regulate the plasma membrane Ca2+ ATPase, ryanodine receptors, IP3 receptors and 
cyclic nucleotide gated Ca2+ channels (Baimbridge et al., 1992, Liu et al., 1994, Patel et 
al., 1997, Balshaw et al., 2001). 
Various downstream substrates of CaM have been studied extensively and the 
studies presented here focus on delineating the role of Ca2+/CaM in regulation of 
TGase-catalyzed transamidation activity. CaM increased TGase activity in human 
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erythrocyte (Billett and Puszkin, 1991), platelets and chicken gizzard (Plank et al., 
1983). In the presence of CaM, TGases are activated at lower Ca2+ concentrations than 
the concentration that is normally needed for activation (Billett and Puszkin, 1991). In 
cells transfected with TGase2 and mutant htt, CaM co-immunoprecipitates with both 
TGase2 and mutant htt. A CaM inhibitor can decrease TGases-catalyzed cross-linking 
of htt (Zainelli et al., 2004). Furthermore, fluorescence confocal microscopy 
demonstrated that CaM colocalizes with TGase2 and with htt in HD intranuclear 
inclusions (Zainelli et al., 2004), suggesting that CaM may play a pivotal role in HD. 
Pathological role of TGases in neurodegenerative diseases 
Protein aggregation and inclusion bodies are the common features of several 
neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, and 
Huntington’s disease. Selkoe and colleagues were the first to propose the role for 
TGases in neurodegeneration. They demonstrated that TGases could catalyze the 
formation of insoluble polymers composed of human neurofilament proteins by 
forming covalently crosslink (Selkoe et al., 1982). Increasing evidence suggests 
TGases may be involved in protein aggregation in those neurodegenerative diseases 
(Ross and Poirier, 2004, Muma, 2007). 
Alzheimer’s disease (AD) and TGase  
Neurofibrillary tangles (NFTs), deposits of tau filaments in the neuronal cell 
body, are one of the most important pathologic characteristics of AD. Numerous 
groups have shown that tau is cross-linked by TGases in vitro, forming insoluble 
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filamentous polymers (Dudek and Johnson, 1993, Appelt and Balin, 1997, Murthy et 
al., 1998, Norlund et al., 1999). In post-mortem studies, it has been reported that 
TGase2 colocalizes with paired helical filaments (PHFs), which are composed of tau, 
in AD brain (Appelt et al., 1996). Our laboratory and others further demonstrated that 
PHF-tau from AD brain contains TGase-catalyzed gamma-glutamyl-lysine 
isodipeptide bonds (Norlund et al., 1999), and there is extensive co-localization of 
TGase-catalyzed isodipeptide bonds and PHF-tau (Citron et al., 2002, Singer et al., 
2002), providing circumstantial evidence for the involvement of TGases in AD 
pathology. Moreover, PHF-tau co-localizes with TGase-catalyzed cross-links in brain 
regions devoid of NFT in stage II AD, which would be expected to contain them in 
stage III, suggesting TGase as a contributing factor in NFT formation induces tau 
cross-links in an early stage of AD (Singer et al., 2002). 
Furthermore, TGase protein expression and cross-linking activity are 
increased in AD brain and cerebrospinal fluid (CSF) as compared to controls (Kim et 
al., 1999, Bonelli et al., 2002). Interestingly, TGase activity are only increased in the 
brain regions with abundant neurofibrillary pathology, but not in the cerebellum, a 
region spared of NFT pathology (Johnson et al., 1997). 
Parkinson's disease (PD) and TGases  
Multiple lines of evidence suggest that TGase-catalyzed bonds are associated 
with Lewy bodies, the major inclusion body in PD. In vitro and in cell culture, TGase 
is also capable of crosslinking a-synuclein, a major component of Lewy bodies in PD, 
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to form intramolecular cross-links and high molecular weight polymers (Jensen et al., 
1995, Junn et al., 2003). Moreover, Glu79 and Lys80 in a-synuclein have been 
identified as the TGase-reactive residues and Lys80 residue is located in a conserved 
sequence in the synuclein gene family (Jensen et al., 1995). Immunohistochemistry 
studies demonstrate that TGase-catalyzed cross-links are elevated in dopaminergic 
neurons in PD substantia nigra, and co-localize with α-synuclein in Lewy bodies 
(Junn et al., 2003, Andringa et al., 2004). On Western blots, the TGase-catalyzed 
cross-link bond comigrates with α-synuclein from PD substantia nigra (Citron et al., 
2002, Andringa et al., 2004).  
Huntington's disease (HD) and TGase 
HD is an autosomal dominant neurodegenerative disorder characterized by 
cognitive and behavioral disturbance, involuntary movements (chorea), striatal and 
cortical neurodegeneration and neuronal inclusions (Gusella and MacDonald, 2000). 
HD is caused by expansion of CAG repeats in exon1 of HTT gene, which is translated 
into an expanded polyglutamine (polyQ) stretch at the N-terminus of the huntingtin 
protein (htt) (Huntington’s Disease Collaborative Research Group, 1993). 
Consequently, N-terminal proteolytic fragments of mutant htt form intranuclear and 
cytoplasmic aggregates in neurons, the prominent neuropathologic hallmarks of HD. 
This CAG “triplet” is normally repeated about 20 times, but an increase in the number 
of repeats to 40 or more results in the expression of the disease (Duyao et al., 1993, 
Huntington’s Disease Collaborative Research Group, 1993). Additionally, there is an 
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inverse correlation between age of onset of HD symptoms and the number of CAG 
repeats (Duyao et al., 1993). 
Several lines of evidence suggest that TGase may be involved in the 
pathophysiology of HD. It was reported firstly by Cariello and colleagues (Cariello et 
al., 1996)  that TGase activity is above maximum control levels in some HD patients 
and is correlated with the CAG repeat length. In vitro and in cell culture, htt is an 
excellent substrate for TGase (Gentile et al., 1998, Kahlem et al., 1998, Karpuj et al., 
1999). The rate of the cross-linking reaction increases over an order of magnitude 
with repeat lengths of over 40 glutamines. Additionally, TGase-catalyzed 
cross-linking of mutant htt resulted in the formation of htt polymers (Kahlem et al., 
1998). TGase mRNA, protein levels, and activity are selectively elevated in HD 
affected brain regions (Karpuj et al., 1999, Lesort et al., 1999, Lesort et al., 2002, 
Zainelli et al., 2003).  
  TGase has become a therapeutic target for HD in both preclinical experiments 
and clinical trials. Knocking-out TGase2 in an HD transgenic mouse model, R6/1 
mice, results in improved motor performance and increases survival (Mastroberardino 
et al., 2002). R6/2 mice treated with cystamine, a TGase inhibitor, showed extended 
survival, improved body weight and motor performance and delayed 
neuropathological sequela (Dedeoglu et al., 2002, Karpuj et al., 2002a). In the other 
mouse model of HD, the YAC 128 mouse, treatment with cystamine ameliorates 
striatal volume loss and decreases striatal neuronal atrophy (Van Raamsdonk et al., 
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2005). Cysteamine, the dimer of cystamine, is an orphan drug approved for the 
treatment of nephropathic cystinosis in humans. In 2008, researchers at Raptor 
Pharmaceuticals Corp began with Phase II clinical trials of cysteamine for HD.  
Distribution and functions htt protein 
As a 350 kDa protein composed of 3,144 amino acids, htt is expressed 
ubiquitously throughout the body. The highest concentrations are found in the brain 
and testes, with moderate amounts in the liver, heart, and lungs (Walker, 2007). In the 
brain, htt has the highest expression in the neocortex, cerebellar cortex, striatum, and 
hippocampus (Fusco et al., 1999). Although htt is found primarily in the cytoplasm, 
smaller amounts have also be detected in other cellular compartments, including the 
nucleus (Hoogeveen et al., 1993, Kegel et al., 2002)  
Several studies have revealed the role of wildtype htt in development. Complete 
knockout of the mouse Htt gene is embryonic lethal between embryonic days 7.5 and 
8.5 (Duyao et al., 1995, Nasir et al., 1995, Zeitlin et al., 1995).  It was later found 
that htt contributes to the formation of the nervous system. Mice carrying reduced 
levels of wild-type htt display profound malformations of the cortex and striatum 
(White et al., 1997). Several lines of evidence indicate that wild-type htt facilitates 
neuronal survival as well. For example, overexpression of wildtype htt exhibits 
neuroprotection against ischemic injury, excitotoxicity, and caspase activation 
(Rigamonti et al., 2000, Zhang et al., 2003, Leavitt et al., 2006), where as disruption 
of the mouse homologue of HTT gene results in a progressive degenerative neuronal 
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phenotype and sterility (O'Kusky et al., 1999, Dragatsis et al., 2000). Moreover, htt 
may also participate in the regulation of apoptosis, control of BDNF production, 
vesicular and mitochondrial transport, neuronal gene transcription, and synaptic 
transmission (Cattaneo et al., 2005).  
Similar to wildtype htt, mutant htt with expanded polyglutamine stretch is found 
in the cytoplasm as well as the nucleus. In HD, cleavage of the full-length mutant htt 
is critical for the formation of htt-containing aggregates which are a prominent 
pathological feature in neurons in the cortex and striatum (DiFiglia et al., 1997, Sapp 
et al., 1997). Htt has been defined as a caspase substrate with numerous sites for 
specific caspase activity, such as amino acids 552 (caspase 2), amino acids 513, 552, 
530, and 589 (caspase 3), and amino acid 586 (caspase 6) (Wellington et al., 1998, 
Wellington et al., 2000). In HD and in transgenic mouse models, the activity of 
caspases 3 and 9 is increased (Wellington et al., 2000, Zeron et al., 2004) and 
inhibition of caspase 3, 6 or 9 activity decreases toxicity in models of HD (Wellington 
et al., 2000, Tang et al., 2005).  
While mutant htt is primarly cytosolic, the cleavage products of mutant htt, 
N-terminal fragment with the polyglutamine stretch, can translocate into the nucleus 
and mediate toxic functions of htt in HD (Hodgson et al., 1999, Graham et al., 2006). 
Mutant htt can induce neurodegeneration by an apoptotic mechanism in a cell model 
(Saudou et al., 1998). Proteasomal activity is decreased and the proteasome is unable 
to process the polyglutamine repeat in htt-transfected cells and HD knock-in mouse 
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brains (Zhou et al., 2003, Venkatraman et al., 2004), suggesting that mutant htt may 
disturb normal proteasome function. Also, mutant htt appears to interfere with other 
cellular mechanisms such as gene transcription. It has been reported that mutant htt 
causes decreased transcription of the brain-derived neurotrophic factor (BDNF) gene 
(Zuccato et al., 2001), which is is necessary for survival of striatal neurons. cAMP 
response element (CRE)-mediated transcription, which promotes the expression of 
several pro-survival genes, are also impaired by mutant htt (Steffan et al., 2000, 
Wyttenbach et al., 2001).  
Although some evidence suggests that htt-associated toxicity is linked to soluble 
htt and its protein–protein interactions (Petersen et al., 1999), it may also be correlated 
with the formation of toxic aggregate species, which are found in the neuronal 
intranuclear inclusions (NIIs) and cytoplasmic aggregates in the cortex and striatum 
of HD brains (Davies et al., 1997, DiFiglia et al., 1997, Sapp et al., 1997). 
Interestingly, htt-containing aggregates are predominately nuclear in juvenile HD 
cases, while they are mainly localized to the neural processes in adult-onset cases 
(DiFiglia et al., 1997).  
CaM-regulated TGase-modification of htt 
We previously reported that CaM associates with htt and TGase2 as 
demonstrated by coimmunoprecipitation in transfeced cells and fluorescence 
colocalization in intranuclear inclusions in HD brains (Zainelli et al., 2004). CaM has 
been shown to increase TGase activity in different cells and tissues (Puszkin and 
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Raghuraman, 1985, Billett and Puszkin, 1991). Inhibition of CaM results in decreased 
TGase-catalyzed modifications of htt in cells transfected with mutant htt and TGase2. 
Using affinity purification, mutant htt with an expanded glutamine repeat binds to 
CaM with a higher affinity than wild-type htt, suggesting in vivo interaction between 
CaM and htt as well (Bao et al., 1996). These data, along with the observation that 
TGase mRNA, protein, and activity are elevated in HD (Karpuj et al., 1999;Lesort et 
al., 1999;Zainelli et al., 2003), and TGase2 colocalizes with both htt protein and 
TGase-catalyzed cross-links in HD intranuclear inclusions (Zainelli et al., 2003), 
implicate CaM and TGase in htt-aggregate formation in HD (Figure 2). 
Hypothetically, interaction of mutant htt with both CaM and TGase results in an 
increase in TGase-modified htt and consequent htt stabilization and aggregate 
formation. 
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Figure 2. Proposed involvement of TGase and CaM in the formation of htt-containing 
aggregates. When there are more than 35 glutamines (Gln) repeat in mutant htt, 
protein conformation is changed. Some proteases such as caspase 3 and calpain can 
cleave mutant htt and generate a toxic N-terminal htt fragment, which can be 
transported to nucleus and neurites. We propose that N-terminal htt associated with 
CaM at a specific binding domain, and htt were modified by TGase. This modification 
may stabilize htt monomers or polymers and contribute to cytotoxicity and formation 
of htt-containing aggregates. 
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CHAPTER TWO 
 
TRANSGLUTAMINASE-CATALYZED TRANSAMIDATION: A NOVEL 
MECHANISM FOR RAC1 ACTIVATION BY 5-HT2A RECEPTOR 
STIMULATION 
 
(Published in J Pharmacol Exp Ther. 2008; 326(1):153-62) 
 
ABSTRACT 
Transglutaminase (TGase)-induced activation of small G proteins via 5-HT2A 
receptor signaling leads to platelet aggregation (Walther et al., 2003). We hypothesize 
that stimulation of 5-HT2A receptors in neurons activates TGase, resulting in 
transamidation of serotonin to a small G protein, Rac1, thereby constitutively 
activating Rac1. Using immunoprecipitation and immunoblotting, we show that in a 
rat cortical cell line, A1A1v cells, serotonin increases TGase-catalyzed transamidation 
of Rac1. This transamidation occurs in both undifferentiated and differentiated cells. 
Treatment with a 5-HT2A/2C receptor agonist, 2,5-dimethoxy-4-iodoamphetamine 
(DOI), but not the 5-HT1A receptor agonist, 5-hydroxy-2-dipropylamino tetralin 
(DPAT), increases transamidation of Rac1 by TGase. In A1A1v cells, 5-HT2A 
receptors mediate the transamidation reaction since expression of 5-HT2C receptors 
was not detectable and the selective 5-HT2A receptor antagonist blocked 
transamidation. Time course studies demonstrate that transamidation of Rac1 is 
significantly elevated after 5 and 15 minutes of serotonin treatment, but returns to 
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control levels after 30 minutes. The activity of Rac1 is also transiently increased 
following serotonin stimulation. Inhibition of TGase by cystamine or siRNA reduces 
TGase-modification of Rac1 and cystamine also prevents Rac1 activation. Serotonin 
itself is bound to Rac1 by TGase following 5-HT2A receptor stimulation as 
demonstrated by co-immunoprecipitation experiments and a dose-dependent decrease 
of serotonin-associated Rac1 by cystamine. These data support the hypothesis that 
Rac1 activity is transiently increased due to TGase-catalyzed transamidation of 
serotonin to Rac1 via stimulation of 5-HT2A receptors. Activation of Rac1 via TGase 
is a novel effector and second messenger of the 5-HT2A receptor signaling cascade in 
neurons. 
 
INTRODUCTION  
      5-HT2A receptors are G-protein coupled receptors which are widely expressed 
in the brain, peripheral vasculature, platelets and skeletal muscle. 5-HT2A receptors 
are involved in diverse physiological functions, from platelet aggregation to 
neuroendocrine release (Van de Kar et al., 2001, Walther et al., 2003). 
Pathophysiologically, 5-HT2A receptor signaling is implicated in a number of 
disorders including hypertension, atherosclerosis, anxiety and depression (Roth, 1994, 
Weisstaub et al., 2006). The classical signal transduction pathway of 5-HT2A receptors 
is Gq/11-coupled activation of phospholipase C (PLC) (Sanders-Bush et al., 2003), 
which hydrolyzes phosphatidylinositol 4,5-bisphosphate to inositol 
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1,4,5-trisphosphate (IP3) and diacyglycerol. IP3 mobilizes calcium from the 
endoplasmic reticulum and thereby increases intracellular Ca2+ (Julius, 1991). 
      TGases (EC 2.3.2.13) are a family of Ca2+-dependent enzymes. Once activated, 
TGases can catalyze the cross-linking of proteins via the γ-carboxamide group of 
peptide-bound glutamine and the є-amino group of peptide-bound lysine, forming an 
inter- or intramolecular isodipeptide bond (Griffin et al., 2002). TGases can also 
covalently link biogenic amines and polyamines, such as serotonin or spermine, to a 
peptide-bound glutamine residue in a transamidation reaction (Folk et al., 1980, Dale 
et al., 2002). In platelets, activation of 5-HT2A receptors stimulates TGase-catalyzed 
transamidation of serotonin to small G proteins, such as RhoA and Rab4, rendering 
them constitutively active (Walther et al., 2003). Furthermore, neuronal differentiation 
of SH-SY5Y cells induced by retinoic acid increases the expression/activation of 
TGases, resulting in transamidation of putrescine to RhoA and activation of RhoA 
(Singh et al., 2003).    
      Rac1 belongs to the Rho family of small G proteins, a subgroup of the Ras 
superfamily. Members of the Rho family (e.g. RhoA, Rac1, Cdc42) are associated 
with a wide array of cellular processes such as cytoskeletal organization, vesicular 
transport, cell cycle progression, cell adhesion and migration, neuronal differentiation 
and a variety of enzymatic activities (Etienne-Manneville and Hall, 2002, Burridge 
and Wennerberg, 2004). Like other small G proteins, Rac1 functions as a molecular 
switch which cycles between two conformational states: a GTP-bound, active state 
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and a GDP bound, inactive state. The GTP/GDP cycling is controlled by many 
regulator molecules such as GTPase-activating proteins (GAPs), guanine nucleotide 
exchange factors (GEFs) and GDP dissociation inhibitors (GDIs) (Hakoshima et al., 
2003). Post-translation modification of Rac1 in the regulator-interaction sites or in the 
GTP-hydrolyzing domain may have an enormous effect on its activation cycle. 
Bearing five glutamine residues in the amino acid sequence (Matos et al., 2000), Rac1 
might serve as a suitable substrate of TGases resulting in the transamidation of 
primary amines to Rac1 and rendering this small G protein constitutively active. 
      A1A1v cells derived from embryonic rat cortex (Scalzitti et al., 1998) provide 
an excellent experimental model to study 5-HT2A receptor signaling. In the present 
study, we use A1A1v cells to test whether 5-HT2A receptor stimulation increases 
TGase-catalyzed transamidation and activation of Rac1 since they endogenously 
express 5-HT2A/1A receptors, Gαq/11, PLC β, TGase 2, the serotonin transporter, and 
small G proteins including Rac1, RhoA and Cdc42. 
 
MATERIALS AND METHODS 
Cell Culture  
A1A1v cells, a rat cortical cell line, were grown on 100 mm2 plates coated with 
poly-L-ornithine (Sigma, St Louis, MO) and maintained in 5% CO2 at 33°C, in 
Dulbecco’s modified Eagle medium (DMEM) (Fisher Scientific, Pittsburgh, PA) 
containing 10% fetal bovine serum (FBS) (Fisher Scientific, Pittsburgh, PA). Cells 
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were induced to differentiate by incubation at 37°C for 4 days. Before each 
experiment, cells were maintained in DMEM with 10% charcoal-treated FBS for 48 
hours. Charcoal adsorption removes most but not all serotonin in the medium. The 
maximal final concentration of serotonin in the medium is approximately 3 nM 
(Unsworth and Molinoff, 1992). Cells from passages 8-15 were used for all 
experiments.  
Drugs 
The following drugs were used in this study: (-)-1-(2,5-dimethoxy-4- 
lodophenyl)-2-aminopropane HCl (DOI) and serotonin (Sigma, St Louis, MO). 
(R)-(+)-8-hydroxy-2-dipropylamino tetralin hydrobromide (DPAT) (Tocris, Ellisville, 
MO). 2-aminoethyl disulfide dihydrochloride (cystamine) (MP biomedicals, Costa 
Mesa, CA). α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine 
methanol (MDL 100907) (a gift from Hoechst Marion Roussel Research Institute, 
Cincinnati, OH). Serotonin was dissolved in 10 µM HCl and MDL 100907 was 
dissolved in a minimal volume of Dimethyl sulfoxide (DMSO) then diluted with 
saline. The remaining drugs were dissolved in purified water. All compounds were 
further diluted (at least 1:100) in cell culture media before they were applied to the 
cells and washed away prior to lysing the cells. 
Immunoprecipitation of TGase-modified Protein  
A1A1v cells were harvested and lysed using lysis buffer A (25 mM Tris-HCl, pH 7.5, 
250 mM NaCl, 5 mM EDTA, 1% Triton X-100 and 1:1000 protease inhibitor cocktail 
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(Sigma, St Louis, MO) containing 104 µM AEBSF, 0.08 µM aprotinin, 2 µM 
leupeptin, 4 µM bestatin, 1.5 µM pepstatin A and  1.4 µM E-64). Protein 
concentration was determined using the BCA Protein Assay kit (Pierce, Rockford, IL). 
Immunopurification of proteins containing TGase-catalyzed bonds was performed 
using 81D4 mAb (mouse IgM) prebound to Sepharose beads (Covalab, Lyon, France) 
using a protocol developed by Covalab and as described previously (Norlund et al., 
1999, Zainelli et al., 2005). The 81D4 antibody is well characterized and has been 
previously shown to be specific for the N epsilon-(gamma-L-glutamy)-L-lysine 
isopeptide and N epsilon-(gamma-L-glutamy)-L-lysine isopeptide cross-link 
generated by TGase (Sarvari et al., 2002, Thomas et al., 2004). The 81D4 antibody 
has been extensively used to demonstrate increases in TGase-catalyzed bonds (Citron 
et al., 2002, Junn et al., 2003, Andringa et al., 2004). The use of the 81D4 antibody in 
a competitive ELISA assay was shown to result in isodipeptide cross-link 
measurements that correlate well to those measured by HPLC analysis but provide 
more sensitivity than the HPLC approach (Sarvari et al., 2002). Transfection of cells 
to over-express TGases, including TGase 1, 2 and 3, and a substrate protein such as 
mutant huntingtin protein results in increased presence of the isodipeptide cross-link 
in mutant huntingtin protein as demonstrated with immunoprecipitation with the 81D4 
antibody (Zainelli et al., 2005).  
Briefly, 20µl of sepharose-81D4 beads were washed three times in TBS/0.1% 
Tween 20 with gentle shaking for 15 minutes, followed by adding 200µg cell lysate (1 
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μg/μl) to the washed beads and incubating for 2 hours at 37°C. After incubation, the 
pellets were washed four times in TBS/0.1% Tween 20 for 15 minutes. Then 20µl of 
loading buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 0.1% bromophenol blue, 10% 
glycerol and 5% β-mercaptoethanol) was added to the washed pellets followed by 5 
minutes incubation at 90°C. The samples were then centrifuged at 9,000 × g for 2 
minutes and the supernatant was transferred and stored at -80°C until immunoblot 
analysis. 
Immunoprecipitation of Rac1 
200 µg of protein from each sample was brought up to a total volume of 100 µl with 
IP buffer (50 mM Tris-HCl, pH 7.4, 10 mM EGTA, 100 mM NaCl, 0.5% Triton-X 
100 and 0.1% protease inhibitor cocktail), then the samples were precleared using 
10µl of recombinant protein G (rProtein G) agarose (Invitrogen, Carlsbad, CA) for 1 
hour. The samples were centrifuged at 9,000 × g for 10 minutes and the supernatant 
was incubated for 1.5 hour at 4ºC with either 2 µg of Rac1 antibody (Upstate, Lake 
Placid, NY) or 2 µg of normal mouse IgG (Santa Cruz, Santa Cruz, CA) as a control 
for non-specific binding. The immuno-complexes were precipitated using 20 µl of 
rProtein G agarose at 4ºC for 1 hour. The agarose-immuno complexes were washed 
three times in IP buffer and centrifuged after each wash at 100 × g for 3 minutes. After 
the last wash, bound proteins were eluted by adding 2× PAGE sample buffer and 
heating for 5 minutes at 90ºC. The samples were centrifuged at 13,000 × g for 5 
minutes and the supernatant was transferred and stored at -80°C until immunoblot 
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analysis. 
Immunoblot  
Immunoaffinity purified proteins and cell lysates were separated on 12% 
SDS-polyacrylamide gels and then electrophoretically transferred to nitrocellulose 
membranes. Membranes were then incubated in blocking buffer (5% non-fat dry milk, 
0.1% Tween 20, 1× TBS) for 1 hour at room temperature. Membranes were incubated 
overnight at 4°C with primary antibodies on a shaker.  Primary antibodies (Upstate 
Biotechnology, NY: anti-Rac1, mouse IgG, 1:700; anti-Na+/K+ ATPase, mouse IgG, 1: 
10000; Abcam, Cambridge, MA: anti-serotonin, rabbit IgG, 1:1000; BD Pharmingen, 
San Jose, CA: anti-5-HT2C receptor, mouse IgG, 1:300; Cell Signaling, Danvers, MA: 
anti-phosphorylated ERK1/2 at residues Thr202/Tyr204, mouse IgG, 1:1,000; 
anti-ERK1/2, rabbit IgG, 1:1,000; MP Biomedicals, Aurora, OH: anti-actin, mouse 
IgG, 1:20,000; CovalAb, Lyon, France: 81D4, mouse IgM, 1: 500; NeoMarkers, 
Fremont, CA: TG100, mouse IgG, 1:100) were diluted in antibody buffer (1% non-fat 
dry milk, 0.1% Tween 20, 1× TBS). The next day, membranes were washed with 
TBS/0.1% Tween 20 and then incubated with goat-anti-mouse or goat-anti-rabbit 
secondary antibody conjugated to HRP (Jackson ImmunoResearch, West Grove, PA) 
diluted in antibody buffer. Membranes were washed and signal was detected using 
enhanced chemiluminescence (ECL) western blotting detection reagents (Amersham 
Biosciences, Piscataway, NJ). Using Scion Image for Windows (Scion, Frederick, 
MD), immunoblots were quantified by calculating the integrated optical density (IOD) 
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of each protein band on the film.  
Expression and Purification of Glutathione S-Transferase (GST)-PAK1 
The pGEX-2T plasmid was used to express Rac1 interactive domain of human PAK1 
(residues 51–135) fused to GST. The BL21 (DE3) E. coli (Invitrogen life technologies, 
Carlsbad, CA) were transformed with plasmid expressing GST-PAK1 and grown 
overnight at 37°C on LB-ampicillin plates. Then a single colony was used to inoculate 
25ml LB-ampicillin (100 µg/ml) which was shaken overnight at 37°C. 10 ml of the 
overnight culture was used to inoculate 500ml LB-ampicillin which was grown for 3 
h at 37°C while shaking. After induction with 0.4 mM isopropyl 
β-D-1-thiogalactopyranoside (IPTG) for 2 h at 30-32ºC, bacteria were lysed in lysis 
buffer B (50 mM Hepes, pH 7.6, 1% Triton X-100, 100 mM NaCl, 5 mM MgCl2, 10% 
glycerol, 1 mM PMSF and 0.1% protease inhibitor cocktail). The lysates were 
sonicated and centrifuged for 15 minutes at 9,000 × g at 4ºC. Then the supernatant 
was added to glutathione-Sepharose 4B (Amersham Biosciences, Piscataway, NJ) and 
the mixture was incubated at 4ºC for 2 hours. The beads were then centrifuged at 4ºC 
at 2,000 × g and were washed four times with lysis buffer B. The beads were 
resuspended in lysis buffer B and were stored at -80ºC for at most two weeks. 
Rac1 Activity Assay  
A1A1v cells were treated for 5 or 15 minutes with 14 µM serotonin or vehicle (10 µM 
HCl). The cells were harvested in lysis buffer C (50 mM Tris–HCl, pH 7.4, 100 mM 
NaCl, 10 mM MgCl2, 1% Triton X-100, 0.1% SDS, 1 mM PMSF and 0.1% protease 
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inhibitor cocktail). Cell lysates were centrifuged at 14,500 × g for 20 minutes at 4°C 
and 200 µl of the supernatant was incubated with 20 µl of GST-PAK1-Sepharose 
beads for 40 minutes at 4°C under constant agitation. The beads were washed three 
times with lysis buffer C, and 2× Laemmli sample buffer was added to the washed 
beads followed by 5 minutes incubation at 90°C. The samples were then centrifuged 
at 9,000 × g for 2 minutes and equivalent amounts of proteins in the supernatants 
were loaded on 12% SDS-PAGE as well as 20 µg cell lysates (in order to detect total 
Rac1 protein levels), followed by immunoblot analysis as described above. 
Small Interfering RNA 
To induce TGase2 gene silencing, two siRNA duplexes to target the coding sequence 
of rat TGase2 mRNA were designed and synthesized by QIAGEN (Germantown, 
MD). The target sequence is 5’-AAGAGCGAGATGATCTGGAAT-3’ for siRNA1 
and is 5’- AGAGCCAACCACCTGAACAAA-3’ for siRNA2. The sense strand of 
each siRNA was labeled at 3' end with Alexa Fluor 488 to monitor transfection 
efficiency. At 30~50% confluence, A1A1v cells were transfected with siRNA at a 
final concentration of 90 nM using Lipofectamine™ 2000 (Qiagen, Germantown, MD) 
according to the manufacturer’s instructions. 24 hours after transfection, siRNA-lipid 
complexes were removed by changing medium. Transfection efficiency was assessed 
based on the percentage of fluorescent cells observed under Nikon Eclipse TE 2000U 
microscopy. 48 hours after transfection, cells were stimulated with DOI or vehicle for 
5 minutes, and then cell lysates were collected to measure TGase2 expression and 
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TGase-modified Rac1 by immunoblot and immunoprecipitation. Cells incubated with 
Lipofectamine™ 2000 alone were used as the nontransfected control.  
Statistical Analyses 
All data are presented as group mean ± the standard error of the mean (SEM) and 
analyzed by one-way or two-way ANOVA. Post hoc tests were conducted using 
Newman-Keuls Multiple Comparison Test. SYSTAT 11 (Systat Software, Inc., San 
Jose, CA) and GraphPad Prism 5.0 (GraphPad Software, Inc., San Diego, CA) were 
used for all statistical analyses. A probability level of p<0.05 was considered to be 
statistically significant for all statistical tests. 
 
RESULTS 
Serotonin treatment induces Rac1 transamidation in A1A1v cells 
In order to determine whether TGase-catalyzed transamidation of Rac1 is increased 
after serotonin treatment, we treated A1A1v cells with 14 µM serotonin for 5, 15 or 
30 minutes. The transamidation of Rac1 is significantly elevated after 5 or 15 minutes 
of serotonin treatment by approximately 2~2.5 fold as compared to vehicle 
(HCl)-treated cells (Fig. 3). However, there is no significant difference in the amount 
of TGase-modified Rac1 in cells treated with serotonin for 30 minutes as compared to 
vehicle-treated cells (Fig. 3A, B). 
5-HT2A receptor stimulation increases the transamidation of Rac1  
In order to explore the serotonin receptor specificity for induction of TGase-catalyzed 
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transamidation, A1A1v cells were stimulated with 14 µM serotonin, 3 µM DOI 
(5-HT2A/2C receptor agonist), 10 nM DPAT (5-HT1A receptor agonist) or 10 µM HCl 
(vehicle) for 15 minutes. Treatment with serotonin or DOI significantly (p<0.05) 
increases the amount of TGase-modified Rac1 2-fold as compared to vehicle-treated 
cells, whereas treatment with DPAT has no effect on the amount of TGase-modified 
Rac1 compared to vehicle-treated cells (Fig. 4A, B). Expression of 5-HT2A receptors 
in A1A1v cells has been previously confirmed using anti-sense oligodeoxynucleotide 
strategies and radioligand binding assays (Scalzitti et al., 1998). Here, 5-HT2C 
receptor expression in undifferentiated and differentiated A1A1v cells was examined 
by immunoblot analysis. Choroid plexus tissue from the fourth ventricle of a rat was 
used as a positive control and HEK 293 cell lysates were used as a negative control. 
We found that 5-HT2C receptors are expressed in rat choroid plexus, but 5-HT2C 
receptor expression was not detected in either HEK293 cells or undifferentiated or 
differentiated A1A1v cells (Fig. 4C). To exclude the possibility that the lack of 
involvement of the 5-HT1A receptors in Rac1 transamidation is not due to insufficient 
concentration of DPAT, we treated cells with 14 µM serotonin and increasing 
concentrations of DPAT (1 nM, 10 nM, and 100 nM) for 5 minutes, and then detected 
ERK phosphorylation by immunoblot. Treatment with 14 µM serotonin and 10 nM or 
100 nM DPAT significantly increased phosphorylation of ERK (Fig. 4D, E), 
indicating 10 nM DPAT is enough to activate 5-HT1A receptors in A1A1v cells. To 
further confirm that the effect of DOI on Rac1 transamidation in A1A1v cells is due 
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to stimulation of the 5-HT2A receptors, cells were pretreated with 100 nM MDL 
100907 (a selective 5-HT2A receptor antagonist) for 15 minutes, and then stimulated 
with DOI for 5 minutes. We found the pretreatment of MDL 100907 significantly 
reduced DOI-induced Rac1 transamidation without itself having any effect on Rac1 
transamidation (Fig. 4F). 
DOI increases Rac1 transamidation in both undifferentiated and differentiated 
A1A1v cells  
After differentiation of A1A1v cells, the cytoskeleton undergoes a dramatic 
reorganization and the cells acquire a neuronal-like cell shape with long processes 
similar to axons and dendrites compared to undifferentiated cells (Fig. 5A). Rho 
family GTPases are critical regulators of the actin cytoskeleton organization 
(Etienne-Manneville and Hall, 2002, Burridge and Wennerberg, 2004). This prompted 
us to explore the effects of cell differentiation on Rac1 transamidation stimulated by 
5-HT2A receptor activation. Stimulation of 5-HT2A receptors with DOI increased 
TGase-catalyzed transamidation of Rac1 in both undifferentiated and differentiated 
cells (Fig. 5B). Treatment with DOI in A1A1v cells significantly increased the amount 
of TGase-modified Rac1 by approximately 2~2.5 fold as compared to vehicle-treated 
cells (p<0.01). In vehicle-treated groups, the amount of TGase-modified Rac1 in 
differentiated cells was similar to the amount in undifferentiated cells, indicating that 
cell differentiation has no effect on basal level of Rac1 transamidation. Although the 
amount of TGase-modified Rac1 in DOI-treated differentiated cells was increased 
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compared to DOI-treated undifferentiated cells, this increase was not significant, 
suggesting that cell differentiation also does not have a significant effect on 
DOI-induced transamidation of Rac1 (Fig. 5C). 
The activity of Rac1 is transiently increased following serotonin stimulation 
Racl is GDP-bound in the inactive state and GTP-bound when activated. Activated 
Rac1 binds to its downstream effectors such as PAK1, therefore a GST-PAK1 fusion 
protein purified from E. coli was used to determine if serotonin stimulation increases 
the activated from of Rac1. A1A1v cells were treated with serotonin for 5 or 15 
minutes, the cells were harvested and cell lysates were incubated with GST-PAK1 
prebound to glutathione-Sepharose beads. Then equivalent amounts of the purified 
proteins were resolved by SDS-PAGE. Immunoblot analysis was performed using an 
antibody against Rac1. As shown in Fig. 6, the activity of Rac1 is increased by 80 
percent after 5 minutes of serotonin treatment, but returns back to baseline after 15 
minutes in the presence of serotonin, indicating that Rac1 becomes transiently 
activated after serotonin treatment in A1A1v cells. In addition, there is no significant 
change in the total amount of Rac1 in the cell lysate after serotonin treatment (Fig. 
6A), suggesting that the activity increase is not due to synthesis of new Rac1.  
TGase inhibition reduces Rac1 transamidation and activity 
The activity of Rac1 is under the direct control of a large set of regulatory proteins. To 
exam whether the serotonin-stimulated increase of Rac1 activity is due to 
TGase-catalyzed transamidation, A1A1v cells were treated with increasing 
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concentrations (0 µM, 100 µM, 500 µM and 1000 µM) of the TGase inhibitor, 
cystamine, for 1 h, followed by treatment with 14 µM serotonin for 5 minutes. 
Precipitation of TGase-modified proteins and the activated Rac1 were performed as in 
previous experiments. Then immunopurified proteins and activated Rac1 were 
examined on immunoblots using anti-Rac1 and 81D4 antibodies. We found that 
pretreatment with cystamine significantly decreases Rac1 transamidation (Fig. 7) and 
activity (Fig. 8) in a dose-dependent manner. Treatment with 100 µM, 500 µM or 
1000 µM of cystamine decreases the amount of TGase-modified Rac1 by 
approximately 50%, 70% or 80%, respectively, as compared to untreated cells (Fig. 
7A, C). A similar dose-dependent decrease in TGase-modified Rac1 was also 
observed when cells were treated with serotonin for 15 minutes following cystamine 
inhibition (data not shown). Treatment with 500 µM or 1000 µM of cystamine 
decreases the amount of activated Rac1 by approximately 20% or 40%, respectively, 
as compared to untreated cells (Fig. 8A, C). These results indicate that 
TGase-catalyzed transamidation of Rac1 contributes to the increase in Rac1 activity 
upon serotonin stimulation. The ubiquitously expressed Na+/K+ ATPase is a 
well-established plasma membrane marker and its function underlies essentially all of 
mammalian cell physiology (Kaplan, 2002). In order to verify that the dose-dependent 
decrease of Rac1 transamidation and activation was not due to cystamine-induced 
total Rac1 reduction or cellular toxicity, cell lysates from the same experiment were 
examined on western blots with antibodies for Rac1 or Na+/K+ ATPase. There is no 
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significant difference in total Rac1 or Na+/K+ ATPase levels between 
cystamine-treated and untreated cells, indicating that the concentrations of cystamine 
were not toxic to the cells (Fig. 7B, 8B).  
Next, a second and more specific approach was used to determine the 
significance of TGase in Rac1 transamidation; we designed two siRNA duplexes to 
inhibit endogenous TGase expression. Several isoenzymes of TGase are found in the 
brain, of which TGase2 is the most abundant, therefore siRNAs were developed to 
silence rat TGase2 gene. At 24 hours post-transfection, transfection efficiency of both 
siRNA reached about 90%. 48 hours after transfection, siRNA1 and siRNA2 
transfection of A1A1v cells resulted in 95% and 65% down-regulation of TGase2 
protein expression, respectively (data not shown). Reprobing of membrane with 
anti-Rac1 antibody revealed that neither siRNA changed Rac1 protein level, 
indicating no off-target effect on Rac1 (Fig. 9A). DOI induced TGase-modification of 
Rac1 was significantly reduced by knocking down TGase2 expression with siRNA1 
or siRNA2. As compared to DOI-stimulated nontransfected cells, siRNA1 and 
siRNA2 transfection caused 70% and 30% decreases in TGase-modified Rac1 
responding to DOI, respectively (Fig. 9B, C). These results confirm that 5-HT2A 
receptor-mediated Rac1 transamidation is dependent on TGase2 expression in A1A1v 
cells. 
TGase-mediated transamidation of serotonin to Rac1 
TGase-modified Rac1 did not show a significant upward shift on immunoblots 
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compared to native Rac1 in cell lysates (data not shown), indicating that the molecular 
weight of Rac1 does not significantly increase after modification by TGase. Therefore, 
a small amine such as serotonin is most likely incorporated into Rac1 upon 
stimulation of 5-HT2A receptors. To test this hypothesis, we stimulated A1A1v cells 
with serotonin or vehicle for 5 minutes then cells were harvested and cell lysates were 
used to immunoprecipitate Rac1 with an anti-Rac1 antibody, or immunoprecipitate 
TGase-modified proteins with the 81D4 antibody. The immunopurified proteins were 
examined on immunoblots using antibodies directed against serotonin. 
Immunoprecipitation of Rac1 and probing for serotonin reveals an association 
between Rac1 and serotonin in A1A1v cells (Fig. 10A). However we were unable to 
detect serotonin in TGase-modified proteins (Fig. 10A). This may be due to a 
compromise of the serotonin antibody epitope during the immunoprecipitation of 
TGase-modified proteins, since this procedure uses higher temperatures and longer 
incubation times compared to the Rac1 immunoprecipitation procedure. Therefore in 
order to confirm that serotonin is associated with Rac1 by a TGase-catalyzed covalent 
bond, we treated cells with increasing concentrations (0 μM, 100 μM, 500 μM, 1000 
μM) of cystamine for 1 hour followed by stimulating the cells with serotonin for 5 
minutes. Then we immunoprecipitated Rac1 and detected associated serotonin by 
immunoblot, as described above. We found that treatment with cystamine decreases 
the serotonin-associated Rac1 in a dose-dependent manner (Fig. 10B, D), thus 
supporting the hypothesis that serotonin is incorporated into Rac1 by a 
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TGase-catalyzed covalent bond. To compare the effects of different agonists on the 
incorporated serotonin, cells were exposed to either serotonin or DOI for 5 min. Then 
Rac1 was immunoprecipitated and the incorporated serotonin was detected by 
immunoblot. There was no significant difference in serotonin incorporation between 
serotonin and DOI-treated cells. Pretreatment with cystamine also inhibited 
DOI-induced serotonin incorporation (Fig. 11).  
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Fig.3 Serotonin-induced increase of Rac1 transamidation in A1A1v cells. (A) After 5, 
15 or 30 minutes of 14 µM serotonin treatment, TGase-modified proteins were 
immunoprecipitated with 81D4 antibody coupled to sepharose. TGase-modified Rac1 
was then detected on immunoblots with anti-Rac1 antibody. (B) Quantitation of 
immunoblots for 3 separate experiments. Data shown are the mean IOD ± SEM and 
normalized to vehicle-treated control levels. One-way ANOVA (F(3,8)=7.31, p<0.05) 
indicates a significant difference among groups. Newman-Keuls Multiple Comparison 
Test indicates p<0.05* as compared to vehicle treatment.    
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Fig. 4 Serotonin receptor specificity on induction of Rac1 transamidation in A1A1v 
cells. (A) Cells were stimulated with 14 µM serotonin, 3 µM DOI (5-HT2A/2C receptor 
agonist), 10 nM DPAT (5-HT1A receptor agonist) or vehicle for 15 minutes. 
TGase-modified Rac1 was detected by immunoprecipitation and immunoblot analysis. 
(B) Quantitation of immunoblots for 3 separate experiments. Data shown are the 
mean IOD ± SEM and normalized to vehicle-treated control levels. One-way ANOVA 
(F(3,8)=10.05, p<0.01) indicates a significant difference among various treatments. 
Newman-Keuls Multiple Comparison Test indicates p<0.05* as compared to vehicle 
treatment. (C) Immunoblot analysis of 5-HT2C receptor expression in undifferentiated 
(UD) and differentiated (DI) A1A1v cells. Rat choroid plexus was used as a positive 
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control and HEK 293 cell was used as a negative control. (D) A1A1v cells were 
treated with vehicle, 14 µM serotonin or DPAT (1 nM to 100 nM) for 5 minutes. Cell 
lysates were then resolved by SDS-PAGE, followed by immunoblotting with an 
anti-phosphorylated ERK antibody. Equal loading was verified by reprobing the same 
membrane with antibodies to total ERK and actin. (E) Quantitation of immunoblots 
for 3 separate experiments. Data shown are the mean IOD ± SEM and normalized to 
serotonin-treated control levels. Each phospho-ERK value was normalized using the 
corresponding total ERK value to control for the possibility of differential loading. 
One-way ANOVA (F(4,10)=18.12, p<0.001) indicates a significant difference among 
various treatments. Newman-Keuls Multiple Comparison Test *indicates p<0.05 as 
compared to vehicle treatment and #indicates p<0.05 as compared to serotonin 
treatment. (F) Upper, cells were stimulated with vehicle, 14 µM serotonin, 3 µM DOI. 
Some cells were pretreated with 100 nM MDL 100907 prior to treatment with DOI or 
treated with MDL100907 alone. TGase-modified Rac1 was detected by 
immunoprecipitation and immunoblot analysis. Lower, quantitation of immunoblots 
for 3 separate experiments. Data shown are the mean IOD ± SEM and normalized to 
vehicle-treated control levels. One-way ANOVA (F(4,10)=38.96, p<0.001) indicates a 
significant difference among various treatments. Newman-Keuls Multiple 
Comparison Test indicates p<0.05* as compared to vehicle treatment and p<0.05# as 
compared to DOI treatment. 
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Fig. 5 The effects of cell differentiation on Rac1 transamidation. (A) A1A1v cells 
were incubated at 37°C for 4 days to induce differentiation. Compared to 
undifferentiated cells (left), differentiated cells (right) develop a neuron-like cell 
shape with long neurites. (B) Cells were treated with 3 µM DOI for 15 minutes, 
followed by immunoprecipitation and immunoblot analysis. Stimulation of 5-HT2A 
receptors by DOI increased the TGase-catalyzed transamidation of Rac1 in both 
undifferentiated and differentiated cells. (C) Quantitation of immunoblots for 3 
separate experiments. Data shown are the mean IOD ± SEM and normalized to 
vehicle-treated control levels in undifferentiated cells. Two-way ANOVA indicates a 
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significant main effect of DOI treatment (F(1,8)=49.48, p<0.01). However, there was 
no significant main effect of cell differentiation on TGase-modified Rac1 (F(1,8)=4.07, 
p=0.08). The interaction between DOI treatment and cell differentiation was also not 
significant for TGase-modified Rac1 (F(1,8)=0.34, p=0.58).      Newman-Keuls 
Multiple Comparison Test indicates p<0.01* as compared to vehicle treatment in 
undifferentiated cells, p<0.01# as compared to vehicle treatment in differentiated cells. 
Scale bar, 105 µm. 
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Fig. 6 Rac1 activity was transiently increased after serotonin treatment. (A) Top , 
activated Rac1 was purified using GST-PAK1 coupled to glutathione-Sepharose beads 
and detected on immunoblot with an antibody against Rac1. Middle, the total amount 
of Rac1 in the cell lysates used for pull-down of activated Rac1 was monitored by 
immunoblot. Bottom, Ponceau staining of GST-PAK1 documents equal amounts of 
protein loading in each lane. (B) Quantitation of immunoblot for 3 separate 
experiments. Data shown are the mean IOD ± SEM and normalized to vehicle-treated 
control levels. The two-way ANOVA reveals a significant (F(1,8)=8.64, p<0.05) main 
effect for serotonin treatment, and a significant (F(1,8)=6.32, p<0.05) interaction 
between serotonin treatment and time course. Newman-Keuls Multiple Comparison 
Test indicates p<0.05* as compared to 5 minutes of serotonin treatment.  
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Fig.7 Dose-dependent effects of cystamine on Rac1 transamidation. (A) 
Immunoprecipitation and immunoblot analyses reveal that cystamine causes a 
dose-dependent (100 to 1000 µM) inhibition of the transamidation of Rac1 as 
indicated by less intense bands. (B) Cells lysates from the same experiment were 
examined on immunoblots with antibodies for Rac1 and Na+/K+ ATPase, which 
indicate that cystamine has no effect of on total Rac1 and cell viability, respectively. 
(C) Quantitation of effects of cystamine on Rac1 transamidation in 3 separate 
experiments. Data shown are the mean IOD ± SEM and normalized to untreated 
control levels. One-way ANOVA (F(3,8)=19.41, p<0.001) indicates a significant effect 
of cystamine on Rac1 transamidation. Newman-Keuls Multiple Comparison Test 
indicates p<0.05* as compared to untreated cells.  
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Fig.8 Rac1 activity is inhibited by cystamine. (A) Top , pull-down and immunoblot 
analyses reveal that cystamine causes a dose-dependent (100 to 1000 µM) inhibition 
of the activation of Rac1. Middle, the same membrane was reprobed with antibody 
81D4, directed against TGase-catalyzed covalent bonds. Bottom, Ponceau staining of 
GST-PAK1 (~35 kDa) documents equal amounts of protein loading in each lane. (B) 
Cell lysates from the same experiment were examined on immunoblots with an 
antibody for Na+/K+ ATPase. (C) Quantitation of the effects of cystamine on Rac1 
activation in 3 separate experiments. Data shown are the mean IOD ± SEM and 
normalized to untreated control levels.  One-way ANOVA (F(3,8)=20.94, p<0.001) 
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indicates a significant effect of cystamine on Rac1 activity. Newman-Keuls Multiple 
Comparison Test indicates p<0.05* as compared to untreated cells, p<0.001** as 
compared to untreated cells.  
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Fig.9 Knockdown of TGase2 by siRNAs prevents Rac1 transamidation. (A) Cells 
were incubated with 90nM of TGase2-specific siRNAs for 24 hours, and then treated 
with 3 µM of DOI or vehicle for 5 minutes at 48 hours post-transfection. Immunoblot 
analyses confirmed that transfection of siRNA1 or siRNA2 significantly inhibited 
TGase2 protein expression compared to nontransfected control (NT). The membranes 
were stripped and reprobed with anti-Rac1 and anti-actin antibodies. (B) 
TGase-modified Rac1 was detected by immunoprecipitation and immunoblot analysis. 
DOI induced TGase-modification of Rac1 were significantly decreased in 
siRNAs-transfected cells compared to NT cells. (C) Quantitation of effects of siRNAs 
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on Rac1 transamidation in 3 separate experiments. Data shown are the mean IOD ± 
SEM and normalized to DOI-stimulated nontransfected cells. Two-way ANOVA 
indicates a significant main effect of transfection (F(2,12)=24.68, p<0.0001), a 
significant main effect of DOI treatment (F(1,12)=63.23, p<0.0001) and a significant 
interaction between transfection and DOI treatment (F(2,12)=9.42, p<0.01) on 
TGase-modified Rac1. Newman-Keuls Multiple Comparison Test indicates p<0.01* 
or p<0.001** as compared to vehicle treatment in nontransfected cells, p<0.01# or 
p<0.001## as compared to DOI treatment in nontransfected cells. 
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Fig.10 Transamidation of serotonin to Rac1 is mediated by TGase. (A) 
Immunoprecipitation of Rac1, but not TGase-modified proteins, reveals an 
association between Rac1 and serotonin in A1A1v cells upon 5 minutes of 14 µM 
serotonin stimulation. (B) Immunoprecipitation and immunoblot analysis reveal that 
cystamine causes a dose-dependent (100 to 1000 µM) reduction of the 
serotonin-associated Rac1. Normal mouse IgG is used as a negative control (NC) for 
immunoprecipitation. (C) Cell lysates from the same experiment were examined on 
immunoblots with an antibody for Na+/K+ ATPase, which indicates cystamine has no 
effect of on cell viability. (D) Quantitation of the effects of cystamine on 
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serotonin-induced transamidation of Rac1. Data shown are the mean IOD ± SEM and 
normalized to untreated control levels. One-way ANOVA (F(3,8) = 7.15, p<0.05) 
indicate a significant difference in serotonin-associated Rac1 among cells treated with 
different concentration of cystamine. Newman-Keuls Multiple Comparison Test 
indicates p<0.05* as compared to untreated cells.  
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Fig.11 DOI stimulates transamidation of Rac1 to serotonin to a similar extent as those 
treated with serotonin. (A) Cells were stimulated with vehicle, 14 µM 5-HT or 3 µM 
DOI for 5 minutes. Some cells were pretreated with 500 µM cystamine (Cys) for 1 
hour prior to stimulation with DOI. Transamidation of serotonin to Rac1 was detected 
by immunoprecipitation and immunoblot analysis. (B) Quantitation of immunoblot 
for 3 separate experiements. Data shown are the mean IOD ± SEM and normalized to 
serotonin-treated levels. One-way ANOVA (F(3,8)=19.80, p<0.001) indicates a 
significant difference in Rac1-incorporated serotonin among groups. Newman-Keuls 
Multiple Comparison Test * indicates p<0.05 as compared to vehicle-treated cells and 
# indicates p<0.05 as compared to serotonin-treated cells.  
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DISCUSSION 
      In platelets, 5-HT2A receptor activation causes TGase-catalyzed 
transamidation of RhoA and Rab4, leading to activation of these proteins and platelet 
aggregation (Walther et al., 2003). In aplysia ganglia, serotonin-treatment induces the 
activation of Cdc42 and its downstream effector PAK to regulate the actin 
cytoskeleton (Udo et al., 2005). In the present study, we extend these findings to a rat 
cortical cell model and find that 5-HT2A receptor stimulation increased 
TGase-catalyzed transamidation of Rac1 and Rac1 activity, both of which can be 
suppressed by TGase inhibition. In elucidating the mechanism further, we identify 
serotonin as an amine that becomes transamidated to Rac1 by TGase. Activation of 
Rac1 via TGase is a novel effector and second messenger of the 5-HT2A receptor 
signaling pathway in neurons. 
      To exam the serotonin receptor specificity on induction of Rac1 
transamidation, we treated cells with different serotonin receptor agonists and found 
that the 5-HT2A/2C receptor agonist DOI, but not the 5-HT1A receptor agonist DPAT 
induces a significant increase in TGase-modified Rac1 with a similar magnitude to 
that observed in serotonin-treated cells. Since there is no 5-HT2C receptor expression 
in A1A1v cells and MDL 100907 reversed the effect of DOI on Rac1 transamidation 
(Fig. 4), serotonin or DOI-induced Rac1 transamidation is selectively mediated by 
activation of 5-HT2A receptors in A1A1v cells.  
      Previous studies demonstrated that TGase-mediated transamidation of the Rho 
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family of small G proteins blocked the GTP-hydrolyzing activity of these proteins, 
rendering these small GTPases constitutively active for their respective signaling 
pathways (Masuda et al., 2000, Walther et al., 2003). Based on these results, we 
hypothesized that 5-HT2A receptor-stimulated transamidation of Rac1 by TGase will 
result in prolonged activation of Rac1. Unexpectedly, we found a transient increase in 
both Rac1 activity and TGase-catalyzed transamidation which returned to baseline 
levels following continuous exposure to serotonin (Figs. 3 and 6). The transient 
response may due to selective degradation of transamidated Rac1. Mammalian cells 
contain multiple proteolytic systems for degradation of various classes of intracellular 
proteins. Most abnormal proteins (mutant or misfolded) are degraded in the 
ubiquitin–proteasome pathway. Rac1 is normally a stable protein, but activation by 
cytotoxic necrotizing factor-1 (CNF-1) in rat bladder carcinoma cells (804G) and 
human umbilical vein endothelial cells resulted in increased sensitization to 
ubiquitination and proteasomal degradation (Doye et al., 2002, Munro et al., 2004). 
Further, dominant-positive forms of Rac1 appeared more susceptible to 
ubiquitin-mediated proteasomal degradation compared to both dominant-negative and 
wild-type Rac1(Doye et al., 2002). Activated and transamidated Rac1 may be targeted 
for proteasomal degradation, resulting in transient activation of Rac1. However, there 
is no significant change in total Rac1 protein 15 min after serotonin stimulation (Fig. 
4A), suggesting that activated or transamidated Rac1 may only account for small 
fraction of total Rac1. 
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      In this study, we found differences in the time course for Rac1 transamidation 
and for its increased activity. After serotonin stimulation for 15 minutes, Rac1 activity 
is reduced to baseline (Fig. 6) while TGase-catalyzed transamidation of Rac1 still 
remains at a relatively high level (Fig. 3). These results suggest that transamidation 
may not only occur at the GTPase activity-related residues, but also at residues which 
do not have an effect on Rac1 activity. Essentially, transamidation of Rac1 at some 
sites may induce activation of the small G proteins, while transamidation at other sites 
may not affect the GTPase activity of Rac1. If activated Rac1 is more sensitive to 
proteasomal degradation, the activated Rac1 may be degraded earlier than 
non-activated Rac1 that is transamidated at sites not involved in activation. 
      Cystamine has been shown to decrease TGase activity and TGase-catalyzed 
є-(γ-glutamyl) lysine bonds in cultured cells and animal models of neurodegenerative 
diseases (Karpuj et al., 2002a, Ientile et al., 2003, Zainelli et al., 2005). As a primary 
amine, cystamine is a potential substrate for TGase, and acts as a competitive 
inhibitor for TGase by blocking access to the active site of the enzyme for the 
glutamine residues in proteins which would otherwise participate in forming 
є-(γ-glutamyl) lysine bonds (Lorand et al., 1979). In our study, pretreatment with 
cystamine reduced both serotonin-stimulated Rac1 transamidation (Fig. 7A, C) and 
activation (Fig. 8A, C) in a dose-dependent manner. Those observations were further 
supported by the use of TGase2-specific siRNAs, which significantly suppressed DOI 
induced TGase-modification of Rac1 (Fig. 9B, C). These results suggest that 
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cystamine prevented Rac1 transamidation through TGase inhibition, and that 
transamidation of Rac1 by TGase may contribute to the increase in Rac1 activity.  
      Post-translational modifications, such as transamidation and phosphorylation 
of Rac1 may affect its ability to interact with regulatory proteins (e.g. GAPs, GEFs 
and GDIs) or to convert GTP back to GDP, resulting in increased activation of Rac1 
and stimulation of its signaling cascade in the cells. The Conserved Domain Database 
(CDD) (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=cdd) provides an 
interactive tool to identify conserved domains present in protein sequences. We 
searched the CDD for GTP/Mg2+ binding sites, and GAPs, GEFs and GDIs interaction 
sites in the Rac1 sequence (PSSM-Id: 57957) because they will be most likely to 
modify Rac1 activity after TGase-catalyzed transamidation at these sites. We 
identified two glutamine residues (Gln61, Gln74) located within these domains. It has 
been reported that site-specific deamidation of a Gln residue in the Rho family G 
proteins (Gln61 in Rac and Cdc42, Gln63 in RhoA) by CNF-1 inhibits both intrinsic 
and GAPs-stimulated GTP hydrolysis activity, resulting in constitutive activation of 
these proteins (Flatau et al., 1997, Schmidt et al., 1997). CNF-1 has also been shown 
to possess in vitro TGase activity. In the presence of primary amines, RhoA is 
transamidated in vitro at Gln63 by CNF-1 and at positions 52, 63 and 136 by guinea 
pig liver TGase (Schmidt et al., 1998). Similarly, in addition to Gln61 which is critical 
in regulating Rac1 activity, the other four glutamine residues in Rac1 may also be 
modified by TGase. It is not surprising, therefore, that the same dosage of cystamine 
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prevents Rac1 transamidation and its activation to different extents (Fig. 7C, 8C).    
      Walther et al. found that in platelets TGase covalently cross-links serotonin to 
RhoA or Rab4 at a position in the phosphate-binding site that is conserved in the 
sequences of all Ras-related small GTPases (Walther et al., 2003). It has also been 
shown that polyamines such as putrescine, spermidine and spermine could be 
incorporated into Rac1 by bacterial TGase in vitro (Masuda et al., 2000). In our study, 
co-immunoprecipitation assays demonstrated that serotonin is associated with Rac1 in 
A1A1v cells after serotonin stimulation (Fig. 10A). To explore the association 
mechanism further, we inhibited TGase by cystamine and found a reduction of 
serotonin-associated Rac1 with increasing concentrations of cystamine (Fig. 10B, D), 
indicating that serotonin is incorporated into Rac1 by a TGase-catalyzed bond. Since 
both serotonin and DOI stimulation can lead to serotonin incorporation to similar 
levels (Fig. 11), the serotonin bound to 5-HT2A receptors is not likely the source of 
Rac1-incorporated serotonin; the serotonin bound to Rac1 may originate from 
endogenously synthesized serotonin or serotonin transported into the cell from serum 
in the cell culture media.  
      The first signal transduction mechanism identified for the 5-HT2A receptor was 
Gq/11 mediated activation of PLC, leading to increased accumulation of IP3 and an 
increase in intracellular Ca2+ (Boess and Martin, 1994). In addition to activation of 
PLC, extensive evidence suggests that 5-HT2A receptors couple to other effector 
pathways, such as phospholipase A2/arachidonic acid cascade (Berg et al., 1994b), 
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Mitogen-Activated Protein Kinase signaling (Watts, 1998) and phospholipase 
D/protein kinase C pathway (Mitchell et al., 1998). On the other hand, TGases are 
subjected to transcriptional regulation by retinoic acid and steroid hormones 
(Fujimoto et al., 1996, Ou et al., 2000), and require the binding of Ca2+ for their 
activity (Burgoyne and Weiss, 2001). Evidence indicates that TGase activity can be 
significantly enhanced in response to increased intracellular Ca2+ through IP3 
generation (Zhang et al., 1998). In aplysia, serotonin mediated activation of Cdc42 
was dependent on PLC and phosphatidylinositol 3-kinase (PI3K) (Udo et al., 2005). 
In RA-induced neuronal differentiation of SH-SY5Y cells, TGase-catalyzed 
transamidation is required for activation of RhoA (Singh et al., 2003), whereas 
activation of Rac1 is mediated by PI3K in a transamidation-independent manner (Pan 
et al., 2005). Further studies are needed to elucidate the underlying molecular 
mechanisms by which the 5-HT2A receptor signaling regulates TGase-catalyzed 
activation of Rac1. 
      The present study provides the first evidence in neurons that stimulation of 
5-HT2A receptors induces an increase in TGase-catalyzed transamidation of serotonin 
into Rac1 and constitutive activation of Rac1. Further studies using alternative 
approaches to measure Rac1 transamidation, such as mass spectroscopy, are needed to 
confirm this hypothesis. Rac1 activation via 5-HT2A receptor stimulation may have an 
important functional impact given the plethora of pathways that utilize this small G 
protein. For example, Rac1 is best known as a regulator for the assembly of the actin 
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cytoskeleton, thereby playing a role in neurite outgrowth and neuronal differentiation. 
We demonstrate that stimulation of 5-HT2A receptor can increase the transamidation 
of Rac1 in both undifferentiated and differentiated A1A1v cells, suggesting that 
transamidation and constitutive activation of this signal transducer are not altered by 
neuronal differentiation of cells. However, the effect of 5-HT2A receptor-mediated 
activation of Rac1 on cytoskeleton organization, cell cycle progression, 
transcriptional activation or other crucial cellular functions in neurons has yet to be 
explored. 
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CHAPTER THREE: 
PHOSPHOLIPASE C, CALCIUM AND CALMODULIN SIGNALING ARE 
REQUIRED FOR 5-HT2A RECEPTOR-MEDIATED TRANSAMIDATION OF 
RAC1 BY TRANSGLUTAMINASE 
 
 
ABSTRACT 
Increasing evidence indicates that small G proteins undergo transglutaminase 
(TGase)-catalyzed transamindation and activation in neurons, platelets, and smooth 
muscle cells. We have previously reported that 5-HT2A receptor stimulation increased 
TGase-catalyzed transamidation and activation of Rac1 small G protein in A1A1v 
cells, a rat embryonic cortical cell line. In this study, we explore the signaling 
pathways involved in 5-HT2A receptor-mediated Rac1 transamidation. In cells 
pretreated with phospholipase C (PLC) inhibitor U73122, the 5-HT2A receptor 
specific agonist, DOI-stimulated increase in intracellular Ca2+ concentration and 
TGase-modified Rac1 were significantly attenuated as compared to those pretreated 
with U73343, an inactive analog. Addition of the membrane-permeant Ca2+ chelator, 
BAPTA-AM strongly reduced TGase-catalyzed Rac1 transamindation upon DOI 
stimulation. Conversely, when cells were treated with Ca2+ ionophore, ionomycin at a 
concentration that produced an elevation of cytosolic Ca2+ to a level comparable to 
cells treated with DOI, ionomycin mediated an increase in TGase-modified Rac1 
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without 5-HT2A receptor activation. Moreover, calmodulin (CaM) inhibitor W-7, 
significantly decreased Rac1 transamindation in a dose-dependent manner in 
DOI-treated cells. To identify potential TGase-targeting residues that could render 
Rac1 constitutively active upon transamidation, a search in NCBI Conserved Domain 
Database was conducted, which revealed that two glutamine residues (Q61, Q74) and 
three lysine residues (K5, K16, and K116) are located within activity-related domains. 
Taken together, these results indicated that 5-HT2A receptor-coupled PLC activation 
and subsequent Ca2+/CaM signaling are necessary in TGase-catalyzed Rac1 
transamidation, and an increase in intracellular Ca2+ is sufficient to induce Rac1 
transamination in A1A1 cells. 
 
INTRODUCTION  
Rac1 (Ras-related C3 botulinum toxin substrate 1), one of the most extensively 
characterized members in the Rho family of small G proteins, was initially discovered 
as a substrate for ADP-ribosylation induced by the C3 component of botulinum toxin 
(Didsbury et al., 1989). Subsequently, Rac1 and its downstream effectors were 
identified as key signaling molecules in various cell functions, such as cytoskeleton 
reorganization, cell transformation, axonal guidance, and cell migration 
(Etienne-Manneville and Hall, 2002, Bosco et al., 2009). 
Like all members of the Rho superfamily, Rac1 functions as a molecular switch, 
cycling between an inactive GDP-bound state and an active GTP-bound state. Rho 
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small G proteins can be activated by different signal transduction pathways initiated 
by extracellular factors such as platelet-derived growth factor, insulin or epidermal 
growth factor (Bishop and Hall, 2000). Serotonin has also been shown to induce 
activation via transglutaminase (TGase)-catalyzed transamidation of small G proteins 
in neurons, platelets, and aortic smooth muscle cells (Walther et al., 2003, Guilluy et 
al., 2007, Dai et al., 2008). TGases catalyze the transamidation of protein-bound 
glutamines and primary amines such as serotonin in a Ca2+-dependent manner 
(Ahvazi et al., 2002). We previously reported that the effect of serotonin on Rac1 
transamidation in A1A1v cells, a rat cortical cell line, is due to stimulation of the 
5-HT2A receptors (Dai et al., 2008). However, the underlying molecular mechanisms 
by which the 5-HT2A receptor signaling regulates TGase-catalyzed transamidation and 
activation of Rac1 are still unclear. 
5-HT2A receptor activation can increase IP3 via Gq/11-mediated activation of 
phospholipase C (PLC) (Conn and Sanders-Bush, 1984, de Chaffoy de Courcelles et 
al., 1985). PLC plays an important role in intracellular signal transduction by 
hydrolyzing phosphatidylinositol 4,5-bisphosphate (PIP2), a membrane phospholipid, 
and thereby generating two second messengers: inositol trisphosphate (IP3) which 
diffuses through the cytosol and releases Ca2+ from intracellular endoplasmic 
reticulum stores and diacylglycerol (DAG) (Boess and Martin, 1994). It has been 
reported that TGase activity can be significantly enhanced in response to increased 
intracellular Ca2+ through inositol 1,4,5-trisphosphate (IP3) generation (Zhang et al., 
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1998). Moreover, serotonin-mediated activation of small G protein cdc42 was 
dependent on PLC signaling pathways (Udo et al., 2005).  
Calmodulin (CaM) has been shown to increase TGase enzymatic activity. In the 
presence of CaM, a membrane-associated erythrocyte TGase is activated at 
physiological and lower than physiological Ca2+ concentrations (Billett and Puszkin, 
1991). Moreover, in the presence of Ca2+, CaM enhanced TGase activity 3-fold in 
human platelets and the chicken gizzard (Puszkin and Raghuraman, 1985). A CaM 
inhibitor prevented TGase-catalyzed cross-linking of huntingtin in cells co-transfected 
with mutant huntingtin and TGase (Zainelli et al., 2004). Taken together, we 
hypothesize that TGase-catalyzed Rac1 modification upon 5-HT2A receptor 
stimulation is dependent on PLC-mediated increases in intracellular Ca2+ and is 
regulated by CaM. To test this hypothesis, we examined the effects of PLC inhibition, 
CaM inhibition, and manipulation of intracellular Ca2+ by means of a Ca2+ ionophore 
or a chelating agent on TGase-modified Rac1 in response to 5-HT2A receptor 
activation in A1A1v cells. 
 
MATERIALS AND METHODS 
Cell Culture  
A1A1v cells, a rat cortical cell line, were grown on 100 mm2 plates coated with 
poly-L-ornithine (Sigma, St Louis, MO) and maintained in 5% CO2 at 33°C, in 
Dulbecco’s modified Eagle medium (DMEM) (Fisher Scientific, Pittsburgh, PA) 
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containing 10% fetal bovine serum (FBS) (Fisher Scientific, Pittsburgh, PA). Before 
each experiment, cells were maintained in DMEM with 10% charcoal-treated FBS for 
48 hours. Charcoal adsorption removes most but not all serotonin in the medium. The 
maximal final concentration of serotonin in the medium is approximately 3 nM 
(Unsworth and Molinoff, 1992). Cells from passages 8-15 were used for all 
experiments.  
 
Drugs 
The following drugs were used in this study: (-)-1-(2,5-dimethoxy-4-lodophenyl)- 
2-aminopropane HCl (DOI) (Sigma, St Louis, MO), U73122 (Tocris Bioscience 
Ellisville, MO), U73343 (Sigma, St Louis, MO), BAPTA AM (Invitrogen, Carlsbad, 
CA), ionomycin (Invitrogen, Carlsbad, CA), and W-7 hydrochloride (Tocris 
Bioscience Ellisville, MO). 
Measurement of intracellular Ca2+ concentration  
Cells were grown to 90% confluence in black-sided 96-well plates (Fisher Scientific, 
Pittsburgh, PA). Cells were washed twice with modified Kreb's medium (135 mM 
NaCl, 5.9 mM KCl, 1.5 mM CaCl2, 1.2 mM MgCl2, 11.5 mM D-glucose, 11.6 mM 
Hepes, pH 7.3) and then incubated in the same medium with 5 µM Fura-2 AM 
(Molecular Probes, Carlsbad, CA), 0.1% bovine serum albumin, and 0.02% Pluronic 
F127 detergent (Poenie et al., 1986) for 60 min at 33°C incubator in the dark. After 
loading, the cells were washed twice and incubated in the dark in modified Kreb's 
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medium or pretreated with drugs for 30 min. Following 1 min of equilibration, the 
cells were stimulated with a single injection of 3 µM DOI, and the response was 
recorded until a plateau was reached (about 4 min). Fura-2 fluorescence (at 510 nm) 
was measured with a BioTek fluorescence plate reader. After background fluorescence 
was subtracted, the ratio of fluorescence at 340 nm excitation to that at 380 nm 
excitation was calculated and used as an index of the intracellular Ca2+ concentration 
(the 340/380 nm fluorescence ratio is positively correlated with the absolute values of 
intracellular Ca2+ concentration). 
Immunoprecipitation of TGase-modified Protein  
A1A1v cells were harvested and lysed using lysis buffer A (25 mM Tris-HCl, pH 7.5, 
250 mM NaCl, 5 mM EDTA, 1% Triton X-100 and 1:1000 protease inhibitor cocktail 
(Sigma, St Louis, MO) containing 104 µM AEBSF, 0.08 µM aprotinin, 2 µM 
leupeptin, 4 µM bestatin, 1.5 µM pepstatin A and  1.4 µM E-64). Protein 
concentration was determined using the BCA Protein Assay kit (Pierce, Rockford, IL). 
Immunopurification of proteins containing TGase-catalyzed bonds was performed 
using 81D4 mAb (mouse IgM) prebound to Sepharose beads (Covalab, Lyon, France) 
using a protocol developed by Covalab and as described previously (Norlund et al., 
1999, Zainelli et al., 2005). The 81D4 antibody has been extensively used to 
demonstrate increases in TGase-catalyzed bonds (Citron et al., 2002, Junn et al., 2003, 
Andringa et al., 2004). The use of the 81D4 antibody in a competitive ELISA assay 
was shown to result in isodipeptide cross-link measurements that correlate well with 
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those measured by HPLC analysis but provide more sensitivity than the HPLC 
approach (Sarvari et al., 2002). Transfection of cells to over-express TGases, 
including TGase 1, 2 and 3, and a substrate protein such as mutant huntingtin protein 
results in increased presence of the isodipeptide cross-link in mutant huntingtin 
protein as demonstrated with immunoprecipitation with the 81D4 antibody (Zainelli et 
al., 2005).  
Briefly, 20µl of sepharose-81D4 beads were washed three times in TBS/0.1% 
Tween 20 with gentle shaking for 15 minutes, followed by adding 200µg cell lysate (1 
μg/μl) to the washed beads and incubating for 2 hours at 37°C. After incubation, the 
pellets were washed four times in TBS/0.1% Tween 20 for 15 minutes. Then 20µl of 
loading buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 0.1% bromophenol blue, 10% 
glycerol and 5% β-mercaptoethanol) was added to the washed pellets followed by 5 
minutes incubation at 90°C. The samples were then centrifuged at 9,000 × g for 2 
minutes and the supernatant was transferred and stored at -80°C until immunoblot 
analysis. 
Immunoblot  
Immunoaffinity purified proteins and cell lysates were separated on 12% 
SDS-polyacrylamide gels and then electrophoretically transferred to nitrocellulose 
membranes. Membranes were then incubated in blocking buffer (5% non-fat dry milk, 
0.1% Tween 20, 1× TBS) for 1 hour at room temperature. Membranes were incubated 
overnight at 4°C with primary antibodies on a shaker.  Primary antibodies (Upstate 
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Biotechnology, NY: anti-Rac1, mouse IgG, 1:700; anti-Na+/K+ ATPase, mouse IgG, 1: 
10000) were diluted in antibody buffer (1% non-fat dry milk, 0.1% Tween 20, 1× 
TBS). The next day, membranes were washed with TBS/0.1% Tween 20 and then 
incubated with goat-anti-mouse or goat-anti-rabbit secondary antibody conjugated to 
HRP (Jackson ImmunoResearch, West Grove, PA) diluted in antibody buffer. 
Membranes were washed and signal was detected using enhanced chemiluminescence 
(ECL) western blotting detection reagents (Amersham Biosciences, Piscataway, NJ). 
Using Scion Image for Windows (Scion, Frederick, MD), immunoblots were 
quantified by calculating the integrated optical density (IOD) of each protein band on 
the film.  
Statistical Analyses 
Data are presented as mean ± the standard error of the mean (SEM) and analyzed by 
one- or two-way ANOVA. Post hoc tests were conducted using Bonferroni's multiple 
comparison tests. GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA) was 
used for all statistical analyses. A probability level of p < 0.05 was considered to be 
statistically significant for all statistical tests. 
 
RESULTS 
PLC inhibitor decreases the response of intracellular Ca2+ and TGase-modified 
Rac1 to 5-HT2A receptor activation 
We previously reported that 5-HT2A receptor stimulation induced 
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TGase-catalyzed Rac1 transamidation and activation in A1A1v cells (Dai et al., 2008). 
To test the dependence of the intracellular Ca2+ response and Rac1 transamidation on 
PLC activation, cells were pretreated with 5 µM of the PLC inhibitor, U73122, or an 
inactive analog, U73343, for 30 min prior to the stimulation of 5-HT2A receptors by 3 
µM DOI. U73122 inhibits both PLC-mediated hydrolysis of PIP2 to IP3 and the 
coupling of G protein-PLC activation (Bleasdale et al., 1990). Changes in intracellular 
Ca2+ were monitored by the 340/380 nm fluorescence ratio of the Fura-2 loaded cells. 
DOI-stimulation induced a robust increase (by at least 200%) in the intracellular Ca2+ 
concentration within cells pretreated with U73343, where as PLC inhibition by 
U73122 reduced the intracellular Ca2+ response to DOI (Fig. 12A). TGase-modified 
Rac1 was evaluated by immunoprecipitation using the 81D4 antibody directed against 
the TGase-catalyzed covalent bond and immunoblots in parallel experiments. There 
were significant increases in TGase-modified Rac1 within DOI-stimulated cells, but 
pretreatment with U73122 significantly attenuated DOI-induced Rac1 modification by 
TGase (Fig. 12B, C). These results suggest a specific role of PLC upstream of Rac1 
transamidation in A1A1v cells. Two-way ANOVA indicates a significant main effect 
of DOI [F(1,8) =108.3; p<0.001] and U73122 [F(1,8) =29.99; p<0.001] on 
TGase-modified Rac1. There was also a significant interaction between DOI and 
U73122 [F(1,8) =17.40; p<0.01]. The ubiquitously expressed Na+/K+ ATPase is a well 
established plasma membrane marker, and its function underlies essentially all of 
mammalian cell physiology (Kaplan, 2002). To verify that the PLC inhibitor-mediated 
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the decrease in Rac1-transamidation by TGase was not due to U73122-induced 
cellular toxicity, cell lysates from the same experiment were examined on immunoblot 
with antibodies for Na+/K+ ATPase. There are no significant differences in Na+/K+ 
ATPase levels among cells with different treatments (Fig. 12B). Similar 
measurements were used in all of the following experiments. 
Ca2+ chelator inhibits DOI-stimulated modification of Rac1 by TGase 
In order to examine whether TGase-modified Rac1 specifically depends on an 
increase in intracellular Ca2+ upon 5-HT2A receptor activation, A1A1v cells were 
pretreated with increasing concentrations of the membrane-permeant Ca2+ chelator, 
BAPTA-AM (0, 5, 10, 20 µM) for 30 min, then the cells were challenged by DOI. 
Dose-dependent reductions in the DOI-mediated Ca2+ response were observed by 
measuring Fura-2 fluorescence (Fig. 13A). Since 20 µM BAPTA caused the most 
significant inhibition in Ca2+ increase, it was used in the parallel experiments that 
evaluated TGase-modified Rac1. DOI-stimulation in cells without 
BAPTA-pretreatment significantly increases the amount of TGase-modified Rac1 
about 2-fold compared with vehicle-stimulated cells, whereas pretreatment with 
BAPTA has a notable inhibitory effect on DOI-induced Rac1 modification by TGase 
(Fig. 13B, C), suggesting that an increase in intracellular Ca2+ is required for 
DOI-mediated Rac1 transamidation. Two-way ANOVA indicates a significant main 
effect of DOI [F(1,8) =37.09; p<0.001] and BAPTA [F(1,8) =9.85; p<0.05] on 
TGase-modified Rac1. There was also a significant interaction between DOI and 
83 
 
 
BAPTA [F(1,8) =9.50; p<0.05].  
Ca2+ ionophore induces TGase-modified Rac1 without 5-HT2A receptor 
activation 
To determine if an increase in intracellular Ca2+ is sufficient to enhance Rac1 
modification by TGase, a Ca2+ ionophore, ionomycin was used to produce an 
elevation of cytosolic Ca2+ concentration without 5-HT2A receptor activation. 
Ionomycin is an effective and specific Ca2+ carrier, so it has been used in studies of 
Ca2+ flux across plasma and ER membranes. To determine the concentration of 
ionomycin that raises the levels of cytosolic Ca2+ to levels comparable to 3µM DOI 
(the concentration of DOI used to induce TGase-modified Rac1), serial dilutions of 
ionomycin (from 1000 nM to 12.5 nM) were tested for their ability to induce 
increases in intracellular Ca2+. As shown in Fig. 14A, 25 nM ionomycin was able to 
produce a comparable increase in cytosolic Ca2+ in comparison to 3 µM DOI, so this 
concentration was used in the parallel experiments to  measure the effects on 
TGase-modified Rac1. After cells were treated with either 3 µM DOI or 25 nM 
ionomycin for 15 min, ionomycin mediated an increase in TGase-modified Rac1 to 
levels similar to those induced by DOI. One-way ANOVA indicated there is no 
significant difference in TGase-modified Rac1 between DOI- and ionomycin-treated 
cells. Taken together, these data suggest an increase in intracellular Ca2+ via an 
ionophore can mimic 5-HT2A receptor-induced cytosolic Ca2+ increases and is 
sufficient to induce TGase-catalyzed Rac1 transamidation. 
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TGase-modified Rac1 is reduced by CaM inhibition in a dose-depend manner 
TGase is not only a Ca2+-dependent enzyme, but its activity is also positively 
regulated by CaM. Moreover, Ca2+ signaling in cells is mainly mediated by CaM, a 
potent Ca2+-binding protein. The CaM inhibitor, W-7, binds with high affinity to CaM 
in the presence of Ca2+ and thereby inhibits the activation of CaM-dependent enzymes 
(Asano and Hidaka, 1984). To test whether CaM modulates TGase-catalyzed 
transamidation of Rac1, cells were pre-incubated for 1 h with 0, 0.5 or 5 µM W-7 
hydrochloride, and then stimulated with 3 µM DOI or vehicle for 15 min. We found 
that in DOI-stimulated cells, the levels of TGase-modified Rac1 were significantly 
higher than in vehicle-stimulated cells, whereas pretreatment with W-7 decreased 
DOI-stimulated Rac1 modification by TGase in a dose-dependent manner (Fig. 15). 
Two-way ANOVA indicates a significant main effect of DOI [F(1,12) =144.6; 
p<0.001] and W-7 [F(2,12) =8.152; p<0.01] on TGase-modified Rac1. There was also 
a significant interaction between DOI and W-7 [F(2,12) =5.01; p<0.05].  
Searching potential TGase-targeting residues at the activity-related domains in 
Rac1  
We have previously reported that TGase-catalyzed transamidation of Rac1 was 
able to transiently increase Rac1 activity (Dai et al., 2008). Like other small G 
proteins, Rac1 acts as a molecular switch and cycles between the GDP-bound inactive 
and GTP-bound active forms. There are at least three types of regulators for small G 
proteins: GTPase activating protein (GAP) which accelerates GTP hydrolysis, 
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resulting in inactivation of small G proteins; guanine nucleotide exchange factors 
(GEF) which stimulates conversion from the GDP-bound to the GTP-bound form; and 
GDP dissociation inhibitor (GDI) which inhibits this reaction. Post-translational 
modifications, such as TGase-catalyzed transamidation, of Rac1 at the conserved 
domains that interact with these regulators may affect its ability to convert GTP to 
GDP, resulting in increased activation. The Conserved Domain Database (available on 
http://www.ncbi.nlm.nih.gov/Structure/cdd/cdd.shtml) provides an interactive tool to 
identify conserved domains present in protein sequences. We searched the Conserved 
Domain Database for GTP/Mg2+ binding sites, and GAP, GEF, and GDI interaction 
sites in the Rac1 sequence (accession numbers: NP_008839) since TGase-catalyzed 
modifications at theses sites would more likely lead to functional changes that would 
impact on Rac1 activity (Fig. 16A). TGase-catalyzed transamidation may not only 
incorporate an amine into the glutamine residue of the acceptor protein, but also form 
intra-molecular cross-links between glutamine and lysine residues within the protein 
(Hand et al., 1993). Two glutamine residues (Q61, Q74) and three lysine residues (K5, 
K16, and K116) are located at the activity-related domains and are highlighted in 
Rac1 structure (Fig. 16B). 
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Figure 12. Effect of PLC inhibition on DOI-induced Ca2+ signals and TGase-modified 
Rac1 in A1A1v cells. (A) After pretreatment with 5 µM U73122 or U73343 (negative 
control) for 30 min, and stimulation with either 3 µM DOI or vehicle (Ve), changes in 
the fluorescence ratio (340/380 nm) were recorded from cells loaded with Fura-2. A 
representative example from three independent experiments conducted in triplicate is 
shown. Arrows indicate the time of drug application.  (B) Upper, 
immunoprecipitation (IP) and immunoblot (IB) analyses revealed that U73122 
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pretreatment inhibited the increase in TGase-modified Rac1 upon DOI stimulation.  
Lower, cells lysates from the same experiment were examined on IB with Na+/K+ 
ATPase antibody, which indicated that U73122 had no effect of on cell viability. (C) 
Quantitation of effects of U73122 and DOI on TGase-modified Rac1 in three separate 
experiments. Data shown were the mean IOD±S.E.M., and they were normalized to 
U73343- and Ve- treated cells. Two-way ANOVA followed by Bonferroni test: * and 
*** indicated p<0.05 and 0.001 as compared to U73343- and Ve- treated cells, 
respectively; # indicated p<0.001 as compared to U73343- and DOI- treated cells. 
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Figure 13. Pre-incubation with a Ca2+ chelator attenuated the DOI-mediated elevation 
of cytosolic Ca2+ and TGase-modified Rac1. (A) Dynamic changes in fluorescence 
ratio (340/380 nm) in Fura-2 loaded A1A1v cells. The Ca2+ response to exposure to 3 
µM DOI was gradually reduced with the increasing concentrations of BAPTA. A 
representative example of three independent experiments conducted in triplicate is 
shown.  (B) Upper, cells were pretreated with 20 µM BAPTA or the vehicle for 
BAPTA (Ve1) for 30 mins, and then stimulated with 3 µM DOI or the vehicle for DOI 
(Ve2) for 15 mins. TGase-modified Rac1 was detected by IP and IB analysis. BAPTA 
inhibited the increase in TGase-modified Rac1in DOI- stimulated cells. Lower, cells 
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lysates from the same experiment were examined on IB with Na+/K+ ATPase 
antibody. There was no significant difference among various treatments. (C) 
Quantitation of effects of BAPTA and DOI on TGase-modified Rac1 in three separate 
experiments. Data shown were the mean IOD±S.E.M., and they were normalized to 
Ve1- and Ve2- treated cells. Two-way ANOVA followed by Bonferroni test: * 
indicated p<0.01 as compared to Ve1- and Ve2- treated cells; # and ## indicated 
p<0.05 and p<0.01 as compared to Ve1- and DOI- treated cells, respectively. 
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Figure 14. The Ca2+ ionophore mimiced the DOI-induced increase in cytosolic Ca2+ 
and TGase-catalyzed transamidation of Rac1. (A) Fura-2 loaded cells were stimulated 
with either 3µM DOI or different concentrations of ionomycin. The changes in the 
fluorescence ratio (340/380 nm) were recorded. A representative example from three 
independent experiments conducted in triplicate is shown.  (B) Upper, cells were 
treated for 15 mins with 3µM DOI, 25 nM ionomycin or vehicles (Ve). Ionomycin 
caused an increase in TGase-modified Rac1 comparble to that induced by DOI. Lower, 
cell viability, as indicated by Na+/K+ ATPase levels was  not significantly different 
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among the various treatments. (C) Quantitation of effects of ionomycin and DOI on 
TGase-modified Rac1 in three separate experiments. Data shown were the mean 
IOD±S.E.M., and were normalized to Ve-1-treated cells. One-way ANOVA followed 
by Bonferroni test: * indicates p<0.01 as compared to Ve-1-treated cells; # indicates 
p<0.01 as compared DOI-treated cells. 
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Figure 15. The CaM inhibitor W-7 caused a dose-dependent reduction in 
DOI-stimulated TGase-modified Rac1. (A) Cells were pretreated with increasing 
concentrations of W-7 for 1 h and then stimulated with either 3 µM DOI or vehicle 
(Ve). TGase-modified Rac1 and Na+/K+ ATPase were measured by IP and/or IB. W-7 
decreased the levels of TGase-modified Rac1 upon DOI stimulation, but did not 
significantly affect Na+/K+ ATPase at the concentrations applied. (B) Quantitation of 
effects of W-7 on TGase-modified Rac1 in three separate experiments. Data shown 
were the mean IOD±S.E.M., and were normalized to Ve-stimulated cells without W-7 
pretreatment. Two-way ANOVA followed by Bonferroni test: * and ***indicate 
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p<0.05 and  p<0.001 as compared to Ve-stimulated cells without W-7 pretreatment, 
respectively; # and ## indicate p<0.01 and p<0.001 as compared to DOI-stimulated 
cells without W-7 pretreatment, respectively. 
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Figure 16. Rac1 activity-related domains and potential TGase-targeted amino acid 
residues. (A) Amino acid sequence alignment of human Rac1. Conserved 
activity-related sites were identified by searching NCBI Conserved Domain Database 
(CDD). # indicates a GTP/Mg2+ binding site; * indicates GAP interaction sites; + 
indicates GEF interaction sites; & indicated  GDI interaction sites.  Two glutamine 
residues (Q61, Q74) and three lysine residues (K5, K16, and K116), highlighted in 
gray, are directly localized in these potential activity-related domains. (B) Rac1 
structure adapted from http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi? 
uid=56843. The potential TGase-targets, glutamine and lysine residues at Rac1 
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activity-related domains are highlighted in yellow. 
 
 
 
 
 
 
 
 
 
 
 
96 
 
 
 
 
Figure 17. Schematic representation showing 5-HT2A receptor signaling-mediated 
transamidation of Rac1 by TGase.  DOI stimulates Gq/11 proteins-coupled 5-HT2A 
receptors, leading to the activation of PLC, which in turn hydrolyses PIP2 into IP3. IP3 
releases Ca2+ from ER and results in the activation of Ca2+-dependent proteins, such 
as CaM and TGase. Positively regulated by both Ca2+ and CaM, TGase catalyzes 
transamidation of Rac1 to bioamines, such as serotonin transported into the cytoplasm 
by SERT. Abbreviations: 5-HT2AR, 5-HT2A receptor; CaM, calmodulin; ER, 
endoplasmic reticulum; PLC, phospholipase C; PIP2, phophatidyl 
inositol-1,4-bisphosphate; IP3, inositol-1,4,5-triphosphate; SERT, serotonin 
transporter; TGase, transglutaminase; α, β, γ, G protein α, β, γ subunits 
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DISCUSSION  
Several lines of evidence indicate Gq/11-protein-coupled receptors, such as 
bradykinin or endothelin-1 receptor, are also able to stimulate the activation of Rac1 
(van Leeuwen et al., 1999, Clerk et al., 2001), but the mechanisms by which Rac1 
becomes activated through these receptors remains poorly characterized. Nevertheless, 
it is worth noting that the activation of Rac1 is highly regulated by physiological 
stimuli, and aberrant activation occurs under many pathological conditions such as 
Salmonella invasion, tumor cell migration, and retinal degeneration (Bourguignon et 
al., 2000, Belmonte et al., 2006, Brown et al., 2007). Therefore, further studies that 
delineate signaling pathways involved in Rac1 activation may uncover new potential 
therapeutic targets for these diseases. We have previously demonstrated that the 
5-HT2A receptor, another Gq/11-protein-coupled receptor, is responsible for 
TGase-catalyzed transamidation and activation of Rac1 (Dai et al., 2008). In the 
present study, we investigated the mechanisms involved in Rac1 transamidation in 
response to 5-HT2A receptor stimulation. Our experimental results identified that 
PLC-mediated increase in intracellular Ca2+ and subsequent CaM activation are 
required for 5-HT2A receptor-mediated Rac1 transamidation. 5-HT2A receptor 
stimulation activates PLC which catalyzes the hydrolysis of PIP2 into IP3. IP3 
mobilizes Ca2+ from ER stores and thereby increases the intracellular Ca2+ and leads 
to the activation of CaM. Our data suggest that both Ca2+ and CaM activate TGase, 
which catalyzes transamidation of Rac1 to bioamines, such as serotonin (Fig. 17).  
98 
 
 
Except for the 5-HT3 receptor, which is a ligand-gated ion channel, the other 
5-HT receptors belong to the G protein-coupled receptor (GPCR) superfamily. G 
proteins such as Gα12 and Gα13, have been shown to transduce signals from GPCR to 
activate Rho small G proteins (Suzuki et al., 2003). One of the GEFs for Rho, 
p115RhoGEF, has served as a direct link between Gα12/Gα13 and Rho (Hart et al., 
1998, Kozasa et al., 1998). However, the signaling pathways between 5-HT2A 
receptors and Rac1 transamidation and activation are not well understood. 5-HT2A 
receptor is primarily coupled to Gq/11 and activates various isoforms of PLC (Conn 
and Sanders-Bush, 1984, de Chaffoy de Courcelles et al., 1985). It also induces the 
activation of phospholipase A2 (PLA2) and the release of arachidonic acid (Felder et 
al., 1990, Kurrasch-Orbaugh et al., 2003). Moveover, through interaction with 
ADP-ribosylation factor 1 (ARF1) via its C-terminal domain, 5-HT2A receptor is able 
to signal through the phospholipase D (PLD) pathway (Mitchell et al., 1998, 
Robertson et al., 2003). Our results suggest that 5-HT2A receptor activation triggers 
TGase-catalyzed Rac1 transamidation at least predominantly through a pathway 
involving PLC (Fig.12).  
Although it has been reported that PLC activates Rac in a manner dependent on 
Iba1, a Ca2+-binding protein specifically expressed in macrophage/microglia 
(Kanazawa et al., 2002), Rac1 transamidation and activation in A1A1v cells, a 
neuronal cell line, could be mediated by other signaling pathways. Cleavage of PIP2 
by PLC yields two important second messengers, IP3 and DAG, to initiate a variety of 
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cellular functions. Since Ca2+ chelation reduces DOI-stimulated Rac1 transamidation 
to basal levels (Fig.13), IP3-induced Ca2+ release from ER rather than DAG signaling 
plays a pivotal role in TGase-catalyzed Rac1 transamidation. These results are in 
agreement with an earlier study suggesting that in thrombin- and collagen-stimulated 
human blood platelets, PLC activity and an increase in intracellular Ca2+ concentration 
were required for Rac activation, whereas PKC inhibition had no effect (Soulet et al., 
2001). Increases in intracellular Ca2+ concentration upon 5-HT2A receptor stimulation 
is achieved by releasing intracellular Ca2+ stores and/or by activating Ca2+ channels, 
depending on the cell of interest. 5-HT2A receptor-induced contraction of rat aorta 
may require the concerted action of voltage-gated Ca2+ channels and phosphoinositide 
turnover (Nakaki et al., 1985, Roth et al., 1986, Watts, 1998). More interestingly, 
stimulation of 5-HT2A receptors on astrocytes caused Ca2+ influx through voltage 
independent Ca2+ channels which were dependent of the IP3 production and 
subsequent Ca2+ release from internal stores (Eberle-Wang et al., 1994, Hagberg et al., 
1998). Therefore, both Ca2+ mobilization from internal stores and influx of 
extracellular Ca2+ could contribute to the PLC/IP3-mediated intracellular Ca2+ 
increase.  
CaM and TGase are Ca2+ dependent proteins. CaM activation is coupled to 
intracellular Ca2+  elevation and also correlates with the spatial pattern of increased 
Ca2+  (Hahn et al., 1992). Upon Ca2+  binding to the EF hand motifs of CaM, both N- 
and C-terminal domains adopt an open confirmation, exposing hydrophobic surfaces, 
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which then interact with a variety of target proteins including TGase (Puszkin and 
Raghuraman, 1985, Zainelli et al., 2004). TGase contains a cysteine in their active site 
that is unmasked only in the presence of Ca2+ (Hand et al., 1993) and Ca2+ activation 
of TGase is further regulated by other signal modulators such as GTP (Monsonego et 
al., 1998) and CaM (Puszkin and Raghuraman, 1985, Zainelli et al., 2004). In order 
for TGase to become receptive to the glutamine substrate, Ca2+ first must bind to 
TGase, inducing its conformational change which permits the glutamine substrate 
binding to the catalytic center (Folk, 1983, Greenberg et al., 1991). A rise of Ca2+ 
concentration increases TGase activity in a dose dependent manner in vitro and in 
cells (Siefring et al., 1978, Shin et al., 2004, Li et al., 2009). Consistent with these 
results, the elevation of intracellular Ca2+ induced via a Ca2+ ionophore lead to 
increased TGase-catalyzed Rac1 transamidation (Fig. 14). 
In addition to Ca2+, CaM also interacts with TGase and regulates its 
cross-linking activity. CaM has been shown to coimmunoprecipitate with TGase2 in 
transfected cells (Zainelli et al., 2004). CaM increased TGase activity in human 
erythrocyte (Billett and Puszkin, 1991), platelets,  chicken gizzard (Puszkin and 
Raghuraman, 1985) and rat liver (Hand et al., 1985). Interestingly, exogenous CaM 
with a binding site on the α-subunits of the hexadecameric phosphorylase kinase 
molecule (αβγδ)4, stimulates TGase-catalyzed incorporation of putrescine into the β- 
and γ-subunits, but inhibits  incorporation of amines into the α-subunit (Nadeau and 
Carlson, 1994). Some of the CaM antagonists, such as dansylcadaverine, inhibit TGase 
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(Lorand et al., 1979) and its protein cross-linking ability. We have previously reported 
that a CaM antagonist or inhibitory CaM fragments, attenuated TGase-modified mutant 
huntingtin in cell and animal models of Huntington's disease (Zainelli et al., 2004, Dai 
et al., 2009, Dudek et al., 2009). CaM antagonists and Ca2+-chelators also have been 
shown to depress the motile progression of sperm cells possibly mediated by 
TGase-catalyzed cross-linking of the contractile proteins (Cariello and Nelson, 1985). 
Our present results revealed that CaM inhibitor, W-7, reduced TGase-modified-Rac1 in 
dose-dependent fashion (Fig. 15), indicating that TGase-catalyzed Rac1 transamidation, 
at least in part, was positively regulated by CaM. Moreover, in the presence of 5-HT2A 
receptor agonist, CaM has been shown to interact with 5-HT2A receptor at the sites 
that are important for G protein coupling, suggesting a putative role for CaM in 
regulating 5-HT2A receptor function (Turner and Raymond, 2005). Thus, one could 
not exclude the possibility that the effect of CaM inhibition is mediated by alterations 
in 5-HT2A receptor signaling.  
The significance of TGase in Rac1 transamidation was confirmed by TGase 
siRNA and inhibitor in our previous studies (Dai et al., 2008). In addition to small G 
proteins such as Rac1 and RhoA (Walther et al., 2003, Dai et al., 2008) that could 
undergo TGase-catalyzed transamidation to serotonin (serotonylation), more recently, 
arterial delete cytoskeletal proteins including actin, myosin heavy chain and filamin A 
have been identified as serotonylated proteins (Watts et al., 2009). However, serotonin 
may not be the only amine that could be incorporated in these proteins. Neuronal 
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differentiation of SH-SY5Y cells induced by retinoic acid increases the 
expression/activation of TGases, resulting in transamidation of putrescine to RhoA and 
activation of RhoA (Singh et al., 2003). Moreover, spermidine and putrescine are 
suitable substrates for transglutamination of RhoA in vitro (Schmidt et al., 2001). In 
addition to amine incorporation, another important TGase-catalyzed modification of 
small G proteins is deamidation of glutamine residue. The site-specific deamidation of 
Gln53 and Gln61 of RhoA and Ras, respectively, by the bacterial toxin TGases 
inhibits the GTPase activity and renders small G proteins constitutively active (Lorand 
and Graham, 2003). 
In addition to TGase-catalyzed reactions, other Ca2+/CaM dependent pathways 
may also contribute to Rac1 activation. For example, platelet-derived growth factor 
(PDGF) stimulates phosphorylation of Tiam1, the Rac1-specific GEF, and this 
phosphorylation was significantly reduced by Ca2+ chelation, inhibition of Ca2+/CaM 
dependent kinase II (CaMKII), or disruption of PLC-γ expression in Swiss 3T3 
fibroblasts (Fleming et al., 1998). Targeted CaMKII knockdown using siRNA resulted 
in the inhibition of wound-induced Rac activation and vascular smooth muscle cell 
migration (Mercure et al., 2008). 
In conclusion, our study provides important new insights into the signaling 
mechanisms underlying 5-HT2A receptor-induced Rac1 transamidation and activation 
by TGase in A1A1v cells, and highlights the necessary role of PLC-mediated Ca2+ 
mobilization and CaM in TGase-catalyzed Rac1 transamidation. As an activating 
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signal for both TGase and CaM, an elevation of intracellular Ca2+ is sufficient to 
induce Rac1 transamidation. Accumulating evidence suggests that Rho family of 
small G proteins is subject to TGase-mediated modification and activation. The 
essential role of Rac1 in cytoskeletal organization is well characterized, while the 
biological functions of Rac1 transamidation by TGase of in neurons have yet to be 
explored.  
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CHAPTER FOUR 
 
STRIATAL EXPRESSION OF A CALMODULIN FRAGMENT IMPROVED 
MOTOR FUNCTION, WEIGHT LOSS AND NEUROPATHOLOGY IN THE R6/2 
MOUSE MODEL OF HUNTINGTON’S DISEASE 
(Published in J Neurosci. 2009; 29(37):11550-9) 
 
ABSTRACT 
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, 
caused by a polyglutamine expansion in the huntingtin protein (htt). Increasing 
evidence suggests that transglutaminase (TGase) plays a critical role in the 
pathophysiology of HD possibly by stabilizing monomeric, polymeric and aggregated 
htt. We previously reported that in HEK293 and SH-SY5Y cells expression of a 
calmodulin (CaM)-fragment, consisting of amino acids 76-121 of CaM, decreased 
binding of CaM to mutant htt, TGase-modified htt and cytotoxicity associated with 
mutant htt and normalized intracellular calcium release. In this study, an 
adeno-associated virus (AAV) that expresses the CaM-fragment was injected into the 
striatum of HD transgenic R6/2 mice. The CaM-fragment significantly reduced body 
weight loss and improved motor function as indicated by improved rotarod 
performance, longer stride length, lower stride frequency, fewer low mobility bouts 
and longer travel distance than HD controls. A small but insignificant increase in 
survival was observed in R6/2 mice with CaM-fragment expression. 
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Immunoprecipitation studies show that expression of the CaM-fragment reduced 
TGase-modified htt in the striatum of R6/2 mice. The percentage of htt-positive nuclei 
and the size of intranuclear htt aggregates were reduced by the CaM-fragment without 
striatal volume changes. The effects of CaM-fragment appear to be selective, as 
activity of another CaM-dependent enzyme, CaM-dependent kinase II, was not altered. 
Moreover, inhibition of TGase-modified htt was substrate-specific since overall 
TGase activity in the striatum was not altered by treatment with the CaM-fragment. 
Taken together, these results suggest that disrupting CaM-htt interaction may provide 
a new therapeutic strategy for HD.     
 
INTRODUCTION 
Patients with Huntington’s disease (HD) present symptoms such as chorea, 
irregular gait, reduced motor coordination and weight loss (Harper, 1991). HD is a 
progressive and fatal neurological disorder caused by expansion of CAG repeats in 
HTT gene, conferring a toxic gain of function to the huntingtin (htt) protein 
(Huntington’s Disease Collaborative Research Group, 1993). It is characterized 
neuropathologically by intranuclear inclusions and cytoplasmic aggregates composed 
of htt with an expanded polyglutamine domain (DiFiglia et al., 1997, Ross et al., 
1998).  Currently, there are no effective treatments to prevent or slow the progression 
of the disease. 
Increasing evidence indicates that TGases may contribute to the 
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pathophysiology of HD (Cooper et al., 1999, Karpuj et al., 2002b). TGases, a family 
of Ca2+-dependent enzymes, catalyze a covalent bond between peptide-bound 
glutamine residues and either lysine-bound peptide residues or mono- or polyamines 
(Folk et al., 1980, Griffin et al., 2002). In cell culture, mutant htt is an excellent 
substrate for TGases (Gentile et al., 1998, Kahlem et al., 1998, Zainelli et al., 2005). 
The mRNA, protein and enzymatic activity of TGases are elevated in HD brain 
(Karpuj et al., 1999, Lesort et al., 1999, Zainelli et al., 2003). TGase 2 ablation in HD 
transgenic mice resulted in a drastic reduction in -(γ-glutamyl) lysine bond levels 
and neuronal death in the cortex and striatum (Mastroberardino et al., 2002). 
Administration of the TGase inhibitor, cystamine, extended survival and improved 
motor performance in HD transgenic mice (Karpuj et al., 2002a).   
Calmodulin (CaM) increased TGase activity in human erythrocyte (Billett and 
Puszkin, 1991), platelets and chicken gizzard (Puszkin and Raghuraman, 1985). CaM 
activates a host of enzymes upon Ca2+ binding (Cheung, 1982) and associates with 
mutant htt as demonstrated by affinity purification (Bao et al., 1996) and 
immunoprecipitation (Zainelli et al., 2004). Moreover, CaM colocalizes with htt and 
TGase 2 in HD intranuclear inclusions (Zainelli et al., 2004). Since a CaM inhibitor 
decreased TGase-catalyzed cross-linking of htt in cells (Zainelli et al., 2004), we 
tested the ability of fragments of CaM to interrupt the interaction of CaM and mutant 
htt and decrease the deleterious effects of TGase in HEK-293 cells (Dudek et al., 
2008). A CaM-fragment, containing amino acids 76-121, reduced binding of CaM to 
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mutant htt in vitro and in HEK-293 cells. AAV-mediated expression of the 
CaM-fragment significantly decreased TGase-modified htt, and mutant htt-associated 
cytotoxicity in differentiated SH-SY5Y cells, a neuroblastoma cell line, which stably 
express mutant htt. Importantly, CaM-fragment did not alter the total activity of 
TGase or another CaM-dependent enzyme, CaM kinase II, suggesting that 
CaM-fragment has specific effects on the CaM-htt interaction (Dudek et al., 2009). In 
the present study, we assessed the therapeutic potential of CaM-fragment in the R6/2 
mouse model of HD. R6/2 transgenic mice express exon 1 of the human HD gene 
with an increased CAG repeat. Consequently, they develop a progressive neurological 
phenotype and pathological changes that resemble many features of HD (Mangiarini 
et al., 1996, Li et al., 2000). Survival, body weight, motor performance and 
neuropathological features were monitored to determine whether AAV-mediated 
expression of the CaM-fragment has beneficial effects on the course of HD in R6/2 
mouse model. 
 
MATERIALS AND METHODS 
Animals. Male R6/2 transgenic mice (with 100-115 CAG repeats in the 
transgene) and wild-type littermate mice were purchased from Jackson Laboratories 
(Bar Harbor, ME) at 6 weeks of age. The mice had free access to food and water in an 
environment controlled for temperature and humidity and a 12 h light/dark cycle. The 
behavioral tests were conducted in the light part of the cycle. All procedures were 
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conducted in accordance with the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals as approved by the University of Kansas Institutional 
Animal Care and Use Committee. 
Adenoassociated Virus (AAV) Injections. Recombinant AAV serotype 2 vectors 
were generated as described in our previous studies (Dudek et al., 2009). Three 
resultant vectors expressed each of the following: GFP and the CaM-fragment 
(containing amino acids 76-121 of calmodulin), GFP and a scrambled peptide 
(containing the same amino acids of the CaM-fragment but in a randomly scrambled 
sequence), and GFP alone. The titers of final AAV products were ranged from 2~5 × 
1014 vector genomes per ml. Bilateral striatal injections of GFP-expressing AAV were 
performed in 7-week-old mice (1 µl per each side with 200 nl/min infusion rate at 
coordinates of anterior/posterior 0.5 mm, lateral/medial ±2 mm and dorsal/ventral -3 
mm relative to bregma (Franklin et al., 1997)). Mice were randomly divided into five 
groups (11~14 mice for each group) with a defined genotype and treatment: CaM-HD 
(R6/2 mice injected with AAV expressing the CaM-fragment), Vec-HD (R6/2 mice 
injected with empty vector AAV expressing GFP alone), Scr-HD (R6/2 mice injected 
with AAV expressing a scrambled version of the CaM-fragment), CaM-WT 
(wild-type mice injected with AAV expressing CaM-fragment) and Vec-WT 
(wild-type mice injected with empty vector AAV). 
Body weight and survival. Body weights were measured twice a week. 
Survival was checked twice daily at 8 h intervals. Brains were removed after death 
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and snap frozen in 2-methylbutane/dry ice bath and stored at -80°C. 
Behavioral tests.  Three behavioral tests were performed between 10 and 14 
weeks of age at weekly intervals. Rotarod performance, gait dynamics and 
locomotion were examined every Wednesday, Friday and Sunday, respectively. 
Gait dynamics. The DigiGait imaging system (Mouse Specifics, Inc., Boston, 
MA) was utilized for gait analyses as previously described (Hampton et al., 2004). 
Briefly, mice were placed on a motorized transparent treadmill belt moving at a speed 
of 14 cm/s. Digital images of paw placement were recorded at 150 Hz through a video 
camera mounted below the animal. The proprietary software analyzed the resulting 
digital images to generate a set of periodic waveforms that described the paw area and 
movement of each limb relative to the treadmill belt through consecutive strides. Gait 
data were pooled from all four paws and used to determine numerous gait dynamic 
measures including stride length and frequency, variability of stance width and paw 
area at peak stance.  
Locomotion. To accurately measure locomotor behaviors including the total 
distance traveled and the number of low mobility bouts (defined as remaining 
continuously in a virtual circle of 15 mm radius for 10 sec), a force-plate actometer 
(constructed in Dr. Fowler’s laboratory, University of Kansas) was used as described 
previously (Fowler et al., 2001). Mice were placed in a 28 cm × 28 cm force-plate 
actometer for a 30-min recording once a week. When the animal moves on the plate, 
its movements are sensed by four supporting force transducers positioned at the 
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corners of the plate. The signals are processed by specialized computer algorithms 
written in house to yield measurements of travel distance and bouts of low mobility. 
Rotarod performance. A rotarod apparatus (MED-Associates, St. Albans, VT) 
was used to measure fore- and hindlimb motor coordination and balance. The mice 
were given a training session at 9 weeks of age (four trials per day for 3 consecutive 
days) to acclimate them to the rotarod apparatus. During the test period, each mouse 
was placed on the rotarod with increasing speed, from 4 rpm to 40 rpm in 300 seconds. 
The latency to fall off the rotarod within this time period was recorded. Mice were 
tested on the rotorod once a week. Each mouse received two consecutive trials and the 
mean latency to fall was used in the analysis. 
Immunoprecipitation (IP).  Mouse brains were bisected mid-saggitally. One 
half was used in IP, CaM Kinase II Activity and TGase assays. The other half was 
used for immunohistochemistry assays. To prepare striatal homogenates for IP, a half 
brain was cut into 300-μm coronal sections with a cryostat (Leica, Nussloch, 
Germany). Striatum was punched out from five consecutive sections and 
homogenized in lysate buffer (10 mM Tris-HCl, pH 7.5, 0.14 M NaCl, 1 mM EDTA, 
and 1:1000 protease inhibitor mixture) in a Tissue Tek homogenizer. Protein 
concentration was determined using the BCA Protein Assay kit (Pierce Chemical, 
Rockford, IL) and tissue homogenates containing 150 µg of protein were centrifuge at 
12,000 × g for 5 min at 4°C to separate the insoluble fraction. After removal of the 
supernatant, the insoluble fraction was resuspended in 60 µl of 95% formic acid and 
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incubated in a shaking water bath at 37°C for 40 min. The formic acid was then 
evaporated using a CentriVap Speed Vacuum (Labconco, Kansas City, MO) for 1.5 h 
at 45°C. The pellets were resuspended in 150 µl of IP wash buffer (10 mM Tris-HCl, 
pH 7.5, 0.14 M NaCl, and 0.1% Tween 20) and sonicated on ice at 10 x 5 sec pulse. 
Immunopurification of proteins containing TGase-catalyzed bonds was performed 
using 81D4 monoclonal antibody prebound to Sepharose beads (Covalab, Lyon, 
France) using a protocol developed by Covalab and as described previously (Norlund 
et al., 1999, Zainelli et al., 2005). 
Immunoblot. Immunoaffinity-purified proteins were separated on 10% 
SDS-polyacrylamide gels and then electrophoretically transferred to nitrocellulose 
membranes. Membranes were then incubated in blocking buffer (5% nonfat dry milk, 
0.1% Tween 20, and 1× TBS) for 1 h at room temperature. Membranes were 
incubated overnight at 4°C with primary antibody on a shaker. Primary antibody 
(Chemicon International, Temecula, CA: anti-Huntingtin amino acids 1-82, mouse 
IgG, 1:500) was diluted in antibody buffer (1% nonfat dry milk, 0.1% Tween 20, and 
1× TBS). The next day, membranes were washed with TBS/0.1% Tween 20, and then 
they were incubated with goat anti-mouse secondary antibody conjugated to 
horseradish peroxidase (Jackson ImmunoResearch Laboratories Inc., West Grove, PA) 
diluted in antibody buffer. Membranes were washed, and signal was detected using 
enhanced chemiluminescence Western blotting detection reagents (GE Healthcare, 
Chalfont, St.Giles, UK). Using Scion Image for Windows (Scion Corporation, 
112 
 
 
Frederick, MD), immunoblots were quantified by calculating the integrated optical 
density (IOD) of each protein band on the film. 
Evaluation of htt aggregates by immunofluorescence. Sections of frozen 
mouse brain tissue (20 µm thick) were mounted on glass slides, and then fixed in 4% 
paraformaldehyde. After fixation, the sections were washed in PBS (pH 7.4), and then 
nonspecific binding was blocked with 5% normal goat serum (NGS). Sections were 
incubated overnight with primary antibody: MAB5374 (mouse IgG, 1:100, directed 
against human huntingtin amino acids 1~256) in 1% NGS + 1X PBS. Next, sections 
were washed and incubated for 1h with secondary antibody: goat anti-mouse IgG, Fcγ 
fragment specific, conjugated to DyLight 649 (1:400) (Jackson ImmunoResearch, 
West Grove, PA). Next, coverslips were mounted on tissue sections with Prolong 
Gold antifade reagent with DAPI (Invitrogen, Carlsbad, CA). As a control for 
nonspecific labeling with secondary antibody, omission of the primary antibody was 
also performed on a slide from each case. Htt-aggregate positive nuclei and size of 
htt-aggregates were measured in each of ten 215 ×215 µm microscope fields by 
Olympus IX-81 microscope (Olympus, Japan), in each of five rostrocaudally spaced 
sections in the striatum of 5 mice from the three groups of R6/2 mice (wild-type 
littermates did not show htt immunoreactivity). At least 450 nuclei per mouse were 
obtained and the percentage of nuclei containing htt-aggregates and area of 
htt-aggregates were calculated by CellProfiler software (Whitehead Institute, 
Cambridge, MA) and a mean value was obtained for each group.  
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Measurement of striatal volume by Nissl staining.  Cryostat sections (20 µm 
thick) were postfixed in 4% paraformaldehyde, then dehydrated in graded alcohols. 
After delipidated in 1:1 alcohol/chloroform for 1.5 h, sections were rehydrated 
through graded alcohols and stained with 0.2% aqueous solution of cresyl violet 
(Sigma, St. Louis, MO) for 5 min, followed by a brief rinse with water and 
dehydration in graded alcohols.   Sections were cleared in xylene (two changes, 5 
min each) and cover-slipped with Permount (Fisher Scientific, Fair Lawn, NJ). The 
volume of the striatum was measured according to the principle of Cavalieri (Cyr et 
al., 2005) (volume=s1d1+s2d2…sndn, where s=surface area and d=distance between 
two sections). We considered 15 coronal levels of the striatal sections (from Bregma 
1.7 mm, with an interval of 200 μm between the sections) for the volumetric 
measurement study. Image capturing was performed by using an inverted microscope 
(Olympus IX-81) coupled to a digital camera (Hamamatsu EMCCD, Japan). The 
montage image of a coronal brain section was constructed by Slidebook (Intelligent 
Imaging Innovations, Denver, CO). The surface area of striatum in each section was 
measured using NIH Image J [http://rsbweb.nih.gov/ij/]. Data were expressed as the 
average Cavalieri volume ±SEM (mm3) of 4~5 mice per group. 
CaM Kinase II Activity Assay.  CaM kinaseII enzyme activity was analyzed 
using the SignaTECT Calcium/Calmodulin-Dependent Protein Kinase Assay System 
(Promega, Madison, WI), according to the manufacturer's protocol. Mouse striatum 
was homogenized in the extraction buffer (20mM Tris-HCl pH 8.0, 2mM EDTA, 
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2mM EGTA, 2mM DTT, 1mM PMSF and 1:1000 Protease Inhibitor Cocktail (Sigma, 
St Louis, MO)). The homogenate was centrifuged at 350 × g for 5 min at 4°C and the 
supernatant was mixed with [γ-32P]ATP (at 3000Ci/mmol, 10mCi/ml), 50 µM 
biotinylated CaM kinase II substrate, reaction buffer containing 50mM Tris-HCl (pH 
7.5), 10mM MgCl2 and 0.5mM DTT, with or without control buffer containing 1mM 
EGTA. After incubation at 30°C for 2 min, the reaction was terminated by adding 7.5 
M guanidine hydrochloride and spotted to a streptavidin-impregnated membrane. 
Membranes were washed and the retained radioactive substrate of CaM kinase II was 
quantitated by liquid scintillation counting (Beckman, Fullerton, CA).  Radioactive 
counts were used as an index of endogenous CaM kinase II activity in the sample. 
TGase II Activity Assay.  TGase activity was measured by detecting the 
incorporation of a biotinylated TGase amine substrate, 5-(biotinamido)pentylamine 
(Pierce, Rockford, IL) into N,N’-dimethylcasein (Calbiochem, San Diego, CA) as 
previously described (Dudek et al., 2009). 96-well Immulon 4 HBX plates (Dynatech, 
Franklin, MA) were coated with 100 µl of N,N’-dimethylcasein (20 mg/ml) in 0.05M 
sodium bicarbonate, and stored at 4°C overnight. After the unbound 
N,N’-dimethylcasein was discarded, the plate was washed with PBS and blocked with 
nonfat dry milk (2% milk in PBS) for 1 hour at 37°C, followed by 3 washes with PBS. 
Striatum from the various mice were homogenized in 0.1 M Tris-HCl pH 8.3, 1 mM 
EDTA, 1 mM PMSF, and protease inhibitor cocktail. Striatal homogenates (15 µg of 
protein/sample) were added to the plate with 0.1 M Tris-HCl pH 8.5, 0.15 M NaCl, 5 
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mM DTT, 0.5 mM biotin-labeled pentylamine, and 5 mM CaCl2. The mixture was 
incubated for 1 hour at 37°C.  The plate was washed with TBS and 0.001% Tween 
followed by incubation with streptavidin conjugated to HRP (Jackson 
ImmunoResearch, West Grove, PA) for 1 hour at room temperature. After five washes, 
1 x TMB substrate solution (eBioscience, SanDiego, CA) was added and color was 
allowed to develop for 3 min. Then the reaction was stopped with 3N sulfuric acid 
and the absorbance was read at 450nm. For GTP-inhibited TGase enzymatic activity, 
the assay was performed in the presence of 500 µM GTPγS (Sigma-Aldrich, St Louis, 
MO). Negative controls were run in the absence of pentylamine or dimethylcasein. 
Each assay also included a standard curve of varying amounts of guinea pig TGase 
(Sigma, St. Louis, MO). Each sample was measured in triplicate. TGase activity was 
converted to a percentage control based on the mean value for the Vec-WT mice. 
Statistics. All data are presented as mean ± S.E.M. and analyzed by one- or 
two-way ANOVA with repeated measures. Post hoc tests were conducted using 
Bonferroni's multiple comparison tests. There were one or two mice dead after week 
13 in each HD group, so the last observed value was used for the subsequent missing 
values. Survival time was demonstrated by Kaplan-Meier survival curves and 
analyzed by a log-rank test. GB-STAT 10.0 (Dynamic Microsystems, Inc., Silver 
Spring, MD) and GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA) were 
used for all statistical analyses. A probability level of p < 0.05 was considered to be 
statistically significant for all statistical tests. 
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RESULTS 
AAV-mediated delivery of CaM-fragment in R6/2 mice attenuated body weight 
loss 
Body weight was monitored from 7 weeks of age onwards. All groups of mice were of 
similar initial body weight (22.9±0.3 g, n＝10~14 mice in each group). Changes in 
body weight were expressed as a percentage of body weight measured at 7 weeks of 
age (Fig. 18a). Body weight in all groups slowly increased or remained unchanged 
until week 10. Thereafter, mice in the two wild-type (WT) groups continued gaining 
body weight. The Vec-HD (R6/2 mice injected with empty vector AAV expressing 
GFP alone) and Scr-HD mice (R6/2 mice injected with AAV expressing a scrambled 
version of the CaM-fragment) had profound weight loss over the duration of the 
observation period, whereas CaM-HD mice (R6/2 mice injected with AAV expressing 
the CaM-fragment) maintained their body weight, or slightly increased their body 
weight (Fig. 18a). One-way ANOVA [F(4,50)=82.48; p<0.0001] followed by 
Bonferroni's multiple comparison test indicated that mice in CaM-HD group had less 
change in body weight than those in the Vec-HD group at 12-16 weeks of age (p < 
0.05), and there was no significant difference in body weight change between Scr-HD 
and Vec-HD at each time point. Similarly, body weight change in the CaM-WT (WT 
mice injected with AAV expressing the CaM-fragment) was not significantly different 
from the Vec-WT (WT mice injected with empty vector AAV expressing GFP alone). 
CaM-fragment expression did not significantly increase R6/2 mice survival 
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Although the first death took place on day 88, 78 and 67 and mean survival time was 
112, 102.9, 99.7 days in CaM-HD, Vec-HD and Scr-HD mice, respectively, 
suggesting a small (about 10%) increase in life span of CaM-HD mice, Kaplan-Meier 
survival curves demonstrated no statistically significant effect of CaM-fragment 
expression on the mortality in R6/2 mice (Fig. 18b). By log-rank comparison, the 
three groups of HD mice did not significantly differ from each other (p > 0.05). None 
of the mice in WT groups died during the observation period (from 6 to 27 weeks of 
age).  
CaM-fragment expression increases stride length and lowers stride frequency in 
R6/2 mice 
Gait dynamics were characterized using the DigiGait Imaging System. Generally, 
there is a clear difference between WT mice and Vec-HD or Scr-HD mice starting 
from week 11 in all the parameters measured, whereas the difference between WT 
mice and CaM-HD mice is not significant in stride length and frequency. At a speed 
of 14 cm/s, WT mice maintained a regular alternating gait at a consistent stride length 
of 5.8±0.3 cm and stride frequency of 2.5±0.1 steps/sec, whereas Vec-HD and Scr-HD 
mice walked at a gradually reduced stride length and higher stride frequency. For 
stride length (Fig. 19a), the two-way ANOVA with repeated measures indicated a 
significant main effect of group [F(4,126)= 35.77; p<0.0001] and week [F(3,126)= 12.12; 
p<0.0001]. There was also a significant interaction between group and week [F(12,126)= 
5.71; p<0.0001]. The post hoc Bonferroni test indicated that stride length of CaM-HD 
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mice is indistinguishable from the two HD control groups at 10 weeks of age, but 
CaM-HD mice displayed a longer stride length as compared to Vec-HD or Scr-HD 
mice at week 11~13. Stride length of CaM-HD mice was not significantly shorter than 
WT mice until at week 13. For stride frequency (Fig. 19b), two-way ANOVA 
indicated significant differences among groups [F(4,126)=11.99; p<0.0001], but there is 
no significant effect of week [F(3,126)= 0.202; p=0.895] or interaction between group 
and week [F(12,126)= 1.368; P=0.190]. The Bonferroni test indicated that CaM-HD 
mice had a significantly lower stride frequency than Vec-HD at week 11-13. Although 
Vec-HD and Scr-HD were statistically indistinguishable at any time point, there was a 
statistically significant difference between CaM-HD and Scr-HD at week 12. There 
was no significant difference between CaM-HD and WT mice in stride frequency. 
Analysis of some other gait dynamics revealed differences between genotypes. For 
example, the measure of stance width variation between steps was greater (Fig. 19c) 
and paw area at peak stance was smaller (Fig. 19d) in HD mice than in WT mice, but 
the CaM-fragment had no beneficial effects on these gait indices. For stance width 
variation, two-way ANOVA followed by Bonferroni test indicated significant 
differences between HD and WT groups [F(4,126)=13.61; p<0.0001], but no significant 
differences among HD groups or WT groups (P>0.05).  There is no significant effect 
of week [F(3,126)= 1.21; p=0.31] although  interaction between group and week is 
significant [F(12,126)= 1.97; P=0.03]. Similar results were obtained in the analysis of 
paw area at peak stance [Group factor: F(4,126)=10.42; p<0.0001], whereas week effect 
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is significant [F(3,126)= 13.68; p<0.0001] and interaction between group and week is 
not [F(12,126)= 1.55; P=0.11]. 
CaM-HD mice had fewer low mobility bouts and longer travel distance than 
Scr-HD or Vec-HD mice 
Force-plate actometers were used to measure the locomotor activity of R6/2 and WT 
mice. The number of low mobility bouts (LMB, defined as remaining continuously in 
a virtual circle of 15 mm radius for 10 sec) is presented in Fig. 20a. Two-way ANOVA 
with repeated measures indicated a significant effect of group [F(4,144) =27.75, p < 
0.001] and a significant effect of week [F(3, 144) = 3.179, p < 0.05], but the interaction 
between group and week was not significant. The number of LMB gradually 
increased in HD mice without CaM-fragment expression, whereas CaM-HD mice, 
similar to WT mice, maintained LMB at a relatively lower level. At week 12 and 13, 
the Bonferroni post hoc test detected significantly fewer LMB in CaM-HD mice as 
compared to either Scr-HD or  Vec-HD mice. Total travel distance in a 30 min session 
provided another index of locomotor activity of HD mice (Fig. 20b). Two-way 
ANOVA with repeated measures indicated a significant effect of group [F(4,138) = 3.40, 
p = 0.02], but the effect of week [F(3,138) = 0.17, p=0.92] and interaction between 
group and week [F(12,138) =1.12, p=0.35] were not significant. Consistent with reduced 
LMB in HD mice treated with CaM-fragment, CaM-fragment expression also 
increased the locomotor activity in HD mice as indicated by a significantly greater 
travel distance in CaM-HD mice than in either Scr-HD (at week 12,13) or Vec-HD 
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mice (at week 12). There was no significant difference between CaM-HD and WT 
mice in distance traveled in 30 min.  
CaM-fragment improved performance on the rotarod in R6/2 mice  
Rotarod was used to measure fore- and hindlimb motor coordination and balance 
starting at 10 weeks of age (i.e., three weeks after the AAV injections). At ten weeks 
of age, the two groups of WT mice were able to stay on the rod during the 300 sec 
time period measured, whereas none of the three groups of HD mice could finish the 
test without falling in 300 sec. Even at this early time point after injection of the AAV, 
the mean latency to fall was significantly differed among the HD groups, 245.9±32.0, 
150.2±29.5, 98.1±19.8 sec in CaM-HD, Vec-HD and Scr-HD mice, respectively. After 
10 weeks of age, there was a progressive decline in performance of all HD mice, but 
the CaM-HD mice still achieved better performance than the other two HD groups 
(Fig 21). Using analysis using two-way ANOVA with repeated measurements, we 
found a significant main effect of group [F(4,188) = 49.35, p < 0.0001], a significant 
main effect of week [F(4,188) = 18.86, p < 0.0001] and a significant interaction between 
group and week [F(16,188) = 4.714, p < 0.0001] on latency to fall off the rotarod. 
Bonferroni post hoc test indicated that CaM-HD mice had longer latency to fall as 
compared to Scr-HD mice at 10-14 weeks of age and Vec-HD mice at 10-11 weeks of 
age (p < 0.05).  
CaM-fragment expression reduced TGase-modified htt in R6/2 mice striatum 
Cell culture studies indicated that AAV-mediated CaM-fragment expression can 
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significantly inhibit the formation of TGase-modified htt (Dudek et al., 2009). Here 
we used striatal homogenates from HD or WT mice to detect TGase-catalyzed 
cross-linking of htt. Immunopurification of proteins containing є-(γ-glutamyl) lysine 
bonds was performed using 81D4 mAb prebound to Sepharose beads. 
TGase-modified htt was then detected on immunoblots as shown in the Fig. 22a. 
TGase-modified htt was only detected in HD but not WT mice. One-way ANOVA 
[F(2,15) =18.44, p<0.0001] followed by Bonferroni's comparison test found there was a 
significant reduction (by approximate 50%) in TGase-modified htt in the striatum of 
CaM-HD mice as compared to Scr-HD or  Vec-HD mice (Fig. 22b).  
CaM-fragment expression decreases the percentage of htt-positive nuclei and the 
size of htt aggregates in the striatum of R6/2 mice  
Striatal intranuclear and neuropil inclusions containing mutant htt are prominent 
neuropathological hallmarks of HD and may play an important role in disease 
progression. In R6/2 mice, intranuclear aggregates are much larger than neuropil 
aggregates and amenable to quantification, so we examined the effect of 
CaM-fragment on intranuclear htt aggregates in the striatum of R6/2 mice. In 
CaM-HD mice, the percentage of htt-positive nuclei was lower and the size of 
intranuclear aggregates appeared smaller than in the control virus-treated HD mice 
(Fig. 23a). These observations were confirmed by quantification of nuclear aggregates 
(Table 1). We found a significant reduction in the percentage of striatal nuclei 
containing htt-aggregates (approximately 18%) and the nuclear aggregate size 
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(approximately 35%) in CaM-HD mice as compared with either Vec- or Scr-HD mice. 
GFP fluorescence was observed in coronal brain sections from AAV-injected mice, 
indicating a widespread infection and expression of CaM-fragment in the striatum 
(Fig. 23a). Both human HD and R6/2 mouse brains are characterized by atrophy of 
the striatum. To exam whether the CaM-fragment delivery decreases gross striatal 
atrophy, we used Nissl staining and the Cavalieri principle to estimate striatal volumes. 
There was no statistically significant difference in mean striatal volumes between 
CaM-HD and the two groups of control HD mice. However, all three groups of HD 
mice had significantly smaller striatal volumes as compared with WT littermates (Fig. 
23b, Table 1). As expected, striatal neuronal atrophy was observed in HD mice in 
high-power images.  
CaM Kinase II activity was not affected by CaM-fragment expression 
To test if expression of the CaM-fragment would interfere with other CaM-dependent 
enzymes, we measured the activity of calmodulin-dependent protein kinase II (CaM 
kinase II) in mouse striatal homogenates. We found no significant differences in CaM 
kinase II activity among the various HD or WT mouse groups in either the presence or 
absence of EGTA, a calcium chelator (Fig. 24a). However, EGTA caused a general 
decrease in CaM kinase II activity in all mouse groups. Two-way ANOVA indicated a 
significant main effect of EGTA [F(1,50)=72.12; p<0.0001, but there was no significant 
effect of mouse group [F(4,50)=0.543; p=0.705] or an interaction between EGTA and 
group [F(4,50)=0.966; p=0.435]. 
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CaM-fragment did not change total TGase activity  
In order to explore whether the reduced TGase-modified htt in CaM-HD mice is due 
to a substrate-dependent inhibition or a general decrease in TGase enzymatic activity, 
we compared total TGase activity in the striatum among the different groups of mice. 
There is a significant increase in TGase activity in the three groups of HD mice as 
compared to CaM-WT or Vec-WT mice (p<0.01). Expression of the CaM-fragment 
did not have an effect on TGase activity in either HD or WT mice. In the presence of 
GTPγS, which specifically inhibits TGase activity, TGase activity is dramatically 
reduced (at least 60%) in all groups (Fig. 24b). Two-way ANOVA indicated a 
significant main effect of GTPγS [F(1,50)=428.149; p<0.0001] and mouse group 
[F(4,50)= 5.535; p<0.01], and there was a significant interaction between GTPγS and 
mouse group [F(4,50)= 5.032; p<0.01]. The activity of guinea pig liver TGase was 
measured in each assay in the range from 0.01 to 0.5 milliunits/ml and resulted in a 
linear correlation with an R-square value from 0.95 to 0.99. The activity of TGase in 
the striatal samples fell within this linear range for guinea pig liver TGase. 
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Fig.18 Effect of CaM-fragment on body weight and survival. (a) Changes in body 
weight were expressed as a percentage of body weight measured at 7 week of age. 
One-way ANOVA and Bonferroni's test found that the change in body weight was 
significantly smaller in CaM-HD than in Vec-HD (p< 0.05) starting from week 12, 
and there is no significant difference between Scr-HD and Vec-HD. * indicates p<0.05 
(CaM-HD vs. Vec-HD). (b) Kaplan-Meier survival curves showed the first death was 
at day 88, 78 and 67 in CaM-HD, Vec-HD and Scr-HD mice, respectively. By 
log-rank comparison, three groups of HD mice did not differ from each other (p>0.05). 
(n＝9~14 in each group) 
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Fig.19 Video-based gait analysis on the treadmill. Mice were placed on a treadmill 
belt moving at a speed of 14 cm/s. Gait data were pooled from all four paws. 
CaM-HD exhibited a significantly greater stride length (a), and a lower stride 
frequency (b). There is no significant difference between CaM-HD and Vec-HD or 
Scr-HD in stance width variability (c) and paw area at peak stance (d). Two-way 
ANOVA with repeated measures followed by Bonferroni test. * indicates p<0.05 
(CaM-HD vs. Vec-HD), # indicates p<0.05 (CaM-HD vs. Scr-HD), n=6-14 in each 
group 
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Fig.20 Expression of CaM-fragment enhanced the locomotor activity in R6/2 mice. 
Spontaneous locomotor activities of R6/2 and WT control mice were recorded in a 
force-plate actometer apparatus for 30 min. (a) CaM-HD mice displayed a 
significantly fewer number of low mobility bouts than the two HD control groups at 
week 12-13. (b) Distance traveled by CaM-HD mice was significantly longer than 
Scr-HD at week 12-13 and Vec-HD at week 12. Two-way ANOVA with repeated 
measures followed by Bonferroni test. * indicates p<0.05 (CaM-HD vs. Vec-HD), # 
indicates p<0.05 (CaM-HD vs. Scr-HD), n=9-14 in each group 
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Fig.21 CaM-fragment expression delayed the onset of the rotarod defects in R6/2 
mice. Mice were placed on a rotating rod with increasing speed, from 4 rpm to 40 rpm 
in 300 seconds. The latency to fall off the rotarod within this time period was 
recorded. Two-way ANOVA with repeated measures followed by Bonferroni test 
found that CaM-HD mice had significantly longer latency to fall than Scr-HD starting 
from week 10, and than Vec-HD at week 10-11. * indicates p<0.05 (CaM-HD vs. 
Vec-HD), # indicates p<0.05 (CaM-HD vs. Scr-HD), n=9-14 in each group 
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Fig.22 TGase-modified htt in R6/2 mice striatum was reduced by CaM-fragment 
expression. (a) The insoluble fraction from mouse striatal homogenates was dissolved 
with formic acid. Immunopurification (IP) of proteins containing є-(γ-glutamyl) 
lysine bonds was performed using 81D4 mAb prebound to Sepharose beads. 
Immunopurified proteins were then examine on immunoblots (IB) using an antibody 
against htt. (b) Quantitation of immunoblots. Data shown are the mean IOD± S.E.M., 
and they are normalized to CaM-HD mice. * indicates p<0.05 as compared to 
CaM-HD (n=5 in each group at 13-14 weeks of age). 
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Fig. 23 Histological evaluation of neuropathology (a) Top and middle, 
immunofluorescent labeling of striatum in R6/2 mice at 14 weeks of age. 
Htt-aggregates were labeled with htt antibody MAB5374 (red), the nuclei were 
labeled with DAPI (blue). The composite images show that the percentage of 
htt-positive nuclei and the size of nuclear htt-aggregates were decreased in CaM-HD 
as compared to the control-HD mice. Scale bar=30µm. Bottom, photomicrographs of 
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GFP protein distribution in the brain of representative AAV-injected animals indicated 
that the same vector-derived CaM-fragment was expressed in the striatum. Scale 
bar=1 mm. (b) Top , montage images of Nissl-stained brain coronal sections from 
CaM-HD, Vec-HD and CaM-WT mice at the level when the corpus callosum starts to 
merge in the middle. Scale bar=1 mm. Bottom, high magnification of micrograph of 
the dorsomedial aspect of the striatum from the sections above. There is marked 
neuronal atrophy with small angulated neurons in Vec-HD mouse, with relative 
preservation of neuronal size in CaM-HD mouse. Scale bar=50 µm. 
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Fig. 24 Expression of CaM-fragment in mouse striatum did not significantly affect the 
activity CaM kinase II or TGase. (a) Mouse striatal homogenates were used to 
measure CaM kinase II activity. Two-way ANOVA indicates a significant main effect 
of EGTA. However, there was no significant main effect of mouse group. The 
interaction between EGTA and group was also not significant. Bonferroni posttest 
indicates no significant differences in CaM kinase II activity among the various 
groups in either the presence or absence of EGTA. (b) The presence of the 
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CaM-fragment did not significantly change the levels of TGase activity in either HD 
or WT mice. However, a significant elevation of TGase activity in three groups of HD 
mice was observed as compared with WT mice. When 500 µM GTPγS was added, 
there is a dramatic reduction in all mouse groups. Two-way ANOVA indicates a 
significant main effect of GTPγS and mouse group, and there is a significant 
interaction between GTPγS and group. Bonferroni posttest *indicates p<0.01 as 
compared to Vec-WT; # indicates p<0.01 as compared to CaM-HD in the absence of 
GTPγS. Each column represents the mean ± SEM. (n=5 in each group at 13-14 weeks 
of age). 
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DISCUSSION 
Although there have been enormous strides in understanding the molecular 
and mechanistic pathways that mediate the progression of HD, an effective treatment 
to slow or prevent the disease-associated physical and mental decline has yet to be 
discovered. A number of reports in cultured cells have shown that interfering peptides 
can selectively inhibit pathological interactions between mutant htt and other proteins, 
and therefore are a potential therapeutic strategy for HD (Nagai et al., 2000, Dudek et 
al., 2008, 2009). However, only a few studies have been performed to verify the 
efficacy of these peptides in vivo (Kazantsev et al., 2002, Tang et al., 2009). We 
previously found that plasmid or AAV-mediated delivery of CaM-fragment 
significantly attenuated TGase-modified htt, htt-associated cytotoxicity and 
intracellular Ca2+ disturbances without interfering with the activity of other 
CaM-dependent enzymes in HD cell models (Dudek et al., 2008, 2009). We now 
report that expression of the CaM-fragment in the striatum ameliorated body weight 
loss, improved motor performance of R6/2 mice, reduced TGase-modified htt and 
decreased the number and size of nuclear htt-aggregates in the striatum.  
Striatal delivery of CaM-fragment significantly delayed the onset of 
movement abnormalities and improved motor function as measured by analysis of 
gait, rotarod performance and locomotor behavior. It has been reported that gait 
deficiencies in R6/2 mice became apparent from 8 weeks of age. As visualized in the 
footprint analysis, R6/2 mice displayed a significantly shorter stride length, a 
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staggering movement and a gait that lacked a uniform step pattern compared to WT 
littermates (Carter et al., 1999). Striatal injection of AAV-CaM-fragment conferred 
significant improvements in stride length and frequency measurements, and a mild, 
insignificant increase in paw area at peak stance in R6/2 mice. Decreased motor 
function on the rotarod is the most commonly reported measure among animal models 
of HD (Schilling et al., 1999, von Horsten et al., 2003). Three weeks after 
CaM-fragment expression, R6/2 mice started to show significantly improved rotarod 
performance and this beneficial effect was maintained from 10 weeks of age onward. 
Although motor abnormalities such as bradykinesia (abnormally slow movements) 
and pronounced hypoactivity were frequently observed in HD animal models 
(Mangiarini et al., 1996, Keene et al., 2002), there have been relatively few 
quantitative studies on spontaneous locomotor activity of R6/2 mice. In the present 
experiments using a force-plate actometer, progressive locomotor deterioration 
(assessed by number of low mobility bouts and travel distance) was observed in R6/2 
mice injected with control AAV, whereas delivery of AAV expressing CaM-fragment 
to R6/2 mice striatum significantly improved their locomotor deficits. 
In comparison to the TGase inhibitor cystamine, which prolonged the life span 
of R6/2 mice by 12%~19% (Dedeoglu et al., 2002, Karpuj et al., 2002a), there was a 
non-significant increase in the mean survival time by approximately 10% in the 
CaM-HD mice. Differences in other mechanisms of action could possibly account for 
the different outcomes. In addition to inhibiting TGase, cystamine increased 
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transcription of neuroprotective genes, increased glutathione levels, and ameliorated 
apoptosis (Dedeoglu et al., 2002, Karpuj et al., 2002a). In contrast, that 
CaM-fragment decreased TGase-modified htt, normalized intracellular calcium 
release, and reduced mutant htt-associated cytotoxicity but had no effect on TGase 
activity (Dudek et al., 2008, 2009). Secondly, the different outcomes could be due to 
the different brain regions treated. The CaM-fragment was expressed in the striatum 
only while the cystamine-treatment was systemically delivered and could affect other 
brain regions that display neuropathology in HD such as the frontal cortex. Rather 
than unspecific inhibition of TGase by cystamine, disrupting the CaM-htt interaction, 
as with the CaM-fragment, is a promising new approach for the treatment HD. 
As a result of its expanded N-terminal polyglutamine region, mutant htt is 
processed and deposited as a component of insoluble protein aggregates that persist in 
neuronal nuclei, perikarya, and processes (DiFiglia et al., 1997). Although some 
evidence suggests that htt-associated toxicity is linked to soluble htt and its 
protein–protein interactions (Petersen et al., 1999), htt aggregates act as a phenotypic 
readout that can reflect pathologically relevant processes such as htt cleavage, 
misfolding, and sequestration (Chopra et al., 2007). A number of compounds which 
are neuroprotective in R6/2 mice, such as the TGase inhibitor cystamine (Dedeoglu et 
al., 2002), the antioxidant coenzyme Q10 (Ferrante et al., 2002) and the energy buffer 
creatine (Ferrante et al., 2000), significantly suppress htt aggregates. Our present 
results revealed that CaM-fragment significantly reduced TGase-modified htt in the 
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insoluble fraction, the percentage of htt-positive nuclei and intranuclear htt-aggregate 
size in the striatum, which may contribute to the benefits of CaM-fragment. These 
findings support the hypothesis that CaM-regulated TGase modification of htt 
contributes to the formation and stabilization of htt-aggregates and may play a role in 
the pathogenesis of HD. However, it is difficult to speculate whether there would be 
an associated increase in soluble or oligomeric htt in the R6/2 mouse striatum with 
CaM-fragment expression. There is evidence that TGase modifications stabilize 
proteins (Tucholski et al., 1999), so inhibiting TGase modifications to htt may 
increase clearance of the htt protein.   
R6/2 mice developed significant striatal atrophy as compared to WT 
littermates, a pathological characteristic associated with the gradual 
neurodegeneration occurring in the mice. Although there is no significant difference 
in striatal volume between CaM-HD and control-HD mice by light microscopy, we 
could not exclude the possibility that expression of CaM-fragment would reduce the 
striatal atrophy if a more sensitive technology (MR scanning) was applied. Moreover, 
if striatal injections of AAV were performed at an earlier age, there might be more 
notable beneficial results including increases in survival and striatal volume. 
Similar to increases in TGase protein level and enzymatic activity in human 
HD brain (Karpuj et al., 1999, Lesort et al., 1999), our results show that TGase 
activity is elevated in R6/2 mice compared with WT littermates. Interestingly, striatal 
delivery of CaM-fragment did not change the overall activity of TGase in either R6/2 
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mice or WT mice. These results are consistent with our previous studies in cell culture 
(Dudek et al., 2009), suggesting that CaM-fragment may specifically affect the 
CaM-mutant htt interaction and selectively alter TGase-catalyzed modifications of 
mutant htt without interfering with the activity of TGase on other substrate proteins. 
Furthermore, CaM-fragment expression did not affect CaM kinase II activity, 
indicating that CaM-fragment had no effect on the activity of other CaM-dependent 
enzymes. Most importantly, expression of  CaM-fragment in WT mice had no effect 
on any of the behavioral tests nor striatal histopathology, suggesting there is minimal, 
if any, deleterious effect of long-term expression of CaM-fragment.  
A prominent hypothesis on the pathogenesis of HD is that the aberrant 
interactions of the extended polyglutamine repeats (polyQs) of mutant htt, either with 
other proteins or with each other result in htt-aggregate formation (Wanker, 2000). 
Glutamine repeats may function as polar zippers and expansion of polyQs may 
increase the affinity of htt for its protein binding partners (Perutz et al., 1994). The 
principal proteins that are known to interact with htt are: htt associated protein 1 (Li et 
al., 1995), htt interacting protein (Kalchman et al., 1997), type 1 inositol 
1,4,5-trisphosphate receptor (InsP3R1) (Tang et al., 2003) and calmodulin (Bao et al., 
1996, Zainelli et al., 2004). As revealed by our previous in vitro assay (Dudek et al., 
2009), the neuroprotective effects of CaM-fragment may depend on its ability to 
competitively bind to mutant htt thereby disrupting the CaM-mutant htt interaction. 
First, this disruption may result in the CaM and mutant htt no longer in close 
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proximity to each other, thus the TGase activity in htt modification and aggregate 
formation may be reduced. Second, the association between mutant htt and 
CaM-fragment may prevent the further interaction of mutant htt with other proteins, 
such as InsP3R1, an intracellular Ca2+ release channel. Since mutant htt selectively 
associates with and activates InsP3R1(Tang et al., 2003), disrupting their interaction 
should stabilize neuronal Ca2+ homeostasis. This hypothesis is supported by in vitro 
experiments that indicated the CaM-fragment (Dudek et al., 2008) or 
InsP3R-fragment (Tang et al., 2009) attenuates mutant htt-associated intracellular 
Ca2+ disturbances.   
Although it will be advantageous to confirm the results from the current study 
using a different HD animal model, special care should be taken to choose a different 
strain other than R6/2 mice. Instead of body weight loss, YAC128 mice have 
significantly (27%) increased body weight at 12 months of age (Van Raamsdonk et al., 
2006, Van Raamsdonk et al., 2007), which in turn can cause bias in most behavioral 
tests. Obvious or diffuse nuclear htt accumulation is not detectable in the striatum or 
cortices of BAC HD mice even in 18-month-old mice (Gray et al., 2008). 
Intergenerational instability and somatic instability of the HD CAG repeat have been 
observed in HdhQ111 knock-in mice in all three background strains: C57BL/6, FVB/N 
and 129Sv (Lloret et al., 2006). The phenotype of N171-82Q mice is more variable 
than that of R6/2 mice, and therefore a much larger number of mice are necessary to 
provide adequate power (Hersch and Ferrante, 2004). 
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Many therapeutic targets for HD today are based on the pathogenesis 
hypotheses, from mitochondrial dysfunction to transcriptional perturbation to TGase 
hyperactivity (Beal and Ferrante, 2004). However, since clinical trials of 
mechanism-based therapies for HD have been limited by insufficient statistical power 
and insignificant improvement (Handley et al., 2006), current clinical treatments are 
symptomatic. The major neurological symptoms associated with HD include 
disordered voluntary movements: uncoordinated, arrhythmic, and slow fine motor 
movements; rigidity; and gait disturbances (Harper, 1991). Our in vivo results 
demonstrated that viral delivery of CaM-fragment to the striatum of R6/2 mice 
significantly improved motor coordination and balance, enhance locomotor activity 
and alleviated gait disturbances, suggesting the possibility of a better quality of life 
for HD patients if this new therapeutic strategy is successfully translated to the 
clinical trials. 
The present studies provide, for the first time, in vivo evidence that 
CaM-fragment has significant efficacy in improving the behavioral deficits and 
neuropathological phenotype in the HD animal model. The positive effects of 
CaM-fragment in R6/2 mice provide further evidence that CaM-regulated TGase 
modification of htt may contribute to HD pathogenesis. More importantly, these 
studies have identified a novel therapeutic strategy for treating HD patients.
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CHAPTER FIVE 
GENERAL CONCLUSION 
 
REVIEW OF RESULTS AND SIGNIFICANCE 
In chapter two, we identified a novel effector mechanism attributed to 5-HT2A 
receptor signaling. This chapter described the effect of 5-HT2A agonists (5-HT or DOI) 
on transamidation and activation of Rac1 in a cell line derived from rat embryonic 
cortex. The transamidation is mediated by TGase, as suggested by a TGase inhibitor, 
cystamine or knockdown of TGase with siRNA. The transamidation of Rac1 
contributed to its transient activation, since TGase inhibition significantly reduced 
both transamidation and activation. Moreover, serotonin was identified as an amine 
that becomes transamidated to Rac1 by TGase. 
TGase-catalyzed transamidation of small G proteins not only occurred in 
platelets, vascular smooth muscle cells and cells derived from cervical cancer (Singh 
et al., 2001, Walther et al., 2003, Guilluy et al., 2007), but also occurred in neuronal 
cell lines, such as SH-SY5Y neuroblastoma cell line (Singh et al., 2003) as well as 
A1A1v cell line derived from rat embryonic cortex (Dai et al., 2008). One of the 
consequences of small G protein transamidation was constitutive activation. Members 
of the Rho family, particularly Rac1, are associated with a wide array of cellular 
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processes such as cytoskeletal organization, vesicular transport, cell cycle progression, 
cell adhesion and migration (Etienne-Manneville and Hall, 2002, Burridge and 
Wennerberg, 2004) and pathological conditions such as Salmonella invasion, tumor 
cell migration, and retinal degeneration (Bourguignon et al., 2000, Belmonte et al., 
2006, Brown et al., 2007). The physiological functions of TGase-catalyzed 
transamidation and activation of small G proteins in the nervous system remains 
poorly understood. Recent studies have demonstrated that activation of TGase and 
transamidation of RhoA to putrescine induced by retinoic acid in SH-SY5Y cells, 
results in activation of ERK1/2, JNK1, and p38 MAP kinases, which may stimulate 
transcription factors and induce gene expression for neuronal differentiation, as 
indicated by neurite outgrowth and neuronal marker expression (Singh et al., 2003). 
In addition to small G proteins, cytoskeletal proteins such as intermediate filaments in 
neurons, have also been shown to undergo TGase-catalyzed transamidation in vitro 
(Selkoe et al., 1982, Miller and Anderton, 1986) and in human cerebral cortex 
(Norlund et al., 1999). We demonstrate that stimulation of 5-HT2A receptors can 
increase the transamidation of Rac1 in both undifferentiated and differentiated A1A1v 
cells, suggesting that transamidation and constitutive activation of this signal 
transducer are not altered by neuronal differentiation of cells. The functional 
consequences of transamidation of Rac1 by TGase especially in neurons needs to be 
further explored. 
The signaling pathways involved in Rac1 transamidation have been 
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investigated in chapter three. The different components in the potential signaling 
pathways have been targeted by the antagonists and /or agonists. We found inhibition 
PLC decreased intracellular Ca2+ concentration as well as TGase-modified Rac1 upon 
5-HT2A receptor activation. The crucial role of Ca2+ signaling in Rac1 transamidation 
was confirmed by manipulation of intracellular Ca2+ by means of a Ca2+ chelating 
agent or an ionophore. When cells were pretreated with a Ca2+ chelator, 
TGase-catalyzed Rac1 transamidation was significantly reduced. Conversely, 
treatment with a Ca2+ ionophore was sufficient to induce an increase in Rac1 
transamidation by TGase. Moreover, the transamidation reaction was also regulated 
by CaM, a Ca2+ binding protein, as demonstrated by a CaM antagonist which 
depresses the stimulatory effect of 5-HT2A receptor activation on Rac1 transamidation. 
Searching the Conserved Domain Database revealed that two glutamine residues (Q61, 
Q74) and three lysine residues (K5, K16, and K116) are located at the activity-related 
domains. These results provided new insights into the signaling mechanisms 
underlying 5-HT2A receptor-induced Rac1 transamidation and activation by TGase in 
A1A1v cells. The present study indicated that 5-HT2A receptor-coupled PLC 
activation and subsequent Ca2+/CaM signaling are necessary in TGase-catalyzed Rac1 
transamidation, and identified potential TGase-targeting residues that could render 
Rac1 constitutively active upon transamidation. 
In the studies presented in chapter four, we shifted our focus from Rac1 to 
mutant htt as another substrate of TGase-catalyzed transamidation reaction. Our 
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previous studies in the cell models of HD screened various CaM fragments based on 
their ability to decrease TGase-modified htt and cytotoxicity, as well as normalize 
intracellular Ca2+ release. In this study, an AAV that expresses a CaM fragment was 
delivered into the striatum of HD transgenic R6/2 mice. Ameliorated body weight loss 
and improved motor performance were observed in those mice as compared to control 
virus-injected HD mice. CaM-fragment expression also specifically reduced 
TGase-modified htt, the percentage of htt-positive nuclei and the size of intranuclear 
htt aggregates in the striatum.  
Although the life span of CaM-fragment treated HD mice was not 
significantly prolonged (there was a non-significant increase in the mean survival 
time by ~10%), our results demonstrated that CaM-fragment expression in the 
striatum of HD mice significantly improved motor coordination and balance, enhance 
locomotor activity and alleviated gait disturbances.  The gene mutation that causes 
HD was identified in 1993 (Huntington’s Disease Collaborative Research Group, 
1993), but there is currently no effective therapy and the disease inevitably leads to 
death within 10 to 15 years of symptom onset (Bates, 2003). Medications are 
available to help manage the signs and symptoms associated with HD, but will not 
stop the progressive physical and mental decline. AAV-mediated gene therapy for HD 
by preventing mutant htt expression or interupting its interaction with other proteins 
has emerged as an attractive new strategy. The AAV-mediated knock-down of htt via 
bilateral injections into the striatum of HD transgenic mice resulted in a reduction in 
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neuronal intranuclear inclusions, and improvements on behavioral phenotypes and 
histological deficits (Harper et al., 2005, Rodriguez-Lebron et al., 2005). Disruption 
interaction mutant htt with either CaM (Dai et al., 2009) or type 1 IP3 receptor (Tang 
et al., 2009) by AAV expressing competitive fragments alleviated motor deficits and 
improved neuropathological abnormalities. Our results demonstrate the importance of 
CaM-htt association for HD pathogenesis and suggested that CaM fragment is a 
potential therapeutic agent for HD. 
According to our in vivo studies, wild-type mice injected with the AAV 
expressing CaM-fragment did not differ from those injected with AAV vector in terms 
of body weight, any of the behavioral tests, striatal histopathology, nor CaM KII or 
TGase enzyme activity up to 29 weeks old, suggesting there are minimal, if any, 
deleterious effects of long term expression of CaM-fragment. The CaM-fragment 
might not be able to disrupt the binding of CaM to other proteins to inhibit other 
biologic functions. The CaM target database 
(http://calcium.uhnres.utoronto.ca/ctdb/flash.htm) provides a program that searches 
for possible CaM-binding motifs in a protein sequence (Yap et al., 2000). The 
database currently includes the CaM-binding sites identified in over 300 proteins. No 
putative binding sites were located in the sequence of CaM-fragment suggesting that 
the interruption of binding of CaM to mutant huntingtin protein is selective. 
LIMITATIONS OF THE PRESENT STUDIES 
There are certain limitations that should be noted when interpreting the data of 
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present studies.  
We did not have direct evidence to establish a causal relationship between 
Rac1 transamidation and activation. Based on the facts that inhibition of TGase 
caused decreases in both Rac1 transamidation and activation, and that two glutamine 
residues (Gln61, Gln74) located in Rac1 activity-related domain are potential targets 
of transglutaminase, we are only able to conclude that 5-HT2A receptor stimulation 
increased TGase-catalyzed transamidation of Rac1, which may contribute to the 
increase in Rac1 activity. Although retinoic acid promoted activation of RhoA by 
TGase-catalyzed transamidation in neuroblastoma SH-SY5Y cells (Singh et al., 2003), 
transamidation-independent activation of Rac1 was observed in SH-SY5Y cells 
stimulated with retinoic acid (Pan et al., 2005). Further experiments could be carried 
out to explore if other mechanisms are also involved in 5-HT2A receptor-mediated 
Rac1 activation in A1A1v cells. 
Although the TGase inhibitor cystamine decreased the serotonin-associated 
Rac1 in co-immunoprecipitation experiments, we could not confirm a direct 
association between Rac1 and serotonin via a TGase-catalyzed covalent bond.  
Another common binding partner could link serotonin to Rac1. However, this 
possibility is undermined by the fact that serotonin-associated Rac1 did not show a 
significant upward shift on immunoblots compared with native Rac1 in cell lysates, 
indicating that the molecular weight of serotonin-associated Rac1 does not 
significantly increase. Therefore, the binding partner, if it exists, should also be a 
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small molecule likely an amine. 
The attempt to replicate 5-HT2A receptor-mediated Rac1 transamidation in rat 
cortex failed. In Sprague Dawley rats that were given subcutaneously injections of 
DOI (2.5 mg/kg) and sacrificed 5 or 15 minutes later, there is no significant increase 
in TGase-modified Rac1 in the frontal cortex compared to saline-treated rats. The 
discrepancy between cell-based and in vivo studies could be attributed to the 
following possibilities. The DOI dosage and route of administration in rats may not be 
able to mimic the circumstances under which 5-HT2A receptor stimulation induces 
Rac1 transamidation in A1A1v cells. Moreover, the time course of reactions for 
DOI-mediated Rac1 transamidation may be different between cultured cells and 
whole animals. Lastly, the cultured cells grow in an environment that lack 
intercellular communication or neurotransmitter cross-talk, which differs from the 
normal surrounding milieu presenting in the brain. 
  In our studies that evaluated protective effects of CaM-fragment in R6/2 
mice, immunofluorescence staining demonstrated that the percentage of htt-positive 
nuclei and the size of intranuclear htt aggregates in the striatum were reduced by 
CaM-fragment expression. Although TGase-modified htt in the striatal homogenates 
was decreased in CaM-expressing HD mice as compared to the other two groups of 
control HD mice (as indicated in immunoprecipitation and immunoblotting 
experiments), we were unable to confirm that the reduction of htt aggregates was due 
to decreased TGase-modification of htt. Our original experimental design that aimed 
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to measure the colocalization of htt aggregates with TGase-modified covalent bonds 
could help to test this hypothesis. However, the only commercially available antibody 
directed against TGase-modified covalent bonds (81D4) is raised in mouse. High 
levels of background staining were observed with the 81D4 antibody in R6/2 mouse 
tissues, likely due to the binding of secondary anti-mouse antibody to endogenous 
mouse tissue Igs and other components. This technical difficulty compromised our 
ability to explore the role of TGase-modified covalent bonds in the formation of htt 
aggregation in HD mice.  
Our previous in vitro experiment indicated that CaM-fragment can directly 
inhibit the binding of mutant htt and CaM (Dudek et al., 2009). In this in vivo study, 
since the striatum of age matched HD mice were used in immunofluorescence 
staining, Nissil staining, immunoprecipitation, TGase and CaM activity assay, we did 
not have enough striatal homogenates to confirm the hypothesis that striatal 
CaM-fragment expression disrupted mutant htt-CaM association in vivo. The other 
experiment that could support the hypothesis that the CaM-fragment can directly 
disrupt the interaction between mutant htt and CaM is co-immunoprecipitation to 
demonstrate the binding of CaM-fragment to mutant htt. However, we have not been 
able to find a specific antibody directed against this CaM-fragment. Moreover, due to 
the small size of the CaM-fragment (consisting of 46 amino acids and weighing 
5,158.6 daltons), detection of the proteins on immunoblots was difficult. 
As for the timing of the delivery of AAV expressing CaM-fragment, our 
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original plan was to inject AAV to R6/2 mice at a much younger age, but the youngest 
mice we could purchase from Jackson Laboratories were at 6 weeks of age due to the 
genotyping process. Therefore, we chose the new R6/2 strain 
(B6CBA-Tg(HDexon1)62Gpb/3J) which has fewer CAG repeats in exon 1 (100-115 
CAG repeats) over the previous strain (B6CBA-Tg(HDexon1)62Gpb/ 1J) with 
154-159 CAG repeats. The new strain exhibited a concomitant decrease in severity 
and delayed onset in the expected neurological phenotype (Jackson Laboratories, 
http://jaxmice.jax.org/strain/002810.html), which actually gave CaM fragment more 
time to perform its function. However, if striatal injection of AAV was performed at a 
younger age, we might have more beneficial results including significant increases in 
survival and striatal volume. 
FUTURE STUDIES: DISRUPTING CAM-HTT INTERACTION AS A 
POTENTIAL THERAPEUTIC STRATEGY IN HUMANS  
Currently there is no cure for HD. On August 15, 2008 the U.S. Food and 
Drug Administration (FDA) approved the use of tetrabenazine to treat Huntington’s 
chorea (the involuntary writhing movements), making it the first drug approved for 
use in the United States to treat the disease. Tetrabenazine works mainly as a 
Vesicular Monoamine Transporter (VMAT)-inhibitor (Zheng et al., 2006) and thereby 
increases the early metabolic degradation of dopamine. Other agents targeting 
dopamine system have also been used to ameliorate chorea and treat irritability, 
hallucinations and delusions. Those agents include dopamine antagonists such as 
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haloperidol, fluphenazine and pimozide (Caine and Shoulson, 1983, Girotti et al., 
1984, Barr et al., 1988). 
Our in vivo studies demonstrated that AAV-mediated striatal expression of 
CaM-fragment improved motor function, weight loss, and neuropathology in HD 
mice. In the long run, to extend the application of CaM-fragment to HD patients, a 
less invasive method has to be developed since AAV-mediated delivery of 
CaM-fragment by stereotaxic surgery could cause brain injury. The less invasive 
approaches include intravenous administration or systemic injection. The delivery of 
CaM-fragment to the brain by the intravenous route could be efficient and widespread 
to all parts of the brain once the blood-brain barrier (BBB) is traversed. Certain 
endogenous large-molecule neuropeptides such as insulin, transferrin, or leptin are 
transported into the brain from blood via receptor mediated transport (RMT) across 
the BBB (Pardridge, 2003). These transporters are regulated by ligand-specific 
receptors such as insulin receptors and transferring receptors, which are highly 
expressed on the capillary endothelium of brain (Rip et al., 2009). Molecular Trojan 
horses (MTH) are certain monoclonal antibodies (MAbs) or peptide ligands that target 
RMT systems (e.g., receptor-binding sequences of insulin) that bind to BBB receptors 
and induce receptor mediated transcytosis through the BBB (Pardridge, 2002). 
Therefore, the construction of fusion proteins between the CaM-fragment and the 
MTH may enable the CaM-fragment to cross the BBB in vivo. It has been reported 
that a fusion protein between the insulin receptor mAb and brain-derived neurotrophic 
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factor (BDNF) enables rapid brain penetration of the neurotrophin in animal models, 
including nonhuman primates and is intended for treatment of stoke and 
neurodegenerative diseases (Boado et al., 2007, Boado et al., 2008, Boado and 
Pardridge, 2009). 
On the other hand, the identification of the sites on mutant htt that binds to 
CaM may also provide an alternative approach to disrupt CaM-htt interaction. A yeast 
two-hybrid assay or affinity purification could be used to rapidly screen the sequential 
deletions of htt to identify binding domain, and then test their ability to disrupt the 
binding of CaM to mutant huntingtin. Next, similar to CaM-fragment (Dudek et al., 
2008, 2009), we could test the ability of these fragments from mutant htt for their 
ability to inhibit TGase-catalyzed modifications to mutant htt and for their ability to 
increase cell viability in HD cell models. Once the beneficial effects were observed, 
we could deliver these fragments to the animal models of HD via different approaches 
depending on their molecular size and charge character. The binding domain in 
mutant htt could be located at the amino acid sequences upstream or downstream of 
the expanded polyglutamine tract or in the middle of the polyglutamine tract. If the 
polyglutamine domain is responsible for binding to CaM, the therapeutic strategy that 
targets CaM-htt interaction could be applied to the other eight polyglutamine repeat 
diseases as well.  
CONCLUSIONS 
TGase-catalyzed transamidation and activation of the small G protein Rac1 in 
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A1A1v cells is regulated by 5-HT2A receptor signaling and Ca2+/CaM (Figure 25). 
Active Rac1 has various physiological functions in neuronal cells, including neurite 
outgrowth and neuronal differentiation, via modulating the activity of diverse effector 
proteins (Leeuwen et al., 1997, Pan et al., 2005). Pathologically, TGase-modification 
of htt is regulated by the association of htt with CaM, which may be involved in the 
formation and stabilization of htt-aggregates and play a role in the pathogenesis of 
HD. Direct inhibition of TGase or CaM may be able to suppress TGase- and 
htt-mediated neuropathological perturbations, but also will interrupt the normal 
physiological functions of TGase and CaM because both enzymes regulate a variety 
of effectors including kinases and cytoskeletal proteins. Alternatively, specific 
disruption of the interaction of CaM with mutant htt, by a competitive 
CaM-fragement, is a useful tool to determine the pathogenic mechanisms involved in 
HD and can be used to develop new therapeutic strategies for HD (Figure 25). Our in 
vivo study demonstrated that striatal expression of the CaM-fragment significantly 
improved motor function and neuropathological perturbations in HD mice. Moreover, 
TGase and CaM activity were not altered by the CaM-fragment in either HD or WT 
mice, suggesting that disrupting CaM-htt interaction is an important new therapeutic 
strategy for HD. 
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Figure 25. Regulation of TGase by 5-HT2A receptor signaling and CaM. In A1A1v 
cells, upon stimulation of Gq/11 protein-coupled 5-HT2A receptor, the phosphatidyl 
inositol pathway was activated, resulting in PLC-mediated hydrolysis of PIP2 to IP3, 
which in turn releases Ca2+ from ER stores. A rise of cytoplasmic Ca2+ is sufficient to 
activate TGase, which catalyzed the transamidation of Rac1 to bioamines, such as 
serotonin transported into the cytoplasm by SERT. CaM, another Ca2+-dependent 
enzyme, also contributed to Rac1 transamidation by positive regulation of TGase. In 
HD cells, mutant htt associated with CaM at a specific binding domain, and htt were 
modified by TGase. This modification may stabilize htt monomers or polymers and 
contribute to cytotoxicity and formation of htt-containing aggregates. CaM-fragment 
may disrupt CaM-htt interaction by competing with endogenous CaM, resulting in 
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decreased TGase-modified htt and aggregates. Abbreviations: 5-HT2AR, 5-HT2A 
receptor; CaM, calmodulin; ER, endoplasmic reticulum; PLC, phospholipase C; PIP2, 
phophatidyl inositol-1,4-bisphosphate; IP3, inositol-1,4,5-triphosphate; SERT, 
serotonin transporter; TGase, transglutaminase; αq/11, , Gq/11 protein α subunits
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